Submission readiness: NOT YET DETERMINED

Computed from this object's own state — the author has not yet attested the surfaces below. This is not a fixed disclaimer: the conditions below are each testable, and a build in which they are met renders READY.

Qualifications that travel with the headline

Sacubitril/valsartan in adults with heart failure and reduced ejection fraction

In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril?

In this section: Registration and administrative information (PROSPERO field set) · Protocol registration · Protocol amendment history · Author attestation · What this object claims to contain

Registration and administrative information (PROSPERO field set)

Table 1. Registration and administrative information (PROSPERO field set)
Review titleSacubitril/valsartan in adults with heart failure and reduced ejection fraction
Review question (PICO)In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril?
Background / rationaleNot recorded — this object holds no background field, and an introduction generated without one would be argument that no source in this review supports
Eligibility criteriaA randomised trial of sacubitril/valsartan against enalapril, in adults with heart failure and reduced ejection fraction, reporting cardiovascular death or heart failure hospitalization as a time-to-first-event hazard ratio. All four conditions, and the last is a condition on the quantity reported, not on the trial's quality: several excluded trials are large, well conducted and directly on topic, and report something that is not this.
Information sources12 source layers, listed on the Extraction tab
Search strategyNot recorded — this object records no search strategy, so no query, date or yield can be shown and nothing on the Search tab describes one
Study selection processTwo independent screens were run, adjudicated by Mahmood Ahmad.
Number of screenersNot recorded — this object records no screener count
Data extraction itemsExtracted per trial on this object: registry id; primary publication; year; design; arms; per-arm counts and the published effect; the randomised total, separately from the analysed denominator. Fields not listed here were not extracted.
Outcomes and prioritisationCardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio
Risk of bias methodA Cochrane RoB-2 assessment has now been performed by two independent AI assessors from different model families, neither of which assembled this object. Both judgement sets are published in full, including every signalling-question answer, and the per-domain agreement rate is reported as measured rather than after reconciliation. No domain in any trial was rated HIGH by either assessor. Five of fifteen domain judgements disagreed and remain unadjudicated.
Synthesis methodsPooled under random-effects with the REML estimator. Whether they were prespecified is not recorded on this object.
Subgroup analysesNot recorded — this object records no subgroup-analysis field at all, so whether any were prespecified is UNKNOWN -- which is not the same as none having been
Meta-bias assessmentNot recorded — no funnel, Egger or Peters value is held on this object, so no meta-bias assessment is claimed
Certainty assessmentGRADE, recorded for 1 outcome(s) (GRADE). The ratings are on the Certainty tab.
Confidence level95%
FundingNot recorded — no funding statement is recorded for this review
Competing interestsNot recorded — no declaration is recorded
Built2026-08-09
Schema2

Protocol registration

Method: timestamped public git commit — repository https://github.com/mahmood726-cyber/rapidmeta-finerenone, path ssot/arni-hfref/arni-hfref.json.

Table 2. Protocol registration
CommitCommitted (UTC)Subject and permalink
961400264a062026-08-10T05:13:40Zssot(arni-hfref): certified build, cross-family gate passed
https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/961400264a06bd940bef11e02b528ea0f73a8dee
6272db4f0ee92026-08-12T19:43:11Zrecover: preserve the only surviving generator; install the destructive-git guard
https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/6272db4f0ee9ec88018ed33db0ee9a1f0997be9d

Permalinks are pinned to the commit SHA, not to a branch. A branch link moves and would prove nothing.

Ordering test: did the protocol precede the search?

Table 3. Ordering test: did the protocol precede the search?
Verdictestablished
Protocol committed2026-08-12T11:27:47Z
Strengthened2026-08-12T12:05:56Z
First query attempted2026-08-12T12:19:18Z
First query executed2026-08-12T12:22:39.556Z
Margin vs registration+51 min 31 s to the attempt, +54 min 52 s to the first successful execution
Margin vs strengthened+13 min 22 s to the attempt, +16 min 43 s to the first successful execution

The protocol commit precedes the first executed query on both readings of 'first query'. The 12:19:18Z attempt is reported even though it returned nothing, because reporting only the successful execution would move the first-query time three minutes later and make the claim look better than it is. This is the test a PROSPERO record cannot offer: the timestamps are set by the repository and by the APIs, not by us, and both are independently checkable.

What this evidence establishes

That the text of this object existed, in this public repository, at the committer timestamp shown, and has not been altered since without producing a new commit. The permalink is pinned to the commit SHA rather than to a branch, so it resolves to that exact state forever; a branch link would move and would prove nothing. Anyone can verify the timestamp and the content independently of this page and independently of its authors.

What it does not

It does not establish prospectiveness. A commit proves when text entered this repository; it cannot prove that no earlier or parallel version existed elsewhere, that the data had not already been seen when the text was written, or that the analysis plan was fixed before the results were known. It also says nothing about the independence of the people who wrote it. Those are claims about conduct, and a timestamp cannot carry them.

Protocol amendment history

Table 4. Protocol amendment history
CommitCommitted (UTC)SubjectRelative to the search
973f031773d32026-08-12T11:27:47Zprotocol(arni-hfref): register the review protocol before the search runs
https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/973f031773d384f54bc1a6107931614aa5fda7ea
before the search
dde5011676662026-08-12T12:05:56Zprotocol(arni-hfref): strengthen section 9 so RoB-2 is pre-registered, not merely intended
https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/dde501167666f41ffdc81a07df1628734ce327a0
before the search
f89e9872418b2026-08-13T15:03:28ZAmendment: post-hoc aetiology-split sensitivity analysis added
https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/f89e9872418bbbd95cbeaf67814d1dbd56371bf2
AFTER the search

The full commit history is projected, not only its head. A log that displays only its current state is no better than a mutable document, and the point of registering by commit is that every earlier state stays readable. Each entry records whether it post-dates the first executed query, because an amendment made after the search is a different act from one made before it and must not be presented as the same.

Author attestation

These are the surfaces a human author discharges by checking them and recording that they did. An attestation records that someone checked what is already here; it never alters a number and never raises a cell's source tier. A slot naming no person, no source or no date reads as absent.

Table 5. Author attestation
SurfaceStatusWhat must be checked
Screening decisionsAwaiting attestationThat every record in `screening.records` was screened against the stated eligibility criteria, that each recorded decision and reason matches the record it names, and that the search was screened by the number of reviewers the write-up claims.
Data extraction against sourceAwaiting attestationThat every extracted cell -- arm sizes, effect estimates, intervals and their scales -- was read back against the source named on that cell, and matches it.
Per-study risk of biasAwaiting attestationThat the RoB-2 assessment recorded in `rob2` was carried out as pre-registered, that both assessors' domain judgements and signalling answers are reproduced without reconciliation, and that the five open disagreements are adjudicated. The assessment now exists; what this attestation still requires is a human adjudication of the disagreements and a check of the assessors' cited sources.
GRADE domain ratingsAwaiting attestationThat each GRADE domain rating and the resulting certainty were reviewed against the evidence cited in its own `basis in sources`.

What this object claims to contain

Full build. Every randomised trial located that compares sacubitril/valsartan with enalapril in heart failure with reduced ejection fraction and reports the composite of cardiovascular death or heart failure hospitalization as a time-to-first hazard ratio is held and pooled. Every trial that was looked at and not pooled is in one screening log, whatever it failed on, including the four that reached this review only by reconciliation against a published review's included-study table. Each row names the criterion it fails and the quantity it reports instead -- with one row that does neither, and says so: a trial that could not be retrieved at all is recorded as undetermined, with what was established, the document it was what could not be, and the date each attempt was made. That row is not an exclusion and is not counted as one. There is exactly one source list, `screening.records`. The object does also hold a second array, `screening.excluded`, and it is not a second table in any sense a reader has to reconcile: it is a view computed from the records at build time, row for row, so it cannot say anything the records do not. An earlier version of this sentence claimed there was no second array at all, which was false of the structure, and a review leg was right to read the structure rather than the sentence.

In this section: Adjudication: ANSWER-HF · PARAGON-HF NCT01920711 · PMID 31475794 · PARADISE-MI NCT02924727 · PARAGLIDE-HF NCT03988634 · PMID 37212758 · ANSWER-HF NCT04853758 · PMID 41396086 · PIONEER-HF NCT02554890 · EVALUATE-HF NCT02874794 · OUTSTEP-HF NCT02900378 · Parallax NCT03066804 · HFN-LIFE NCT02816736 · Pathadka 2020 PMID 33553256 · Bano 2021 PMID 34395116 · Zhao 2022 PMID 35874853 · Li 2019 · Every record the search retrieved

Adjudication: ANSWER-HF

Screener A said: excluded at stage 1 on the outcome axis, then held as undetermined. Resolved by named human adjudication — Mahmood Ahmad, 2026-08-13T13:55:30Z.

Screener A's exclusion and its subsequent undetermined holding both stand unaltered in the screening record. The adjudication overrides them; it does not erase them.

PARAGON-HF NCT01920711 · PMID 31475794

This review's decision: excluded.

Fails the frozen question on all three axes, and any one of them is sufficient. Population: it enrolled an ejection fraction of 45% or higher, which is preserved rather than reduced. Comparator: it randomised against valsartan, not enalapril. Measure: its primary is the cumulative number of cardiovascular deaths and total, first and recurrent, heart failure hospitalizations, analysed as a rate ratio.

  • population
  • comparator
  • measure

What it actually reports: a rate ratio of 0.87 with a 95% interval of 0.75 to 1.01 for total heart failure hospitalizations and cardiovascular death

Why that is not this review's measure: A recurrent-event rate ratio counts repeat events per person over time; a time-to-first hazard ratio counts each person once, at their first event. The two share a scale and a direction and answer different questions, and storing this trial's 0.87 in a hazard-ratio field would be indistinguishable, to any reader and to most software, from a hazard ratio of 0.87. It is stored nowhere in this object except in this sentence.

registry: https://clinicaltrials.gov/study/NCT01920711

PARADISE-MI NCT02924727

This review's decision: excluded.

Population: acute myocardial infarction with left-ventricular dysfunction or pulmonary congestion, not chronic heart failure with reduced ejection fraction. Comparator: ramipril, not enalapril. Outcome: its composite counts incident heart failure -- a first presentation in people who did not have heart failure at randomisation -- which is not hospitalization for heart failure in an established heart failure population.

  • population
  • comparator
  • outcome

registry: https://clinicaltrials.gov/study/NCT02924727

PARAGLIDE-HF NCT03988634 · PMID 37212758

This review's decision: excluded.

Population: ejection fraction above 40% after a worsening heart failure event. Comparator: valsartan. Measure: the primary is the time-averaged proportional change in NT-proBNP, a biomarker ratio-of-change, and its hierarchical secondary is a win ratio. Neither is a hazard ratio for a clinical event.

  • population
  • comparator
  • measure

What it actually reports: a ratio of change in NT-proBNP of 0.85 with a 95% interval of 0.73 to 0.999, and an unmatched win ratio of 1.19 with a 95% interval of 0.93 to 1.52

registry: https://clinicaltrials.gov/study/NCT03988634

ANSWER-HF NCT04853758 · PMID 41396086

This review's decision: excluded.

This is the hardest exclusion in the table and the only one that passes the population and the comparator: 190 patients with heart failure with reduced ejection fraction due to Chagas cardiomyopathy, randomised double-blind against enalapril. It fails on the measure. Its primary endpoint is the change in left-ventricular ejection fraction at six months, and its only composite analysis of cardiovascular death and heart failure hospitalization is inside a hierarchical endpoint analysed by win ratio, reported as 1.80 with a 95% interval of 1.27 to 2.63. No time-to-first hazard ratio for the composite is separately reported. The registry record is consistent with all of this and posts no results of its own, which is why this row is sourced to the publication.

  • measure

primary_oa: https://pubmed.ncbi.nlm.nih.gov/41396086/

PIONEER-HF NCT02554890

This review's decision: screened, not eligible.

Right population and right comparator -- acute decompensated heart failure with reduced ejection fraction, randomised against enalapril -- and the wrong quantity over the wrong horizon. The brief noted a conflict between a rule excluding follow-up under twelve weeks and a rule keyed to the trial's own endpoint, and left both standing. It is resolved here against the frozen question and only one rule survives: the trial is excluded because it reports no time-to-first hazard ratio for cardiovascular death or heart failure hospitalization, which is section 3.2.4, the outcome axis. Follow-up length is a consequence of that endpoint and is not an independent criterion in this object, because a short trial that did report the composite as a hazard ratio would be eligible and a long one that did not would still not be. Two rules that disagree are one object with two descriptions, which is the failure this batch has paid for before. [Upgraded 2026-08-13: this exclusion is now read at primary source rather than inferred. The trial methods define the composite as death, rehospitalisation for heart failure, lvad implantation, transplant listing, an unplanned acute heart failure visit, a diuretic dose increase over 50%, or an added heart failure drug, with Cox hazard ratios computed for that set. That is a broader composite than our estimand and includes all-cause rather than cardiovascular death.]

  • measure

What it actually reports: the time-averaged proportional change in NT-proBNP over eight weeks

registry: https://clinicaltrials.gov/study/NCT02554890

Primary source read — how this decision is known
Table 8. PIONEER-HF NCT02554890
Evidence basisPrimary source read
Previouslythird-party convergent inference
Upgraded (UTC)2026-08-13T08:25:07Z
What was readthe trial methods, endpoint definition, and analysis section of the primary publication
CitationVelazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380(6):539-548.
Analysis the trial reportsCox proportional-hazards ratios computed for that composite
Sourcehttps://pubmed.ncbi.nlm.nih.gov/30415601/

The composite as the trial itself defines it:

  • death
  • rehospitalisation for heart failure
  • implantation of a left ventricular assist device
  • listing for cardiac transplantation
  • unplanned outpatient visit for acute heart failure
  • an increase in diuretic dose of more than 50%
  • the addition of a further heart failure drug

Our frozen estimand is the time to a first event of cardiovascular death or hospitalisation for heart failure. The trial computes a hazard ratio, so the measure matches, but the composite it is computed over is a different and substantially broader event set: it counts all-cause death rather than cardiovascular death, and it adds four events that are not hospitalisations at all -- an lvad, a transplant listing, an unplanned outpatient visit, and two purely pharmacological events, a diuretic increase over 50% and the addition of another heart failure drug. A hazard ratio over that set is not an estimate of our quantity and pooling it would silently redefine the outcome.

The exclusion decision is unchanged. What changed is its basis: it previously rested on agreement between third-party sources about what the trial reported, and it now rests on the endpoint definition read in the trial methods. A decision that is right for a reason nobody checked is not the same as one that is right for a reason someone read.

EVALUATE-HF NCT02874794

This review's decision: screened, not eligible.

Randomised against enalapril in heart failure with reduced ejection fraction, and its endpoint is a vascular-mechanics measurement. It reports no hazard ratio for the composite.

  • measure

What it actually reports: the change from baseline in aortic characteristic impedance at twelve weeks

registry: https://clinicaltrials.gov/study/NCT02874794

OUTSTEP-HF NCT02900378

This review's decision: screened, not eligible.

Randomised against enalapril in heart failure with reduced ejection fraction. Its endpoint is an activity measure, not a clinical event, and it reports no hazard ratio for the composite.

  • measure

What it actually reports: change in daily physical activity measured by accelerometry

registry: https://clinicaltrials.gov/study/NCT02900378

Parallax NCT03066804

This review's decision: screened, not eligible.

Fails the population as well as the measure: it enrolled an ejection fraction above 40%, and its comparator is individualised medical therapy rather than enalapril alone.

  • population
  • comparator
  • measure

What it actually reports: change in NT-proBNP and in six-minute walk distance

registry: https://clinicaltrials.gov/study/NCT03066804

HFN-LIFE NCT02816736

This review's decision: screened, not eligible.

Advanced, NYHA class IV heart failure, randomised against valsartan rather than enalapril, with a biomarker endpoint. Recorded because the brief listed a trial called life and this is the trial that name resolves .

  • population
  • comparator
  • measure

What it actually reports: the area under the curve for NT-proBNP over twenty-four weeks

registry: https://clinicaltrials.gov/study/NCT02816736

Pathadka 2020 PMID 33553256

This review's decision: screened, not eligible.

This is the only excluded record in this object that reports the quantity this review pools, for the composite this review pools, and it is excluded anyway. It is not a randomised trial: it is a population-based new-user cohort drawn from the Hong Kong-wide electronic health record, 1056 people dispensed sacubitril/valsartan against 2181 dispensed enalapril, with treatment assigned by prescribers rather than by allocation. The frozen question is answered from randomised evidence only, so design decides this row before the endpoint is reached. Recording the endpoint anyway is deliberate: its 0.58 sits below the lower bound of this object's randomised pooled interval, so a reader can see what the design rule is holding out, rather than being asked to take the rule on trust. The prior meta-analysis that surfaced it reached the same decision from the other direction -- its own sensitivity analysis removes this study for being retrospective, and the heterogeneity of the pool it sat in falls from severe to none when it does.

  • randomisation

What it actually reports: a hazard ratio of 0.58 with a 95% interval of 0.45 to 0.75 for the composite of cardiovascular mortality or heart-failure-related hospitalization, estimated by Cox regression with inverse-probability-of-treatment weighting

primary_oa: https://pubmed.ncbi.nlm.nih.gov/33553256/

Bano 2021 PMID 34395116

This review's decision: screened, not eligible.

Right population and right comparator: a randomised comparison of sacubitril/valsartan with enalapril, in equal allocation, in heart failure at a tertiary hospital in Pakistan, 181 against 183, followed for twelve months or to an event. It fails on the measure. Its full text contains no hazard ratio, no Cox model and no time-to-event analysis of any kind; it reports proportions and relative risk reductions, and it keeps hospitalization and death apart instead of combining them. Neither of those quantities can be converted into a time-to-first hazard ratio without the event times the paper does not report.

  • measure

What it actually reports: heart-failure-related hospitalization as a proportion in each arm -- 13.8% against 22.4%, p = 0.03 -- with a relative risk reduction of 38.3% for hospitalization and of 52% for heart-failure-related death, the two counted separately rather than as one composite

primary_oa: https://pubmed.ncbi.nlm.nih.gov/34395116/

Zhao 2022 PMID 35874853

This review's decision: screened, not eligible.

A randomised comparison of sacubitril/valsartan with enalapril, 52 against 45, in pulmonary hypertension due to heart failure with reduced ejection fraction, followed for six months. Population and comparator hold; the measure does not. Its declared primary endpoint is echocardiographic right-ventricular function, and it reports no hazard ratio for any clinical event -- it states only that readmission for recurrent heart failure did not differ. Worth recording how that was confirmed: the full text does contain four instances of the string "HR", and every one of them is the abbreviation for heart rate in a table of baseline characteristics. A search for the quantity rather than for the string is the reason this row says no hazard ratio instead of the reverse.

  • measure

What it actually reports: right-ventricular function at six months -- tricuspid annular plane systolic excursion, systolic pulmonary artery pressure and their ratio -- as means with standard deviations, alongside major adverse cardiac events given as counts per arm

primary_oa: https://pubmed.ncbi.nlm.nih.gov/35874853/

Li 2019

This review's decision: screened, eligibility could not be established.

Eligibility is undetermined, not decided. Neither inclusion nor exclusion is asserted here, and the trial is not pooled -- so this row records a limit of the search rather than a judgement about the trial. Its likely weight is small and is stated rather than used as a reason to stop looking: 126 randomised participants against the 8399 of the largest trial already pooled. If this trial does report the composite as a time-to-first hazard ratio, this object is missing it, and this row is the place that will say so.

What it actually reports: Not established, and this row links the only document in which this trial was actually read. What that document states is that it is a randomised trial of sacubitril/valsartan against enalapril in elderly patients with dilated cardiomyopathy, 62 against 64, followed for six months, and that it contributed to that review's all-cause mortality pool, which that review analysed as a dichotomous risk ratio rather than as a time-to-event quantity. What could not be established is what the trial itself reports, because the trial itself could not be retrieved: it is cited to Chinese Journal of Geriatrics 2019, pages 520 to 524, with no DOI to resolve; a PubMed search returns no record for it, and a Crossref bibliographic query returns no matching work. All three were tried on the date in this row. It is therefore recorded as undetermined rather than assigned the exclusion its neighbours received -- an earlier version of the reconciliation block did assert that it reports no time-to-first hazard ratio, which nothing staged supported then and nothing supports now.

prior_meta: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710849/

Every record the search retrieved

Every record the registered search retrieved, listed individually with the decision, the stage at which it was taken, and for an exclusion the axis it failed and the quantity it reports instead. Exclusions are on the outcome axis as often as on quality, which is what the pre-registered estimand criterion produces: a large, well-conducted, on-topic trial is excluded when it reports something that cannot be converted into a time-to-first-event hazard ratio. Two records are undetermined, not excluded.

Table 9. Every record the search retrieved
FullText/INCLUDE7
FullText/exclude2
TiAb/exclude412
TiAb/undetermined2
Table 10. Every record the search retrieved
SourceRecordTitleStageDecisionAxis failedWhat it reports instead
PubMed42542200Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: insights from the premier study
American heart journal 2026
TiAbexcludeCOMPARATORNT-proBNP response; Premier randomised against standard treatment, not enalapril
PubMed42382224Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment
Journal of cardiac failure - intersections 2026
TiAbexcludeRANDOMISATIONdiscrete-choice preference weights
PubMed42211603Expert Opinion on Optimising Guideline-Directed Medical Therapy and Expanding the Role of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) for Heart Failure Management in India
Cureus 2026
TiAbexcludeRANDOMISATIONnarrative expert opinion
PubMed41923142Sacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
Cardiology in review 2026
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed41912806The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial
Nature medicine 2026
TiAbexcludeINTERVENTIONXXB750 is the intervention; sacubitril/valsartan is an active reference arm
PubMed41910669You evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas disease
Heart failure reviews 2026
TiAbexcludeRANDOMISATIONnarrative commentary on PARACHUTE-HF
PubMed41870675ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling
Heart failure reviews 2026
TiAbexcludeRANDOMISATIONnarrative commentary on ANSWER-HF
PubMed41773097Efficacy and Safety of Sacubitril/Valsartan Versus Enalapril in the Treatment of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
Cureus 2026
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed41725865Challenges in managing pediatric heart failure, especially in resource-limited settings
Annals of pediatric cardiology 2025
TiAbexcludeRANDOMISATIONeditorial narrative
PubMed41501364Early drop in blood pressure following angiotensin receptor-neprilysin inhibitor initiation in decompensated heart failure
Hypertension research 2026
TiAbexcludeRANDOMISATIONobservational blood-pressure change
PubMed41396086Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial
Journal of the American College of Cardiology 2026
FullTextINCLUDE—
PubMed41335448Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial (PARACHUTE-HF)
Jama 2026
FullTextINCLUDE—
PubMed41085477Reply to the letter regarding the article Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial
European journal of heart failure 2025
TiAbexcludeRANDOMISATIONcorrespondence
PubMed41085412Letter regarding the article Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial
European journal of heart failure 2025
TiAbexcludeRANDOMISATIONcorrespondence
PubMed40916703Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial
European journal of heart failure 2025
TiAbexcludeOUTCOMEbaseline characteristics only; no effect estimate of any kind
PubMed40839760Sacubitril/valsartan and quality of life assessed using the EQ-5D-3L level sum score in patients with HFrEF and HFmrEF/HFpEF
European heart journal. Cardiovascular pharmacotherapy 2025
TiAbexcludeOUTCOMEEQ-5D-3L level sum score change
PubMed40835369Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines
Journal of the American College of Cardiology 2025
TiAbexcludeRANDOMISATIONnarrative review
PubMed40755965Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis
Clinical kidney journal 2025
TiAbexcludeRANDOMISATIONpooled renal outcome estimates
PubMed40678912Changes in cardiac structure and function are associated with health-related quality of life in HFrEF: Results from the EVALUATE-HF trial
European journal of heart failure 2025
TiAbexcludeOUTCOMEassociation between echocardiographic change and KCCQ score
PubMed40510943Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial
Journal of pharmacy and bioallied sciences 2025
TiAbexcludeOUTCOMEchange in LVEF at 6 months
PubMed40450497Effects of Sacubitril/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Heart, lung and circulation 2025
TiAbexcludeRANDOMISATIONpooled renal function estimates
PubMed40389107Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the premier Study
Journal of cardiac failure 2026
TiAbexcludeCOMPARATORPremier randomised against standard treatment, not enalapril
PubMed40353367Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF
ESC heart failure 2025
TiAbexcludeOUTCOMEassociation between NT-proBNP change and outcomes
PubMed40319618Cost-Effectiveness Analysis of ARNI Compared With ACEI Among Patients With HFrEF in Malaysia
Value in health regional issues 2025
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed40268473Effects of Sacubitril/Valsartan on Myocardial Tissue in Heart Failure With Left Ventricular Ejection Fraction Below 50
Circulation journal 2025
TiAbexcludeOUTCOMEmyocardial tissue characterisation measures
PubMed40265590Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With HFrEF in PARADIGM-HF
Journal of the American Heart Association 2025
TiAbexcludeOUTCOMEsex-subgroup hazard ratios, not the trial-level estimand; secondary report of PARADIGM-HF
PubMed40088233Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
Jacc. Heart failure 2025
TiAbexcludeOUTCOMEnatriuretic-peptide subgroup estimates pooled across an HFrEF and an HFpEF trial
PubMed39970741Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials
Jacc. Advances 2025
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed39927747Impact of heart failure medications on cognitive function: A systematic review
European journal of clinical investigation 2025
TiAbexcludeRANDOMISATIONnarrative synthesis of cognitive outcomes
PubMed39888167Real-world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure
ESC heart failure 2025
TiAbexcludeRANDOMISATIONadjusted estimates from a non-randomised cohort
PubMed39792134Sacubitril/valsartan versus valsartan initiation in patients naive to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF
European journal of heart failure 2025
TiAbexcludeCOMPARATORcomparator is valsartan
PubMed39661383Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure
Jama cardiology 2025
TiAbexcludeRANDOMISATIONprescribing proportions
PubMed39563094Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with HFrEF: Insights from PARADIGM-HF
European journal of heart failure 2025
TiAbexcludeOUTCOMEbackground-therapy subgroup estimates; secondary report of PARADIGM-HF
PubMed39544776Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan
American journal of translational research 2024
TiAbexcludePOPULATIONpost-acute myocardial infarction, not chronic HFrEF
PubMed39473218The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis
ESC heart failure 2025
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed39439294Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of PARADIGM-HF and PARAGON-HF
European journal of heart failure 2025
TiAbexcludeOUTCOMEheart-rate change and its association with outcome
PubMed39387766Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials
Jacc. Heart failure 2025
TiAbexcludeOUTCOMErace-subgroup estimates pooled across an HFrEF and an HFpEF trial
PubMed39320292Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in HFrEF in PARADIGM-HF
Journal of the American College of Cardiology 2024
TiAbexcludeOUTCOMEhypotension event rates
PubMed39319469Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial
Circulation 2024
FullTextexcludePOPULATIONchildren 1 month to <18 years. Also fails outcome: global rank endpoint, Mann-Whitney probability 0.52 (0.47-0.58), MW odds 0.91 (0.72-1.14).
PubMed39284545Incidence and risk factors of hypotension-related adverse events among Japanese patients receiving sacubitril/valsartan or enalapril: PARALLEL-HF
Journal of cardiology 2025
TiAbexcludeOUTCOMEhypotension-related adverse event incidence
PubMed39262640Influenza Vaccination and Cardiovascular Events in Japanese Patients With Heart Failure - Findings From the PARALLEL-HF Trial
Circulation reports 2024
TiAbexcludeOUTCOMEvaccination-stratified event rates
PubMed39260836Comparative effects of sacubitril/valsartan and ACEI/ARB on endothelial function and arterial stiffness: a protocol for systematic review and meta-analysis
BMJ open 2024
TiAbexcludeRANDOMISATIONprotocol for a synthesis; no results
PubMed39217458Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: IPD Analysis of 6 Randomized Clinical Trials
Circulation 2024
TiAbexcludeOUTCOMEstandardised kidney composite outcomes
PubMed39215531In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the premier trial
European heart journal 2024
TiAbexcludeCOMPARATORrandomised against standard treatment, not enalapril
PubMed39210725Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of PARADIGM-HF and PARAGON-HF
Jama cardiology 2024
TiAbexcludeOUTCOMEall-cause hospitalisation rates
PubMed39163041Sacubitril-Valsartan in Patients Requiring Hemodialysis
Jama network open 2024
TiAbexcludePOPULATIONhaemodialysis population
PubMed39111953Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial
Jacc. Heart failure 2024
TiAbexcludeOUTCOMEtrial design description; no effect estimate
PubMed38938237Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction
Jacc. Advances 2023
TiAbexcludeOUTCOMEcognitive outcome measures
PubMed38904251Aptamer Proteomics for Biomarker Discovery in HFpEF: The PARAGON-HF Proteomic Substudy
Journal of the American Heart Association 2024
TiAbexcludePOPULATIONHFpEF
PubMed38863978Effect of sacubitril-valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary PCI: a systematic review and meta-analysis
Frontiers in pharmacology 2024
TiAbexcludeRANDOMISATIONpooled remodelling estimates
PubMed38842957Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2
Jacc. Heart failure 2024
TiAbexcludeOUTCOMErenal-function subgroup estimates
PubMed38764991Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials
Hospital pharmacy 2024
TiAbexcludeRANDOMISATIONnarrative review of trials
PubMed38705701Sacubitril-valsartan vs ACE/ARB in pediatric heart failure: A retrospective cohort study
Journal of heart and lung transplantation 2024
TiAbexcludeRANDOMISATIONretrospective cohort estimates
PubMed38635062Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in AMI complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial
Heart and vessels 2024
TiAbexcludePOPULATIONacute myocardial infarction with mitral regurgitation
PubMed38597935Sacubitril/valsartan compared to equivalent/sub-equivalent dose ARB or ACEI in HFrEF: a meta-analysis of randomized trials
European journal of clinical pharmacology 2024
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed38588927Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
Journal of the American College of Cardiology 2024
TiAbexcludeOUTCOMErenal-function subgroup estimates
PubMed38508844Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Journal of the American College of Cardiology 2024
TiAbundetermined—title does not name comparator or reported quantity; abstract not retrieved before the ClinicalTrials.gov 429 halt. Carried to full text.
PubMed38465175The Safety and Efficacy of the Early Use of Sacubitril/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials
Cureus 2024
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed38216822Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy
Cardiology and therapy 2024
TiAbexcludeCOMPARATORno enalapril comparator; add-on design
PubMed38134075Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia
Medicine 2023
TiAbexcludeRANDOMISATIONdescriptive real-world statistics
PubMed37989299Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients According to Baseline Systolic Blood Pressure - Subgroup Analysis of PARALLEL-HF
Circulation journal 2023
TiAbexcludeOUTCOMEblood-pressure subgroup estimates; secondary report of PARALLEL-HF
PubMed37917889Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Alternative therapies in health and medicine 2024
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed37619492Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
The American journal of cardiology 2023
TiAbexcludeRANDOMISATIONpooled ascvd event estimates
PubMed37601056The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis
Frontiers in pharmacology 2023
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed37554618Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis
Cureus 2023
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed37427009Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
Cardiac failure review 2023
TiAbexcludeRANDOMISATIONnarrative review
PubMed37407154Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
Jacc. Heart failure 2023
TiAbexcludeOUTCOMEanaemia incidence and prevalence
PubMed37313196Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
Archives of medical science 2023
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed37195574The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis
International urology and nephrology 2024
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed37077749Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with ACEI and spironolactone
Frontiers in cardiovascular medicine 2023
TiAbexcludeOUTCOMEechocardiographic reverse-remodelling measures
PubMed37000983Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis
Journal of cardiovascular pharmacology 2023
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed36943907Urinary cGMP/BNP Ratio, Sacubitril/Valsartan, and Outcomes in HFrEF: An Analysis of the PARADIGM-HF Trial
Circulation. Heart failure 2023
TiAbexcludeOUTCOMEbiomarker ratio and its association with outcome
PubMed36874318The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With HFrEF
Cureus 2023
TiAbexcludeOUTCOMEventricular arrhythmia burden
PubMed36871177Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis
Journal of cardiovascular electrophysiology 2023
TiAbexcludeRANDOMISATIONpooled atrial fibrillation incidence
PubMed36812948Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure
Journal of the American College of Cardiology 2023
TiAbexcludeOUTCOMErenal function change
PubMed36808581Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in HFrEF in Argentina
Health economics review 2023
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed36712243Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
Frontiers in cardiovascular medicine 2022
TiAbexcludePOPULATIONacute myocardial infarction
PubMed36609948Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Cardiovascular drugs and therapy 2024
TiAbexcludeRANDOMISATIONadjusted estimates from a comparative non-randomised study
PubMed36601956Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial
Circulation. Heart failure 2023
TiAbexcludePOPULATIONpaediatric population
PubMed36561058Effectiveness of sacubitril-valsartan versus ACE inhibitors in patients hospitalized for acute heart failure: a retrospective cohort study of the rica registry
Journal of geriatric cardiology 2022
TiAbexcludeRANDOMISATIONretrospective registry estimates
PubMed36530836Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension
Circulation reports 2022
TiAbexcludeOUTCOMEglycaemic measures
PubMed36527023Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials
BMC medicine 2022
TiAbexcludeRANDOMISATIONpooled glycaemic estimates
PubMed36475871Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis
The Annals of pharmacotherapy 2023
TiAbexcludeRANDOMISATIONpooled quality-of-life estimates
PubMed36404386Estimating the Time to Benefit for Therapies in HFrEF: A Case Study of Sacubitril-Valsartan Using Reconstructed Data from a Randomized Controlled Trial
Drugs and aging 2022
TiAbexcludeOUTCOMEtime-to-benefit estimate reconstructed from published curves
PubMed36304540A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction
Frontiers in cardiovascular medicine 2022
TiAbexcludeRANDOMISATIONpooled remodelling estimates
PubMed36148074Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
Frontiers in cardiovascular medicine 2022
TiAbexcludeRANDOMISATIONpooled arrhythmia and sudden-death estimates
PubMed36132549The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure (retracted)
Computational and mathematical methods in medicine 2022
TiAbexcludePOPULATIONHFpEF; record is a retracted publication
PubMed36062622Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease
Journal of the American Heart Association 2022
TiAbexcludePOPULATIONend-stage kidney disease
PubMed35990952Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials
Frontiers in cardiovascular medicine 2022
TiAbexcludeRANDOMISATIONpooled quality-of-life estimates
PubMed35921043Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
ESC heart failure 2022
TiAbexcludeRANDOMISATIONnarrative review
PubMed35874853The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
Pulmonary circulation 2022
TiAbexcludeOUTCOMEpulmonary haemodynamic measures
PubMed35859597Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Frontiers in cardiovascular medicine 2022
TiAbexcludeRANDOMISATIONpooled arrhythmia estimates
PubMed35772853Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the life Trial Run-In
Jacc. Heart failure 2022
TiAbexcludeCOMPARATORLife randomised against valsartan; this record reports run-in tolerability
PubMed35761118The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review
Drugs and aging 2022
TiAbexcludeRANDOMISATIONpooled adverse-event prevalence
PubMed35717169Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
Cardiovascular diabetology 2022
TiAbexcludeOUTCOMEglycaemic measures
PubMed35654526Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF
Jacc. Heart failure 2022
TiAbexcludeOUTCOMEdiuretic-use subgroup estimates
PubMed35560696Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in HFrEF: the EVALUATE-HF trial
European journal of heart failure 2022
TiAbexcludeOUTCOMEbiomarker and echocardiographic change
PubMed35523577Angiotensin-converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects
Clinical transplantation 2022
TiAbexcludePOPULATIONheart transplant recipients
PubMed35469709Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: Position Paper of the Italian Society of Cardiology
European journal of internal medicine 2022
TiAbexcludeRANDOMISATIONconsensus statement
PubMed35400328Effects of Sacubitril/Valsartan Versus Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: Rationale and Design
Cardiovascular and hematological disorders drug targets 2022
TiAbexcludePOPULATIONhypertension without heart failure
PubMed35343504Position paper of the Italian Society of Cardiology: Raas blockade in heart failure patients - Part I (Italian)
Giornale italiano di cardiologia 2022
TiAbexcludeRANDOMISATIONconsensus statement
PubMed35282662Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial
Cardiovascular diagnosis and therapy 2022
TiAbexcludePOPULATIONacute anterior STEMI, not chronic HFrEF
PubMed35222898The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, apn, mmp-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure
Journal of healthcare engineering 2022
TiAbexcludeCOMPARATORcomparator is valsartan
PubMed35200707What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
Journal of cardiovascular development and disease 2022
TiAbexcludeRANDOMISATIONnarrative review
PubMed35081164Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials
PloS one 2022
TiAbexcludeRANDOMISATIONpooled atrial fibrillation estimates
PubMed35035857Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis (retracted)
Journal of healthcare engineering 2022
TiAbexcludeRANDOMISATIONpooled estimate; record is a retracted publication
PubMed35027945Long-Term Mortality and Morbidity Related to CHFrEF in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study
Journal of the renin-angiotensin-aldosterone system 2021
TiAbexcludeRANDOMISATIONsingle-arm pilot statistics
PubMed34988519Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement
Heart rhythm O2 2021
TiAbexcludeRANDOMISATIONdescriptive prescribing statistics
PubMed34969175Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF
European journal of heart failure 2022
TiAbexcludeOUTCOMEventricular arrhythmia event estimates
PubMed34889576Variation in early diffusion of sacubitril/valsartan and implications for understanding novel drug diffusion
The American journal of managed care 2021
TiAbexcludeRANDOMISATIONprescribing diffusion statistics
PubMed34797518Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis
Clinical drug investigation 2022
TiAbexcludeRANDOMISATIONnetwork meta-analysis estimates
PubMed34783839Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in HFpEF: The parallax Randomized Clinical Trial
Jama 2021
TiAbexcludeCOMPARATORcomparator is individualised standard medical therapy; population HFpEF
PubMed34758252Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction (PARADISE-MI)
The New England journal of medicine 2021
TiAbexcludeCOMPARATORcomparator is ramipril; population acute myocardial infarction
PubMed34716749The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis
ESC heart failure 2021
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed34703947The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with HFrEF
Archives of medical sciences. Atherosclerotic diseases 2021
TiAbexcludeINTERVENTIONintervention is dapagliflozin
PubMed34675566Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
ClinicoEconomics and outcomes research 2021
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed34668596Rationale and design of a multi-center randomized controlled trial on sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study
Clinical cardiology 2021
TiAbexcludePOPULATIONST-elevation myocardial infarction
PubMed34645527Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data
Cardio-oncology 2021
TiAbexcludeRANDOMISATIONreal-world descriptive statistics
PubMed34617669Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis
Pharmacology research and perspectives 2021
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed34591356A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs enalapril on peak oxygen consumption in HFrEF: the ACTIVITY-HF study
European journal of heart failure 2021
TiAbexcludeOUTCOMEpeak oxygen consumption
PubMed34570120Anmco Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure (Italian)
Giornale italiano di cardiologia 2021
TiAbexcludeRANDOMISATIONconsensus statement
PubMed34464468Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis
Clinical cardiology 2021
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed34456644Anmco position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure
European heart journal supplements 2021
TiAbexcludeRANDOMISATIONconsensus statement
PubMed34428592Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With HFrEF
Journal of cardiac failure 2021
TiAbexcludeOUTCOMEaccelerometer-derived sleep measures
PubMed34402869Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis
European journal of preventive cardiology 2021
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed34395116Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
Cureus 2021
TiAbundetermined—title names the right comparison but neither design nor reported quantity is determinable from it; abstract not retrieved before the halt. Carried to full text.
PubMed34350772Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
Journal of the American Heart Association 2021
TiAbexcludeRANDOMISATIONobservational effectiveness estimates
PubMed34125356Five Years of Sacubitril/Valsartan - a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
Cardiovascular drugs and therapy 2022
TiAbexcludeRANDOMISATIONpooled safety estimates and pharmacovigilance signals
PubMed34101308Effect of sacubitril/valsartan vs enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial
European journal of heart failure 2021
TiAbexcludeOUTCOMEchanges in background heart failure therapy over time
PubMed34101002Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and atmosphere
Clinical research in cardiology 2021
TiAbexcludeOUTCOMEprognostic model discrimination and calibration
PubMed33997628Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or ACEI/ARB
Mayo Clinic proceedings. Innovations, quality and outcomes 2021
TiAbexcludeRANDOMISATIONobservational renal outcome estimates
PubMed33992607Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study
American heart journal 2021
TiAbexcludeOUTCOMEexercise capacity (peak VO2 / 6-minute walk)
PubMed33984319Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and charm trials
American heart journal 2021
TiAbexcludeOUTCOMEdays alive and out of hospital
PubMed33931815Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper
Heart failure reviews 2022
TiAbexcludeRANDOMISATIONconsensus statement
PubMed33929386Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials
Journal of cardiovascular pharmacology 2021
TiAbexcludeRANDOMISATIONpooled adverse-event estimates
PubMed33879733A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial
Medicine 2021
TiAbexcludeINTERVENTIONsequential recombinant human BNP strategy; no enalapril comparator
PubMed33850915Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
Annals of translational medicine 2021
TiAbexcludeRANDOMISATIONnarrative review
PubMed33847047Prospective ARNI vs ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics
European journal of heart failure 2021
TiAbexcludeCOMPARATORcomparator is ramipril; population acute myocardial infarction
PubMed33822031Renal protection in chronic heart failure: focus on sacubitril/valsartan
European heart journal. Cardiovascular pharmacotherapy 2021
TiAbexcludeRANDOMISATIONnarrative review
PubMed33733623The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long-term studies
ESC heart failure 2021
TiAbexcludeOUTCOMErestricted mean survival time (methodological paper)
PubMed33731544Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study
Circulation journal 2021
FullTextINCLUDE—Meets all four. Randomised 1:1; 225 Japanese adults NYHA ii-iv LVEF<=35%; sacubitril/valsartan 200 mg bid vs enalapril 10 mg bid; composite of CV death or HF hospitalisation as hazard ratio 1.09 (95% CI 0.65-1.82), P=0.6260, median follow-up 33.9 months.
PubMed33663237Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study
Circulation. Heart failure 2021
TiAbexcludeOUTCOMEhaemodynamic and aortic stiffness measures
PubMed33624080Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure
European journal of preventive cardiology 2021
TiAbexcludeRANDOMISATIONnarrative review
PubMed33545266Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review
International journal of cardiology 2021
TiAbexcludeRANDOMISATIONsynthesis of observational studies
PubMed33530704Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
Circulation. Heart failure 2021
TiAbexcludeOUTCOMEtime-averaged proportional change in NT-proBNP
PubMed33522249Clinical Characteristics and Outcomes of Patients With HFrEF and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF
Journal of the American Heart Association 2021
TiAbexcludeOUTCOMECOPD subgroup estimates
PubMed33489085Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Therapeutic advances in endocrinology and metabolism 2020
TiAbexcludeRANDOMISATIONnarrative mechanistic review
PubMed33357641Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
Indian heart journal 2020
TiAbexcludeOUTCOMEregional subgroup estimates; secondary report of PARADIGM-HF
PubMed33314487OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in HFrEF
European journal of heart failure 2021
TiAbexcludeOUTCOMEaccelerometer-measured daily physical activity
PubMed33305513Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
ESC heart failure 2021
TiAbexcludeOUTCOMEleft ventricular remodelling measures
PubMed33301829Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence
International journal of cardiology 2021
TiAbexcludeRANDOMISATIONnarrative viewpoint
PubMed33292750Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
Cardio-oncology 2020
TiAbexcludePOPULATIONchemotherapy-induced cardiotoxicity
PubMed33277825Heart failure in the last year: progress and perspective
ESC heart failure 2020
TiAbexcludeRANDOMISATIONnarrative review
PubMed33257469Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
Open heart 2020
TiAbexcludeRANDOMISATIONpooled estimate with trial sequential analysis
PubMed33211601Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction
Journal of applied physiology 2021
TiAbexcludeOUTCOMEvascular function and inflammatory markers
PubMed33189630Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction
Jacc. Heart failure 2021
TiAbexcludeRANDOMISATIONobservational health-status change
PubMed33155868Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic
Metabolic syndrome and related disorders 2021
TiAbexcludeRANDOMISATIONobservational metabolic parameter change
PubMed33068250Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study
Internal and emergency medicine 2021
TiAbexcludeRANDOMISATIONobservational management statistics
PubMed33039448Estimating the Lifetime Benefits of Treatments for Heart Failure
Jacc. Heart failure 2020
TiAbexcludeOUTCOMEprojected event-free survival gain
PubMed32978755The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure
American journal of cardiovascular drugs 2021
TiAbexcludeOUTCOMEaccelerometer-measured activity and sleep
PubMed32977362Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials
ESC heart failure 2020
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed32945737Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure
Journal of medical economics 2020
TiAbexcludeRANDOMISATIONhealth-system adoption case study
PubMed32919915Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial
Jacc. Heart failure 2020
TiAbexcludeOUTCOMENT-proBNP change by race subgroup
PubMed32919914Similar Yet Different: Examining the Effects of Sacubitril/Valsartan by Race in the PIONEER-HF Trial
Jacc. Heart failure 2020
TiAbexcludeRANDOMISATIONeditorial comment
PubMed32868662Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention
Coronary artery disease 2021
TiAbexcludePOPULATIONST-elevation myocardial infarction
PubMed32854838Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
Journal of the American College of Cardiology 2020
TiAbexcludeOUTCOMEsubgroup estimates by prior therapy history
PubMed32848403Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
Therapeutics and clinical risk management 2020
TiAbexcludeRANDOMISATIONnarrative review
PubMed32809261Serum potassium in the PARADIGM-HF trial
European journal of heart failure 2020
TiAbexcludeOUTCOMEserum potassium and hyperkalaemia rates
PubMed32801725Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
Therapeutics and clinical risk management 2020
TiAbexcludeRANDOMISATIONnarrative review
PubMed32800511Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial
Jacc. Heart failure 2020
TiAbexcludeOUTCOMENT-proBNP change by achieved dose
PubMed32800508NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: Transition Study
Jacc. Heart failure 2020
TiAbexcludeCOMPARATORpre-discharge vs post-discharge initiation; no enalapril comparator. Reports NT-proBNP response.
PubMed32739172Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis
European journal of pharmacology 2020
TiAbexcludeRANDOMISATIONpooled estimate across trials
PubMed32648251Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure
Cardiology journal 2020
TiAbexcludeRANDOMISATIONfeasibility and tolerability proportions
PubMed32641226Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the life Trial
Jacc. Heart failure 2020
TiAbexcludeCOMPARATORcomparator is valsartan
PubMed32468672Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in HFrEF
European journal of heart failure 2020
TiAbexcludeOUTCOMEaccelerometer-measured physical activity
PubMed32466836Use of the Win Ratio in Cardiovascular Trials
Jacc. Heart failure 2020
TiAbexcludeOUTCOMEwin ratio (methodological paper)
PubMed32407608Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction
European journal of heart failure 2020
TiAbexcludeOUTCOMEliver-function subgroup and prognostic estimates
PubMed32369265Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (theseus)
ESC heart failure 2020
TiAbexcludeRANDOMISATIONprospective observational statistics
PubMed32297449Angiotensin receptor neprilysin inhibition versus individualized raas blockade: design and rationale of the parallax trial
ESC heart failure 2020
TiAbexcludeCOMPARATORcomparator is individualised raas blockade
PubMed32259909LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials
Reviews in cardiovascular medicine 2020
TiAbexcludeRANDOMISATIONpooled renal estimates
PubMed32248695Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction
Circulation. Heart failure 2020
TiAbexcludeRANDOMISATIONrepresentativeness proportions
PubMed32221582Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
European heart journal 2020
TiAbexcludeINTERVENTIONintervention is dapagliflozin
PubMed36263291Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
International journal of heart failure 2020
TiAbexcludeRANDOMISATIONnarrative review
PubMed32153122Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease
ESC heart failure 2020
TiAbexcludePOPULATIONend-stage renal disease
PubMed32128057Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
Journal of community hospital internal medicine perspectives 2020
TiAbexcludeRANDOMISATIONsingle-centre tolerability proportions
PubMed32021227Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
Vascular health and risk management 2020
TiAbexcludeRANDOMISATIONnarrative review
PubMed32000355New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis
Medicine 2020
TiAbexcludeRANDOMISATIONBayesian network meta-analysis estimates
PubMed31997538Highlights in heart failure
ESC heart failure 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed31995119Prognostic Models Derived in PARADIGM-HF and Validated in atmosphere and the Swedish Heart Failure Registry
Jama cardiology 2020
TiAbexcludeOUTCOMEprognostic model performance
PubMed31906682Innovations in pharmacological treatment of heart failure (Czech)
Vnitrni lekarstvi 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed31838035Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction
Jacc. Heart failure 2020
TiAbexcludeRANDOMISATIONobservational comparative effectiveness estimates
PubMed31825471Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial
Jama cardiology 2020
TiAbexcludeOUTCOMENT-proBNP change in open-label extension
PubMed31789711The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016
Journal of cardiovascular medicine 2020
TiAbexcludeRANDOMISATIONeligibility proportions in a cohort
PubMed31772612LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
Cardiovascular therapeutics 2019
TiAbexcludePOPULATIONrat model, not adult humans
PubMed36262737Real-World Eligibility for Sacubitril/Valsartan in HFrEF Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry
International journal of heart failure 2019
TiAbexcludeRANDOMISATIONregistry eligibility proportions
PubMed31638338Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rationale and design of the AWAKE-HF study
ESC heart failure 2019
TiAbexcludeOUTCOMEaccelerometer-measured activity
PubMed31625704Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction (retracted)
Minerva cardioangiologica 2019
TiAbexcludeOUTCOMElongitudinal strain; record is a retracted publication
PubMed31617977ARNI (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how? (French)
Revue medicale suisse 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed31559483Optimizing heart failure treatment following cardiac resynchronization therapy
Clinical research in cardiology 2020
TiAbexcludeOUTCOMEpost-CRT optimisation outcomes
PubMed31531687ARNIs: balancing the good and the bad of neuroendocrine response to HF
Clinical research in cardiology 2020
TiAbexcludeRANDOMISATIONcommentary
PubMed31514513Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan
Journal of cardiovascular pharmacology and therapeutics 2020
TiAbexcludeRANDOMISATIONobservational real-world estimates
PubMed31510768Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With HFrEF: PARADIGM-HF
Circulation 2019
TiAbexcludeOUTCOMEprognostic association of congestion score
PubMed31498903Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System
Pharmacotherapy 2019
TiAbexcludeRANDOMISATIONeligibility proportions
PubMed31475296Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (EVALUATE-HF)
Jama 2019
TiAbexcludeOUTCOMEchange in aortic characteristic impedance
PubMed31219361Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
Expert review of pharmacoeconomics and outcomes research 2020
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed31172710Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
Korean circulation journal 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed31132222Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry
European journal of heart failure 2019
TiAbexcludeRANDOMISATIONregistry eligibility and outcome proportions
PubMed31119890Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction
ESC heart failure 2019
TiAbexcludeINTERVENTIONintervention is hydralazine/nitrates
PubMed31101372Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea
Clinical therapeutics 2019
TiAbexcludeRANDOMISATIONcost-utility ratio
PubMed31093657Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
European heart journal 2019
TiAbexcludeOUTCOMEbiomarker concentration change
PubMed31078482Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF
Jacc. Heart failure 2019
TiAbexcludeOUTCOMEaetiology subgroup estimates; secondary report of PARADIGM-HF
PubMed31029493Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure
Revista portuguesa de cardiologia 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed31023122Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus ACEI or ARB in a Retrospective Analysis of Patients With Heart Failure
Journal of the American Heart Association 2019
TiAbexcludeRANDOMISATIONretrospective cost and utilisation estimates
PubMed30982680Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation
Journal of cardiology 2019
TiAbexcludeRANDOMISATIONobservational tolerability statistics
PubMed30955360Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
Circulation 2019
TiAbexcludeOUTCOMEexploratory composite of death, HF rehospitalisation, lvad implantation or transplant listing; not the pre-specified estimand and not the trial primary
PubMed30846338B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial
Journal of the American College of Cardiology 2019
TiAbexcludeOUTCOMEBNP and NT-proBNP concentrations
PubMed30796605Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities
Irish journal of medical science 2019
TiAbexcludeRANDOMISATIONeligibility proportions
PubMed30788621Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction
Clinical research in cardiology 2019
TiAbexcludeRANDOMISATIONobservational arrhythmia burden change
PubMed30784673Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF
Journal of the American College of Cardiology 2019
TiAbexcludeOUTCOMEextracellular matrix biomarker change
PubMed30741494Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial
European journal of heart failure 2019
TiAbexcludeOUTCOMEloop diuretic dose change
PubMed30679005Sacubitril/valsartan: A practical guide
Revista portuguesa de cardiologia 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed30484837Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With ARNI vs Standard Therapy for HFrEF: An Analysis of Data From the PARADIGM-HF Trial
Jama cardiology 2018
TiAbexcludeOUTCOME5-year number needed to treat
PubMed30415601Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure (PIONEER-HF)
The New England journal of medicine 2019
TiAbexcludeOUTCOMEtime-averaged proportional change in NT-proBNP from baseline to weeks 4 and 8
PubMed30414818Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization
Jacc. Heart failure 2019
TiAbexcludeRANDOMISATIONnarrative review of prescribing practice
PubMed30359220Novel Possibilities in Pharmacotherapy of Patients With Chronic Heart Failure (Russian)
Kardiologiia 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed30281045Anmco position paper on sacubitril/valsartan in the management of patients with heart failure (Italian)
Giornale italiano di cardiologia 2018
TiAbexcludeRANDOMISATIONconsensus statement
PubMed30204280Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with HFrEF: the PARADIGM-HF trial
European journal of heart failure 2018
TiAbexcludeOUTCOMEGDF-15 concentration and its prognostic association
PubMed30122239Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
Indian heart journal 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed30054868Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
PharmacoEconomics 2018
TiAbexcludeRANDOMISATIONcost-effectiveness and budget impact estimates
PubMed30047502Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial
Circulation journal 2018
TiAbexcludeOUTCOMEbaseline characteristics only; no effect estimate
PubMed29979147Sacubitril/Valsartan: potential treatment for paediatric heart failure
Cardiology in the young 2018
TiAbexcludePOPULATIONpaediatric
PubMed29945530The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series
Journal of oncology pharmacy practice 2019
TiAbexcludeRANDOMISATIONcase series
PubMed29926350Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost
American journal of cardiovascular drugs 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed29917003Sacubitril/valsartan: from a large clinical trial to clinical practice
Journal of cardiovascular medicine 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed29895587Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial
Journal of the American Heart Association 2018
TiAbexcludeRANDOMISATIONregistry-vs-trial descriptive comparison
PubMed29891240Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction
International journal of cardiology 2019
TiAbexcludeRANDOMISATIONnarrative review
PubMed29776559Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study
International journal of cardiology 2018
TiAbexcludeOUTCOMEangioedema event counts
PubMed29748349Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With HFrEF in the PARADIGM-HF Trial
Circulation. Heart failure 2018
TiAbexcludeOUTCOMEbiomarker prognostic association
PubMed29687191Sacubitril/Valsartan: From Clinical Trials to Real-world Experience
Current treatment options in cardiovascular medicine 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed29661699Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure receiving target doses of RAS inhibitors: a secondary analysis of the PARADIGM-HF trial
The lancet. Diabetes and endocrinology 2018
TiAbexcludeOUTCOMEeGFR decline rate
PubMed29655829Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Jacc. Heart failure 2018
TiAbexcludeOUTCOMErenal function change and associated outcomes
PubMed29653636Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
American heart journal 2018
TiAbexcludeOUTCOMENT-proBNP change (trial design paper)
PubMed29643067Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial
Circulation. Heart failure 2018
TiAbexcludeOUTCOMEhypotensive episode incidence
PubMed29617523Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial
Jama cardiology 2018
TiAbexcludeOUTCOMEKCCQ physical and social limitation scores
PubMed29601093Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States
Pharmacotherapy 2018
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed29544929Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction
International journal of cardiology 2018
TiAbexcludePOPULATIONexperimental animal model
PubMed29542073Combination Therapy of Renin Angiotensin System Inhibitors and Beta-Blockers in Patients with Heart Failure
Advances in experimental medicine and biology 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed29501368A novel agent in the treatment of heart failure with depressed systolic function (Spanish)
Archivos de cardiologia de Mexico 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed29469206Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design
ESC heart failure 2018
TiAbexcludeOUTCOMEapnoea-hypopnoea index
PubMed29464879Insights into implementation of sacubitril/valsartan into clinical practice
ESC heart failure 2018
TiAbexcludeRANDOMISATIONimplementation descriptive statistics
PubMed29464817The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease - existing evidence, knowledge gaps, and future directions
European journal of heart failure 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed29431251Effect of sacubitril/valsartan on recurrent events in PARADIGM-HF
European journal of heart failure 2018
FullTextexcludeOUTCOMERecurrent-event rate ratio: negative binomial RR 0.77 (0.67-0.89); Lwyy RR 0.78 (0.68-0.90); Wlw HR 0.79 (0.71-0.89); joint frailty HR 0.75 (0.66-0.86). Counts repeat events per person; the estimand counts each person once at first event.
PubMed29369824Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
Cardiology in review 2018
TiAbexcludeRANDOMISATIONnarrative review
PubMed29318651Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
British journal of clinical pharmacology 2018
TiAbexcludeOUTCOMEpharmacokinetic and pharmacodynamic parameters
PubMed29269379Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
Heart 2018
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed29265423PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions
Pharmacotherapy 2018
TiAbexcludeRANDOMISATIONnarrative review of secondary analyses
PubMed29239515Rationale and design of transition: a randomized trial of pre-discharge vs post-discharge initiation of sacubitril/valsartan
ESC heart failure 2018
TiAbexcludeCOMPARATORcomparator is a different initiation timing, not enalapril
PubMed29193563Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
European journal of heart failure 2018
TiAbexcludeOUTCOMEserum uric acid concentration
PubMed29185253Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
Swiss medical weekly 2017
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed29137346Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
Oncotarget 2017
TiAbexcludeRANDOMISATIONnarrative safety review
PubMed29129252Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study)
American heart journal 2017
TiAbexcludePOPULATIONpaediatric
PubMed29042791Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
Vascular health and risk management 2017
TiAbexcludeRANDOMISATIONnarrative review
PubMed28959905Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
Journal of medical economics 2018
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed28844335Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure
Revista portuguesa de cardiologia 2017
TiAbexcludeRANDOMISATIONnarrative review
PubMed28800834Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction
The American journal of cardiology 2017
TiAbexcludeRANDOMISATIONnarrative/systematic review of benefits and harms
PubMed28793821The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials
Journal of cardiovascular pharmacology and therapeutics 2017
TiAbexcludePOPULATIONhypertension, not heart failure
PubMed28784687Health-Related Quality of Life Outcomes in PARADIGM-HF
Circulation. Heart failure 2017
TiAbexcludeOUTCOMEKCCQ quality-of-life scores
PubMed28720639Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results
Journal of the American Board of Family Medicine 2017
TiAbexcludeRANDOMISATIONnarrative safety commentary
PubMed28577679The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
American heart journal 2017
TiAbexcludeOUTCOMEcoronary event outcomes, not the pre-specified composite
PubMed28330649Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
The lancet. Diabetes and endocrinology 2017
TiAbexcludeOUTCOMEHbA1c and glycaemic measures
PubMed28292483An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands
Value in health 2017
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed28285069Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure
The American journal of medicine 2017
TiAbexcludeRANDOMISATIONnarrative review
PubMed28281174Potential Expanded Indications for Neprilysin Inhibitors
Current heart failure reports 2017
TiAbexcludeRANDOMISATIONnarrative review
PubMed28244205What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
European journal of heart failure 2017
TiAbexcludeRANDOMISATIONeligibility proportions
PubMed28158398Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
European heart journal 2017
TiAbexcludeOUTCOMEblood-pressure subgroup estimates; secondary report of PARADIGM-HF
PubMed28133468Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
Journal of geriatric cardiology 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed28060547The safety of sacubitril-valsartan for the treatment of chronic heart failure
Expert opinion on drug safety 2017
TiAbexcludeRANDOMISATIONnarrative safety review
PubMed28024961Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study
Journal of cardiology 2017
TiAbexcludeOUTCOMEtrial design description; no effect estimate
PubMed28004291Sacubitril/Valsartan (LCZ696) in Heart Failure
Handbook of experimental pharmacology 2017
TiAbexcludeRANDOMISATIONnarrative review
PubMed27908347Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Journal of the American College of Cardiology 2016
TiAbexcludeOUTCOMEprognostic association of NT-proBNP change
PubMed27868321Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
European journal of heart failure 2017
TiAbexcludeOUTCOMEdementia-related adverse event rates
PubMed27842179Reduced Risk of Hyperkalemia During Treatment of Heart Failure With MRAs by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial
Jama cardiology 2017
TiAbexcludeOUTCOMEhyperkalaemia event rates
PubMed27747488Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Current cardiology reports 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed27618854Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial According to Background Therapy
Circulation. Heart failure 2016
TiAbexcludeOUTCOMEbackground-therapy subgroup estimates; secondary report of PARADIGM-HF
PubMed27574931Limitations of Sacubitril/Valsartan in the Management of Heart Failure
American journal of therapeutics 2017
TiAbexcludeRANDOMISATIONnarrative commentary
PubMed27573608Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience
International journal of cardiology 2016
TiAbexcludeRANDOMISATIONeditorial
PubMed27571284Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
Annals of internal medicine 2016
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed27471351Critical Questions about PARADIGM-HF and the Future
Acta Cardiologica Sinica 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed27438344Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Jama cardiology 2016
TiAbexcludeRANDOMISATIONincremental cost-effectiveness ratio
PubMed27417000Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
Journal of the American College of Cardiology 2016
TiAbexcludeOUTCOME30-day readmission rate
PubMed27395349Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial
Jacc. Heart failure 2016
TiAbexcludeOUTCOMEsubgroup estimates by prior decompensation; secondary report of PARADIGM-HF
PubMed27324636Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
Current atherosclerosis reports 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed27296397Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial
Circulation. Heart failure 2016
TiAbexcludeOUTCOMErun-in noncompletion proportions and their influence
PubMed27283779Efficacy of sacubitril/valsartan vs enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial
European journal of heart failure 2016
TiAbexcludeOUTCOMEachieved-dose subgroup estimates; secondary report of PARADIGM-HF
PubMed27274196Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date
Drug design, development and therapy 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed27207980The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
Heart 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed27170530Initiating sacubitril/valsartan (LCZ696) in heart failure: results of titration, a double-blind, randomized comparison of two uptitration regimens
European journal of heart failure 2016
TiAbexcludeCOMPARATORcomparator is a second uptitration regimen, not enalapril
PubMed27143684Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From PARADIGM-HF
Circulation 2016
TiAbexcludeOUTCOMEoutpatient worsening event rates
PubMed27092662Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies
Journal of cardiovascular pharmacology 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed27038730The paradigm of ARNIs: Assessing reasons for non-implementation in heart failure
International journal of cardiology 2016
TiAbexcludeRANDOMISATIONeditorial
PubMed29144684Sacubitril / Valsartan -- Benefit Assessment According to Social Code Book V section 35a (IQWiG report; esummary title and journal fields were empty, resolved by efetch)
IQWiG Reports (non-journal) 2016
TiAbexcludeRANDOMISATIONhealth-technology-assessment benefit rating
PubMed26976916Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Circulation 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed26915374Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: PARADIGM-HF
Circulation. Heart failure 2016
TiAbexcludeOUTCOMEejection-fraction subgroup estimates; secondary report of PARADIGM-HF
PubMed26873495Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction
Drugs 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed26873036Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure
Expert review of clinical pharmacology 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed26754626Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF
Circulation. Heart failure 2016
TiAbexcludeOUTCOMEdiabetes-status subgroup estimates; secondary report of PARADIGM-HF
PubMed26746371Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial
Jacc. Heart failure 2016
TiAbexcludeOUTCOMEvaccination uptake and associated event rates
PubMed26626162A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction
Journal of clinical pharmacology 2016
TiAbexcludeRANDOMISATIONnarrative review
PubMed26541915Comparing LCZ696 with enalapril according to baseline risk using the maggic and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF
Journal of the American College of Cardiology 2015
TiAbexcludeOUTCOMErisk-score subgroup estimates; secondary report of PARADIGM-HF
PubMed26469827A new class of drugs for systolic heart failure: The PARADIGM-HF study
Cleveland Clinic journal of medicine 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed26386501Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure
Clinical therapeutics 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed26231885Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
European heart journal 2015
TiAbexcludeOUTCOMEage subgroup estimates; secondary report of PARADIGM-HF
PubMed26209000Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact
Journal of cardiac failure 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed26175499Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New paradigm
The Annals of pharmacotherapy 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed26049379Chronic heart failure: what does the horizon look like?
Current opinion in cardiology 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed26022006Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
European heart journal 2015
TiAbexcludeOUTCOMEmode-of-death specific hazard ratios, not the pre-specified composite
PubMed25864789LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
Journal of pharmacy practice 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed25849438Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
BMC medicine 2015
TiAbexcludeRANDOMISATIONcommentary
PubMed25833460LCZ696: the next step in improving RAS inhibition?
Current hypertension reports 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed25813256The new drug is much more effective than ACE inhibitors in chronic heart failure (Czech)
Vnitrni lekarstvi 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed25766951The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure
Journal of the American College of Cardiology 2015
TiAbexcludeRANDOMISATIONhistorical article
PubMed25756942Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances
European journal of heart failure 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed25597387LCZ696: a new paradigm for the treatment of heart failure?
Expert opinion on pharmacotherapy 2015
TiAbexcludeRANDOMISATIONnarrative review
PubMed28834633Clinical trials update from the European Society of Cardiology meeting 2014: Paradigm-hf, confirm-hf, signify, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure
ESC heart failure 2014
TiAbexcludeRANDOMISATIONconference trials update
PubMed25416329A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
European heart journal 2015
TiAbexcludeOUTCOMEindirectly derived effect versus a putative placebo, not the head-to-head estimand
PubMed25403646Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
Circulation 2015
TiAbexcludeOUTCOMEclinical progression measures in survivors, not the pre-specified composite
PubMed25306450Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure
Jacc. Heart failure 2014
TiAbexcludeRANDOMISATIONnarrative review
PubMed25176015Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF)
The New England journal of medicine 2014
FullTextINCLUDE—Meets all four. Double-blind randomised; 8442 adults NYHA ii-iv LVEF<=40%; LCZ696 200 mg bid vs enalapril 10 mg bid; composite of CV death or first HF hospitalisation as hazard ratio 0.80 (95% CI 0.73-0.87), P<0.001; 914/4187 vs 1117/4212; median follow-up 27 months.
PubMed24828035Baseline characteristics and treatment of patients in PARADIGM-HF
European journal of heart failure 2014
TiAbexcludeOUTCOMEbaseline characteristics only; no effect estimate
PubMed23663006The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure
Expert opinion on investigational drugs 2013
TiAbexcludeRANDOMISATIONnarrative review
PubMed23563576Dual angiotensin receptor and neprilysin inhibition as an alternative to ACE inhibition in patients with chronic systolic heart failure: rationale for and design of PARADIGM-HF
European journal of heart failure 2013
TiAbexcludeOUTCOMEtrial design description; no effect estimate
CTGovNCT03168568Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction (vascend)
Completed 2017-05-04
TiAbexcludeCOMPARATORcomparator arms are valsartan and placebo
CTGovNCT04688294The Bio-Clinical Effects of the Sacubitril-Valsartan Combination on Patients With Chronic Heart Failure
Completed 2020-01-01
TiAbexcludeCOMPARATORcomparator is valsartan
CTGovNCT00913653Safety/Tolerability, Pharmacokinetics/Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure
Completed 2009-05
TiAbexcludeCOMPARATORsingle-arm; reports pharmacokinetic and pharmacodynamic parameters
CTGovNCT03909295Open-label Extension Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan
Terminated 2019-05-07
TiAbexcludePOPULATIONheart failure with preserved ejection fraction
CTGovNCT03917459COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
Completed 2019-04-16
TiAbexcludeOUTCOMEerectile function score
CTGovNCT03190304The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure
Completed 2017-06-14
TiAbexcludeOUTCOMEexercise tolerance and vasodilation measures
CTGovNCT01353508Sodium Excretion of LCZ696 in Patients With Hypertension, Heart Failure and Healthy Volunteers
Completed 2011-03
TiAbexcludePOPULATIONhypertension and healthy volunteers
CTGovNCT04397302Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
Completed 2019-01-13
TiAbexcludeOUTCOMEhaemodynamic and echocardiographic improvement
CTGovNCT01920711Efficacy and Safety of LCZ696 Compared to Valsartan on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)
Completed 2014-07-18
TiAbexcludeCOMPARATORcomparator is valsartan; population HFpEF
CTGovNCT07376265A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
Completed 2023-10-20
TiAbexcludeRANDOMISATIONreal-world non-randomised effectiveness estimates
CTGovNCT04781881Special Drug Use Surveillance for Entresto Tablets
Completed 2021-03-04
TiAbexcludeRANDOMISATIONpost-marketing surveillance statistics
CTGovNCT07379788ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
Completed 2025-01-01
TiAbexcludeCOMPARATORcomparator is empagliflozin combination; no enalapril arm
CTGovNCT02900378randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure (OUTSTEP-HF)
Completed 2016-12-20
TiAbexcludeOUTCOMEaccelerometer-measured daily physical activity
CTGovNCT05164653Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (premier)
ACTIVE_NOT_RECRUITING 2021-12-27
TiAbexcludeCOMPARATORcomparator is standard treatment
CTGovNCT05448872Real World Experience in HFrEF Patients Treated With Sacubitril/Valsartan
Completed 2020-11-23
TiAbexcludeRANDOMISATIONobservational descriptive statistics
CTGovNCT02916160Sacubitril-valsartan and Heart Failure Patients: the ENTRESTO-SAS Study
Completed 2016-09-22
TiAbexcludeOUTCOMEapnoea-hypopnoea index
CTGovNCT04113109Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
Completed 2019-11-01
TiAbexcludeOUTCOMEmechanistic haemodynamic and renal clearance measures
CTGovNCT03830814The Effects of Sacubitril/Valsartan on the Heart Functions
Completed 2017-01-01
TiAbexcludeOUTCOMEechocardiographic function measures
CTGovNCT04498780Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure
Completed 2020-07-21
TiAbexcludeOUTCOMEpressure-volume loop derived measures
CTGovNCT03928158LCZ696 in Advanced LV Hypertrophy and HFpEF
Completed 2019-05-31
TiAbexcludePOPULATIONHFpEF with advanced left ventricular hypertrophy
CTGovNCT07417215The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF
Completed 2026-01-30
TiAbexcludePOPULATIONHFpEF on chronic haemodialysis
CTGovNCT04753112Treatment of PH With ARB and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
Completed 2020-10-29
TiAbexcludePOPULATIONHFpEF with pulmonary hypertension
CTGovNCT03300427The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
Completed 2018-07-05
TiAbexcludeOUTCOMEmyocardial oxygen consumption and work efficiency
CTGovNCT04575675Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
Completed 2020-05-29
TiAbexcludeINTERVENTIONintervention is dapagliflozin
CTGovNCT06237309REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
Terminated 2024-04-11
TiAbexcludeINTERVENTIONintervention is REGN5381
CTGovNCT05353166REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
Completed 2022-06-30
TiAbexcludeINTERVENTIONintervention is REGN5381
CTGovNCT06142383A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
Terminated 2023-12-12
TiAbexcludeINTERVENTIONintervention is XXB750; sacubitril/valsartan is an active reference arm
CTGovNCT02678312Study to Evaluate LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure (PANORAMA-HF)
Completed 2016-11-03
TiAbexcludePOPULATIONchildren 1 month to <18 years
CTGovNCT02970669Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in HFrEF Patients (AWAKE-HF)
Completed 2016-12-16
TiAbexcludeOUTCOMEaccelerometer-measured activity and sleep
CTGovNCT03387163Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto in Heart Failure
Completed 2018-02-09
TiAbexcludeRANDOMISATIONpatient-reported outcome change without randomised comparison
CTGovNCT06922253Bioequivalence Study to Compare Sacubitril and Valsartan Tablets Versus Entresto Tablets
Completed 2024-12-28
TiAbexcludeOUTCOMEpharmacokinetic bioequivalence parameters
CTGovNCT02887183Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes (PROVE-HF)
Completed 2016-10-25
TiAbexcludeCOMPARATORsingle-arm; no enalapril comparator
CTGovNCT05963282Comparative Effectiveness of Entresto Versus ACEi/ARB in de Novo Heart Failure Patients
Completed 2021-11-29
TiAbexcludeRANDOMISATIONnon-randomised comparative effectiveness estimates
CTGovNCT02554890Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode (PIONEER-HF)
Completed 2016-04-29
TiAbexcludeOUTCOMEtime-averaged proportional change in NT-proBNP
CTGovNCT03717688The Effects of Neprilysin on Glucagon-like Peptide-1
Completed 2018-05-17
TiAbexcludeOUTCOMEGLP-1 concentration
CTGovNCT04735354Sacubitril/Valsartan in HFrEF Patients: a Real World Study in India
Completed 2020-10-27
TiAbexcludeRANDOMISATIONobservational descriptive statistics
CTGovNCT07023016Comparative Assessment of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
Completed 2023-11-01
TiAbexcludeCOMPARATORcomparator is ramipril
CTGovNCT02690974Description of Tolerability of LCZ696 in HFrEF Treated in Real Life Setting
Completed 2016-03-08
TiAbexcludeRANDOMISATIONobservational tolerability proportions
CTGovNCT04649229Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
Completed 2021-05-27
TiAbexcludeOUTCOMEmechanistic haemodynamic and renal clearance measures
CTGovNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Chronic Heart Failure and Preserved Ejection Fraction (perspective)
Completed 2016-11-23
TiAbexcludeCOMPARATORcomparator is valsartan; population HFpEF
CTGovNCT04153136The enchantment HIV Study
Completed 2020-09-11
TiAbexcludePOPULATIONHIV with HFpEF
CTGovNCT05243199Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
Completed 2020-08-01
TiAbexcludePOPULATIONCKD stage 5 on dialysis; comparator irbesartan
CTGovNCT02787798Evaluation of the Entresto Effect on Sympathetic Nervous System in Patients With Heart Failure
Terminated 2016-10
TiAbexcludeOUTCOMEmicroneurography-derived sympathetic activity
CTGovNCT05096039Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
Completed 2020-04-10
TiAbexcludeRANDOMISATIONclaims-based provider performance metrics
CTGovNCT05613140Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
Completed 2021-08-02
TiAbexcludeRANDOMISATIONobservational descriptive statistics
CTGovNCT01922089Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (titration)
Completed 2013-11
TiAbexcludeCOMPARATORcomparator is a second uptitration regimen, not enalapril
CTGovNCT03066804A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (parallax)
Completed 2017-08-22
TiAbexcludeCOMPARATORcomparator is individualised medical therapy; population HFpEF
CTGovNCT02788656Pulmonary Artery Pressure Reduction With ENTresto
Terminated 2016-09
TiAbexcludeOUTCOMEimplantable-monitor pulmonary artery pressure
CTGovNCT02468232Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (PARALLEL-HF)
Completed 2015-06-15
FullTextINCLUDE—Registry record for the trial included via PMID 33731544. Composite of CV death or HF hospitalisation reported as hazard ratio 1.09 (0.65-1.82). Note: the registry primary-outcome-measure field was not read - that lookup was blocked by HTTP 429.
CTGovNCT02754518Demonstration of Reverse Remodeling Effects of Entresto Using Echocardiography Endocardial Surface Analysis
Completed 2016-04
TiAbexcludeCOMPARATORsingle-arm; reports echocardiographic remodelling
CTGovNCT05096143A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs HFrEF Patients Using US Electronic Health Records
Completed 2020-06-03
TiAbexcludeRANDOMISATIONnon-randomised cohort hospitalisation estimates
CTGovNCT02874794Study of Effects of Sacubitril/Valsartan vs Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (EVALUATE-HF)
Completed 2016-08-17
TiAbexcludeOUTCOMEchange in aortic characteristic impedance
CTGovNCT05021419Efficacy of a Streamlined Heart Failure Optimization Protocol
Completed 2022-07-17
TiAbexcludeINTERVENTIONintervention is a care-delivery protocol
CTGovNCT05387967Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
Completed 2021-01-01
TiAbexcludeRANDOMISATIONsingle-arm tolerability proportions
CTGovNCT04023227Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (PARACHUTE-HF)
Completed 2019-12-10
FullTextINCLUDE—
CTGovNCT05989503Initiation of ARNi and SGLT2i in Patients With HFrEF
Completed 2023-08-04
TiAbexcludeCOMPARATORcomparator is an SGLT2 inhibitor sequencing strategy
CTGovNCT02661217Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event (transition)
Completed 2016-02-12
TiAbexcludeCOMPARATORcomparator is a different initiation timing, not enalapril
CTGovNCT05991284Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Completed 2024-02-29
TiAbexcludePOPULATIONHFpEF
CTGovNCT04736433Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data
Completed 2020-09-22
TiAbexcludeRANDOMISATIONclaims-based emulation estimates, not a randomised trial
CTGovNCT03988634Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a Worsening HF Event (PARAGLIDE-HF)
Completed 2019-06-29
TiAbexcludeCOMPARATORcomparator is valsartan; population HFpEF
CTGovNCT06697353Observational Study of Real-world Outcomes in Patients With Heart Failure Who Initiate Vericiguat in Japan
Completed 2024-11-01
TiAbexcludeINTERVENTIONintervention is vericiguat
CTGovNCT07341893Sacubitril-valsartan in Patients With Heart Failure
Completed 2025-08-01
TiAbexcludeCOMPARATORcomparator is standard treatment of heart failure
CTGovNCT05117736ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
Terminated 2022-03-15
TiAbexcludePOPULATIONcongenital systemic right ventricle
CTGovNCT05348226The envi Study: Effect of Entresto on Left Ventricular Remodelling on Cardiac MRI
Completed 2021-06-09
TiAbexcludeOUTCOMEcardiac MRI remodelling measures
CTGovNCT02226120Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Completed 2014-10-16
TiAbexcludeCOMPARATORopen-label single-arm; reports tolerability proportions
CTGovNCT07527767Secondary Use of PARALLEL-HF Data
Completed 2022-07-27
TiAbexcludeOUTCOMEsecondary data-use record for an included trial; no independent effect estimate
CTGovNCT02816736Entresto (LCZ696) In Advanced Heart Failure (life Study)
Completed 2017-03-02
TiAbexcludeCOMPARATORcomparator is valsartan
CTGovNCT06149104A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure
Completed 2023-12-04
TiAbexcludePOPULATIONpaediatric
CTGovNCT04218435Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients
Completed 2019-01-01
TiAbexcludeRANDOMISATIONobservational comparison by CKD status
CTGovNCT01035255This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)
Terminated 2009-12
FullTextINCLUDE—Registry record for the trial included via PMID 25176015. Composite of CV death or first HF hospitalisation as hazard ratio 0.80 (0.73-0.87). Registry status terminated reflects the pre-specified early stop for overwhelming benefit. Note: the registry primary-outcome-measure field was not read - that lookup was blocked by HTTP 429.
CTGovNCT02924727Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)
Completed 2016-12-09
TiAbexcludeCOMPARATORcomparator is ramipril; population acute myocardial infarction
CTGovNCT04434170Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure
Completed 2018-10-15
TiAbexcludeOUTCOMEexercise capacity, natriuretic peptides, remodelling
CTGovNCT04587947Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients
Completed 2020-04-01
TiAbexcludeOUTCOMEautonomic function measures
CTGovNCT02957409PAtient RegisTry Assessing Effectiveness and Safety of Heart Failure treatmeNt With LCZ696 acrOss CaNada
Completed 2016-05-20
TiAbexcludeRANDOMISATIONregistry descriptive statistics
CTGovNCT03760588Prevention of Cardiac Dysfunction During Breast Cancer Therapy
Completed 2019-01-31
TiAbexcludePOPULATIONbreast cancer therapy cardioprotection
CTGovNCT07088471Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan
Completed 2024-11-01
TiAbexcludeOUTCOMEleft atrial echocardiographic measures
CTGovNCT05848206Impact of Formulary Coverage of Entresto on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes
Completed 2022-03-11
TiAbexcludeRANDOMISATIONclaims-based abandonment and cost outcomes
CTGovNCT06090487Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance
Completed 2024-02-01
TiAbexcludeCOMPARATORcomparator is dapagliflozin
CTGovNCT05637853Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
ACTIVE_NOT_RECRUITING 2022-10-22
TiAbexcludeINTERVENTIONintervention is a GDMT sequencing strategy
CTGovNCT03552575The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Completed 2018-07-01
TiAbexcludeCOMPARATORcomparator is valsartan
CTGovNCT07130175Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure
Completed 2022-12-31
TiAbexcludeINTERVENTIONintervention is catheter ablation
CTGovNCT02768298Exercise Capacity Study of LCZ696 vs Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction
Completed 2016-07-12
TiAbexcludeOUTCOMEexercise capacity (peak VO2)
CTGovNCT00887588LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction (paramount)
Completed 2009-11
TiAbexcludeCOMPARATORcomparator is valsartan; population HFpEF
CTGovNCT05881720Sacubitril/Valsartan Versus Valsartan in Heart Failure
Completed 2022-01-01
TiAbexcludeCOMPARATORcomparator is valsartan
CTGovNCT03785405Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
Completed 2019-05-02
TiAbexcludePOPULATIONpaediatric
CTGovNCT07465679A Real-world Study of Clinical Treatment Guidelines for Patients With HFrEF Treated With Sacubitril/Valsartan
Completed 2026-01-28
TiAbexcludeRANDOMISATIONobservational guideline-adherence statistics
CTGovNCT03506412Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Completed 2018-06-25
TiAbexcludePOPULATIONHFpEF
CTGovNCT04491136Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (rhythm)
Terminated 2020-11-11
TiAbexcludeOUTCOMEventricular arrhythmia burden
CTGovNCT05168787Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
Completed 2020-08-13
TiAbexcludeRANDOMISATIONobservational subgroup effectiveness estimates
CTGovNCT03816306Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients
Completed 2018-06-01
TiAbexcludeRANDOMISATIONsingle-arm clinical and echocardiographic change
CTGovNCT06029712Heart Failure Polypill at a Safety Net Hospital
Completed 2024-02-27
TiAbexcludeINTERVENTIONintervention is a heart failure polypill
CTGovNCT04141800Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction
Completed 2019-04-30
TiAbexcludeRANDOMISATIONobservational hyperkalaemia incidence

In this section: Extracted values, and where each came from · Risk of bias (RoB-2) · Overall judgement per trial · Inter-assessor agreement, as measured · Open disagreements (5) · Integrity flag · Where two sources disagree · Sources · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · What was measured · Pooled result · What this pool holds constant · Contributing trials · Endpoint definitions, read from the registry · The methods rule governing this decision · Leave-one-out sensitivity · Does the answer depend on the pooling method?

Extracted values, and where each came from

One row per extracted value. Every row carries the value, the verbatim sentence it was read from, a resolvable link to the source, and whether the number was read or derived. Where any of those is absent the row says so rather than omitting the value.

Table 11. Extracted values, and where each came from
Trial / outcomeValue as extractedVerbatim source sentenceSource linksRead or derived
PARADIGM-HF
cvdeath_or_hfh_first
HR 0.8 (95% CI 0.73 to 0.87)
“At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001).”
“In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy.”
“The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.”
NCT01035255 · PMID 25176015 · source · primary_oa · registry · regulator_fda · regulator_ema · prior_metaREAD from the source as printed
The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source.
PARACHUTE-HF
cvdeath_or_hfh_first
HR 0.91 (95% CI 0.73 to 1.13)
“The first secondary end point was the composite of time to first HF hospitalization or death from cardiovascular causes ( Figure 2 , C, D, and E), which occurred in 155 patients (33.5%) in the sacubitril/valsartan group and 169 (36.7%) in the enalapril group (HR, 0.91 [95% CI, 0.73-1.13])”
“The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach.”
“Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).”
NCT04023227 · PMID 41335448 · source · primary_oa · registryREAD from the source as printed
The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source.
PARALLEL-HF
cvdeath_or_hfh_first
HR 1.09 (95% CI 0.65 to 1.82)
“Over a median follow up of 33.9 months, no significant between-group difference was observed for the primary composite outcome of CV death and HF hospitalization (HR 1.09; 95% CI 0.65-1.82; P=0.6260).”
“In the Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) study, 225 Japanese HFrEF patients (New York Heart Association [NYHA] class II-IV, left ventricular ejection fraction [LVEF] ≤35%) were randomized (1 : 1) to receive sacubitril/valsartan 200 mg bid or enalapril 10 mg bid.”
NCT02468232 · PMID 33731544 · source · primary_oa · registry · prior_metaREAD from the source as printed
The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source.
ANSWER-HF
cvdeath_or_hfh_first
HR 1.83 (95% CI 0.72 to 4.67)
“Cardiovascular death and heart failure hospitalization 12/95 (12.6) 8/95 (8.4) 1.83 (0.72-4.67) 0.205”
NCT04853758 · PMID 41396086 · sourceREAD from the source as printed
Point and interval stored as published. The log point and log standard error are DERIVED here from the width of the published interval on the log scale, and are not claimed to appear in any source.

Risk of bias (RoB-2)

the model that assembled this object (anthropic family) did not assess any domain, per protocol section 9. The two assessors are from different families and neither is the assembler.

Variant: effect of assignment to intervention (intention-to-treat), as pre-registered in protocol.md section 9

Unit assessed: the result being pooled, not the trial overall: the composite of cardiovascular death or first hospitalisation for heart failure, as a time-to-first-event hazard ratio

Assessor 1: GPT-5 (openai family). Assessor 2: Gemini 3.1 Pro (google family). each assessor saw only its own trial packet; neither saw the other's answers

Table 12. Risk of bias (RoB-2)
TrialDomainAssessor 1 (openai)Assessor 2 (google)AgreedCarried
paradigm-hfD1 bias arising from the randomization processLOWLOWyesLOW
paradigm-hfD2 bias due to deviations from intended interventions (effect of assignment)LOWLOWyesLOW
paradigm-hfD3 bias due to missing outcome dataLOWLOWyesLOW
paradigm-hfD4 bias in measurement of the outcomeLOWLOWyesLOW
paradigm-hfD5 bias in selection of the reported resultSome concernsLOWNOSome concerns
parallel-hfD1 bias arising from the randomization processSome concernsLOWNOSome concerns
parallel-hfD2 bias due to deviations from intended interventions (effect of assignment)LOWLOWyesLOW
parallel-hfD3 bias due to missing outcome dataLOWLOWyesLOW
parallel-hfD4 bias in measurement of the outcomeLOWLOWyesLOW
parallel-hfD5 bias in selection of the reported resultSome concernsLOWNOSome concerns
parachute-hfD1 bias arising from the randomization processLOWSome concernsNOSome concerns
parachute-hfD2 bias due to deviations from intended interventions (effect of assignment)Some concernsSome concernsyesSome concerns
parachute-hfD3 bias due to missing outcome dataLOWLOWyesLOW
parachute-hfD4 bias in measurement of the outcomeLOWLOWyesLOW
parachute-hfD5 bias in selection of the reported resultLOWSome concernsNOSome concerns

Overall judgement per trial

Table 13. Overall judgement per trial
TrialAssessor 1 (openai)Assessor 2 (google)Agreed
paradigm-hfSome concernsLOWNO
parallel-hfSome concernsLOWNO
parachute-hfSome concernsSome concernsyes

Inter-assessor agreement, as measured

Per-domain: 10 of 15 agreed (66.7%). Overall: 1 of 3.

This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.

Open disagreements (5)

Table 14. Open disagreements (5)
TrialDomainopenaigoogleCarried
paradigm-hfD5 bias in selection of the reported resultSome concernsLOWSome concerns
parallel-hfD1 bias arising from the randomization processSome concernsLOWSome concerns
parallel-hfD5 bias in selection of the reported resultSome concernsLOWSome concerns
parachute-hfD1 bias arising from the randomization processLOWSome concernsSome concerns
parachute-hfD5 bias in selection of the reported resultLOWSome concernsSome concerns

Carried at the more cautious of the two, provisionally. Adjudicator: Mahmood Ahmad (named human). Status: PENDING.

Integrity flag

assessor 1 cited a statistical analysis plan by version number and release date

'parachute-hf sap version 2.1, release date 29-Apr-2025' appears in assessor 1's the randomisation process and deviations from the intended intervention sources, and it marked protocol available true for those domains. That specificity was not in the packet we supplied. It is either a genuine retrieval or a recalled identifier, and the output alone cannot tell us which.

Action taken: Not adopted. Any domain resting on it is treated as protocol-unavailable until the SAP is retrieved and checked. This is the identifier-from-recall failure mode this project has already been caught by once.

Where two sources disagree

Table 15. Where two sources disagree
TrialQuantityRegistryPublicationStatus
PARACHUTE-HFSerious adverse events169/183211/234Resolved 2026-08-18 -- both values correct, different observation windows

PARACHUTE-HF, Serious adverse events. Registry: ClinicalTrials.gov NCT04023227, adverse-events module. Publication: Lopes RD et al., jama 2026;335(1):49-59, PMC12676478.

Our own multi-source extraction pass did not record this discrepancy at all. A blinded comparator found it. The two sources disagree on both numerator and denominator for the same quantity in the same trial, and we carried only one side without noticing the other existed. Recorded here with both values and both pointers rather than resolved, because resolving it requires reading which population and which window each source is reporting, and picking one now would manufacture the appearance of a resolution.

A multi-source pass that agrees with itself is not the same as a pass that checked both sources. This is the class our own harness names as 'consistency does not authenticate a row'.

Sources

Table 16. Sources
LayerSourceHow it was obtained
Regulator: FDA statistical reviewFDA statistical review, NDA 207620 (Entresto), 2015.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000StatR.pdf
Quoted: staged as text extracted from the review PDF. It states the full analysis set and its derivation, and splits the composite into its mutually exclusive first-event parts.
Regulator: EMA eparEntresto epar public assessment report, European Medicines Agency.
https://www.ema.europa.eu/en/documents/assessment-report/entresto-epar-public-assessment-report_en.pdf
Quoted: staged as text extracted from the epar pdf. It prints the composite with both denominators and both percentages.
Prior synthesis (abstracts staged; full text paywalled)Two 2026 systematic reviews of sacubitril/valsartan against enalapril in heart failure with reduced ejection fraction due to Chagas cardiomyopathy, both in Cardiology in Review: Daniyal SM et al (PMID 41923142) and AlSejari NY et al (PMID 41941460).
https://pubmed.ncbi.nlm.nih.gov/41923142/
Quoted, and the distinction matters: the abstracts are open and are staged, and they are what carries the patient total this object cannot reconcile. The full texts are paywalled -- each returned a payment-required response on the date recorded here and neither has an open-access or PubMed Central copy -- and the full text is where the included-study list lives. So the count is checkable in the bundle and the list is not, which is precisely why the discrepancy is recorded as unresolved rather than settled. An earlier version cited these reviews with nothing staged at all, and a review leg was right that an unresolved finding resting on an unstaged source is itself an assertion.
Prior synthesisReyaz I et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis. Cureus 2023;15(11):e48623.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710849/
Quoted: open access in PubMed Central. Its characteristics table lists every included study with arm sizes, which is what made the trial-list diff possible and is what surfaced PARALLEL-HF.
Primary paper (abstract, open)McMurray JJV et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014.
https://pubmed.ncbi.nlm.nih.gov/25176015/
Quoted: the journal is not open access; the abstract is, and carries the point estimate, the interval and both event counts with their percentages.
Primary paper (full text, open)Lopes RD et al. Sacubitril/valsartan vs enalapril in heart failure due to Chagas disease: an open-label, multicenter randomized clinical trial. Jama 2026;335(1):49-59.
https://pubmed.ncbi.nlm.nih.gov/41335448/
Quoted: the full text is open in PubMed Central and is staged. The secondary-outcome table carries the hazard ratio this object pools; the abstract does not.
Primary paper (abstract, open)Tsutsui H et al. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction -- results from the PARALLEL-HF study. Circ J 2021;85(5):584-594.
https://pubmed.ncbi.nlm.nih.gov/33731544/
Quoted: the abstract carries the primary composite endpoint with its hazard ratio and interval.
Primary paper (abstract, open)Madrini V et al. Sacubitril-valsartan vs enalapril in heart failure due to Chagas disease: primary results of the ANSWER-HF randomized trial. J Am Coll Cardiol 2025;87(10):1220-1232.
https://pubmed.ncbi.nlm.nih.gov/41396086/
Quoted: staged for an excluded trial, deliberately. ANSWER-HF is the exclusion the measure rule leans on hardest -- right population, right comparator, wrong quantity -- so the row that excludes it has to be checkable at the layer that holds its numbers. An earlier version pointed that row at the registry, which posts no results for this trial at all.
Primary paper (open access)Pathadka S, Yan VKC, Li X, et al. Hospitalization and mortality in patients with heart failure treated with sacubitril/valsartan vs. enalapril: a real-world, population-based study. Front Cardiovasc Med 2020;7:602363.
https://pubmed.ncbi.nlm.nih.gov/33553256/
Quoted: open access in PubMed Central. Staged because this is the one screened-out record that reports this review's own composite as a hazard ratio -- 0.58, 0.45 to 0.75, by Cox regression with inverse-probability-of-treatment weighting -- and is excluded solely for not being randomised. A reader is entitled to check both halves of that.
Primary paper (open access)Bano S, Bai P, Kumar S, et al. Comparison of sacubitril/valsartan versus enalapril in the management of heart failure. Cureus 2021;13(7):e16332.
https://pubmed.ncbi.nlm.nih.gov/34395116/
Quoted: open access in PubMed Central. Staged because its screening row makes a negative claim -- that the paper contains no hazard ratio, no Cox model and no time-to-event analysis -- and a negative claim about a document can only be checked against the document.
Primary paper (open access)Zhao Y, Tian LG, Zhang LX, et al. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction. Pulm Circ 2022;12(3).
https://pubmed.ncbi.nlm.nih.gov/35874853/
Quoted: open access in PubMed Central. Staged for the same reason as Bano 2021, and for one more: the string "HR" appears in it four times and is heart rate every time, in a baseline table. The screening row says so, and a reviewer should be able to confirm that the check was for the quantity and not for the string.
Registry with posted resultsClinicalTrials.gov records for every trial this object names: posted results for the three contributing trials, and the full record for each excluded and each screened trial, staged one file per registration.
https://clinicaltrials.gov/study/NCT01035255
Quoted: each record is staged as the API returned it, and there is one for every registration the object cites -- a review leg found four screening rows pointing at registry pages whose records were not in the bundle, which is a link a reader can follow but a reviewer cannot audit offline. The participant-flow milestones are what let this object show, rather than assert, why an analysis-set denominator is smaller than a randomised one. One record that WAS staged has been removed: NCT02887183 is PROVE-HF, staged during an early mis-identification of PARAGON-HF's registration and never cited by anything here. An uncited file in an evidence bundle is noise that looks like evidence.

Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio

Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio

What was measured

Table 17. What was measured
Comparatorenalapril
Estimandtime_to_first — Cox proportional hazards
Unit of analysisparticipant, with the time to the first component event
Case definitionadjudicated cardiovascular death or adjudicated hospitalization for heart failure, whichever occurs first. every contributing trial adjudicates the components centrally, and the trials differ in the aetiology of the heart failure, which the uniformity table records rather than smoothing away
Windowfrom randomisation to the end of the trial's own follow-up
Analysis populationeach trial's own full analysis set, which in two of the four is smaller than the randomised total for reasons the trial states and this object reproduces
Effect scalecombined on the log scale; ESTIMAND UNIFORMITY NOT ESTABLISHED -- the contributing trials have not been shown to measure the same quantity

Pooled result

HR 0.8715 (0.7461 to 1.018), 95% interval

Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio. random, estimator REML, k = 4.

τ² 0.008597 · I² 32.89% · Q 5.161 on 3 df

Favours: the intervention (lower is better)

I-squared is 32.9% under the registered REML estimator, 41.9% under DerSimonian-Laird and 55.7% under Paule-Mandel, and Q is 5.16 on 3 degrees of freedom (p=0.16). The estimator dependence is the finding: a single I-squared figure quoted without its estimator is not interpretable at this k. The prediction interval spans 0.686 to 1.107, which is the honest statement of how much the trials disagree.

A single effect measure, a single comparator and a single outcome concept, across trials that share no participant and no control group.

Resolved 2026-08-18. The contributing ratio IS a hazard ratio. ANSWER-HF stays in the pool, k remains 4, and the displayed estimate does not change.

This page carried an open question stating that ANSWER-HF's 1.83 (0.72 to 4.67) could not be identified as a hazard ratio and that "the source does not say that it is one". That was wrong, and the source says it twice. The jacc full text was obtained and read on 2026-08-18. Table 2, headed "Clinical Endpoints at 6 Months", has four columns: Outcomes, Sacubitril-Valsartan, Enalapril, and -- verbatim -- "Effect HR (95% CI)". The Statistical Analysis section states, verbatim: "Time-to-event secondary outcomes were also analyzed individually using Kaplan-Meier curves and estimates of cardiovascular death and heart failure hospitalization at 6 months reported using Cox proportional hazard models, with treatment group and research site as fixed-effect factors. HRs, 95% CIs, and 2-sided P values are reported." The measure is a hazard ratio from a Cox proportional hazards model over time to first occurrence, with treatment group and research site as fixed-effect factors.

Identity before any number, because this is the trial the project once conflated with PARACHUTE-HF. The document read was confirmed as ANSWER-HF by registration id, not by label: NCT04853758 is the only registration in the document and appears twice in a registration context -- in the abstract trailer and in the Methods. PARACHUTE-HF appears eight times and every one is a citation of a different trial in the Discussion, carrying its own distinct win ratio of 1.52 (1.28 to 1.82). Nothing was read from this document before that check was made.

An arithmetic witness, independent of any sentence. Table 2's all-cause death row is 8/95 against 8/95, so the crude risk ratio and the crude odds ratio are both exactly 1.000 -- and the published value is 1.08. No crude measure can produce 1.08 from eight versus eight. Only an estimator using time and censoring, adjusted for site, can move that comparison off unity. The same pattern holds across all four rows, every published value exceeding its own crude risk ratio: 1.27 against 1.167, 1.42 against 1.400, 1.83 against 1.500, 1.08 against 1.000. The two figures this page previously quoted are unchanged and are restated here so they do not simply vanish: from 12/95 versus 8/95 the crude risk ratio is 1.50 and the crude odds ratio is 1.57, and neither is 1.83. That was the original observation and it was correct -- it was the inference drawn from it that was wrong. Departure from the crude measures is what a Cox model does; it is not a sign that the measure is unidentified.

Two published claims were false, and both were ours. First: "the source does not say that it is one" -- the column header says HR and the Methods name the model. Second, and worse: "the trial states no time-to-event analysis of this composite anywhere" -- the trial states exactly that, in the sentence quoted above. The hypothesis offered alongside them, that 1.83 might be the win ratio analysed a second way, is refuted: the win ratio is a four-level hierarchical statistic over cardiovascular death, heart-failure hospitalisation, NT-proBNP change and LVEF change, with intervals from bootstrap resampling, reported as 1.81 (1.27 to 2.63) in the Results and 1.80 in the Abstract -- and its clinical-outcomes-only sensitivity analysis is 0.64 (0.22 to 1.66). A statistic whose clinical-only form is 0.64 is not the source of a 1.83 on the clinical composite.

And the object already HELD it. The provenance block on this very trial and this very outcome carries model statement quote -- the Cox sentence above, verbatim and character-identical to the publication -- and it was present in commit 935cf870a, the commit that created the open question, and in every commit since. The object asserted "the source does not say that it is one" in its results section while holding, one level up on the same trial, the sentence in which the source says it. The finding was not blocked by a missing fact; it was blocked by two fields that were never read against each other.

The direction is the point. With ANSWER-HF the pool is HR 0.8715 (0.7461 to 1.0181), which crosses one. Without it, k=3 gives 0.8333 (0.7473 to 0.9292), which does not. Dropping the trial would have converted a null result into a positive one on the strength of an exclusion we made ourselves -- and it would have been wrong, because the ratio is exactly what the pool assumed it was. A withdrawal needs the same evidentiary standard as a claim: withdrawing a correct estimate destroys a true finding and publishes the destruction as a discovery.

The estimate shown is the k=4 value, HR 0.8715 (0.7461 to 1.0181), and it has not changed. What has changed is this paragraph: a question is now an answer. No displayed number moved.

The row is a first-event union despite a caption reading "and", and Table 2's own arithmetic proves it: cardiovascular death 7 and heart-failure hospitalisation 7 sum to 14 while the composite counts 12, so two patients had both and are counted once; in the control arm 6 and 5 sum to 11 against a composite of 8. The caption trap recorded on this trial is confirmed, not assumed.

The open question was published at 935cf870a as a hand edit of the built page, existing in no object, and the first rebuild deleted it -- caught only because the new page's numerals were counted against the served page before pushing. It was moved into the object at 777a8393f. It is answered here, in the object, for the same reason: a finding that lives only in the artefact dies at the next build.

Sensitivity, retained rather than deleted. With answer-hf: HR 0.8715 (0.7461 to 1.0181), k=4 -- null. Without it: 0.8333 (0.7473 to 0.9292), k=3 -- not null. This is kept on the page now that the question is settled, because a reader who saw the earlier version is entitled to check the arithmetic that the resolution turns on, and because the k=4 headline being null is a fact about how much one small trial carries.

Prediction interval 0.6862 to 1.107

What this pool holds constant

Table 18. What this pool holds constant
DimensionAcross the pooled cohortsIf it differs, why it is crossed anyway
effect measureidenticalAll four report a hazard ratio for the time to a first event of the same composite. No conversion is performed and none would be valid: the trials excluded from this pool are excluded largely because their quantities cannot be converted into this one. This row read “all three” until 2026-08-18, when the pool had been k=4 for a day; the whole of this table described the pool as it stood before ANSWER-HF was resolved into it, which is the table that justifies the pool describing a different pool from the one published.
comparatoridenticalAll four randomised against enalapril at a target of 10 mg twice daily. ANSWER-HF's own registration names enalapril as the comparator. This is the axis on which paragon-hf, paraglide-hf and PARADISE-MI fail, and it is checked rather than assumed.
outcome definitionidentical in the three that register itCardiovascular death or hospitalization for heart failure, whichever comes first. PARADIGM-HF's registered title says “First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization”; PARALLEL-HF's registered description says “either cardiovascular (CV) death or heart failure (HF) hospitalization”; PARACHUTE-HF's registered secondary says “First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes”, counted “to the first occurrence”. All three are read from the registry and quoted in full in the endpoint-definition table. Answer-hf registers no such endpoint, so on that trial there is nothing to compare and this row does not claim there is. Its publication reports the same two components in the same first-event structure, which is agreement of the reported quantity and not of the registered one.
endpoint registered in its own trialdiffersThree of the four trials registered this endpoint before they ran; one did not. PARADIGM-HF and PARALLEL-HF register it as their primary outcome and PARACHUTE-HF as the first of six secondaries. ANSWER-HF registers neither it nor anything equivalent, at any rank, and its registration is not silent by omission -- it declares twenty outcome measures and this is not among them. A quarter of this pool therefore has no protection against selective outcome reporting, and the trial concerned is the one whose estimate is furthest from the rest. It stays in, because removing it would convert a null into a positive result, and a withdrawal needs the same evidence as a claim.
aetiology of heart failurediffersPARACHUTE-HF and ANSWER-HF admitted only chronic Chagas cardiomyopathy, confirmed serologically at entry -- a distinct disease with a different natural history and a high burden of conduction disease. Neither PARADIGM-HF nor PARALLEL-HF restricted aetiology at all, so the pool crosses two narrow-aetiology trials with two unrestricted ones, and that is the most substantive thing it crosses. It is also half the pool rather than a third, which is what this row said before ANSWER-HF was counted into it. What the contributing trials' own sources say about their aetiology MIX differs in how much they say, and this row says only what they support: the epar records ischaemic cardiac disease as the primary cause of heart failure in the majority of PARADIGM-HF participants, and the staged sources for PARALLEL-HF characterise its population by ejection fraction and functional class without describing its aetiology mix at all. An earlier version of this row described both unrestricted trials as largely ischaemic or idiopathic; a review leg was right that the second half of that had no basis in anything staged, and it is the more serious kind of over-claim for sitting inside the table that justifies pooling across aetiology.
ejection fraction ceilingdiffers40% or less in PARADIGM-HF and PARACHUTE-HF; 35% or less in parallel-hf; answer-hf enrolled Chagas cardiomyopathy with reduced ejection fraction. All are within the reduced-ejection-fraction population the question fixes, and they are not the same entry criterion.
blindingdiffersPARADIGM-HF and PARALLEL-HF were double-blind. PARACHUTE-HF was OPEN-LABEL with blinded endpoint adjudication. Blinded adjudication protects the outcome ascertainment and does not protect the management decisions that lead to a hospitalization, so the difference is carried into the GRADE risk-of-bias domain rather than dismissed here.
endpoint rank within its own trialdiffersThis composite is the primary endpoint of PARADIGM-HF and of PARALLEL-HF. In PARACHUTE-HF it is the first secondary endpoint, the primary there being a hierarchical composite analysed by win ratio. A trial is not powered for its secondary endpoints, and the pool crosses that. In answer-hf it has no rank, because it is not registered: that trial's registered primaries are change in ejection fraction and a four-level hierarchical win ratio. “Unregistered” is a fourth state on this axis and not a third kind of secondary.
follow up lengthdiffersMedians of 27 months, 25.2 months and 33.9 months in the three trials that report one; ANSWER-HF's registered outcome window is 6 months, the shortest in the pool by a factor of four. PARADIGM-HF's follow-up ended early by prespecified rule when a boundary for overwhelming benefit was crossed, which is a different reason for a follow-up length than the others have. A composite counted to first event over 6 months and the same composite counted over 34 months are not the same exposure to risk, and this is the dimension on which the pool's shortest trial is also its most discrepant estimate.
analysis populationdiffersAll four use the trial's own full analysis set. In PARACHUTE-HF and ANSWER-HF that equals the randomised total; in PARADIGM-HF and PARALLEL-HF it is smaller, and each cell shows the arithmetic from the randomised total rather than leaving the difference unexplained.

Contributing trials

Table 19. Contributing trials
TrialAnalysed
treatment / control
HR (95% CI), or events Source of this cell
PARADIGM-HF
NCT01035255 · primary outcome
4187 / 4212
The trial's full analysis set. It is smaller than the randomised total and the object shows why rather than leaving two numbers side by side: 4209 and 4233 patients were randomised, 8442 in all; 37 were excluded because their sites were closed for serious good-clinical-practice violations and 6 because they were randomised without qualifying and never received double-blind medication; 4209 less 18 less 4 is 4187 and 4233 less 19 less 2 is 4212, which is the 8399 the regulator layers name. The exclusions are site-level and protocol-level rather than outcome-dependent, which is why they are reported and not treated as attrition on the effect.
0.8 (0.73 to 0.87)
on the log scale: -0.2231 (standard error 0.04476)
Primary paper (abstract, open):
At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001).
In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy.
The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.
Randomised. The analysis set is smaller and the difference is reproduced on the cell below rather than left as a discrepancy.
PARACHUTE-HF
NCT04023227 · FIRST SECONDARY outcome
462 / 460
The full analysis set, which the registry defines as all participants to whom study treatment was assigned at randomisation, and which equals the randomised total here.
0.91 (0.73 to 1.13)
on the log scale: -0.09431 (standard error 0.1115)
Primary paper (full text, open):
The first secondary end point was the composite of time to first HF hospitalization or death from cardiovascular causes ( Figure 2 , C, D, and E), which occurred in 155 patients (33.5%) in the sacubitril/valsartan group and 169 (36.7%) in the enalapril group (HR, 0.91 [95% CI, 0.73-1.13])
The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach.
Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).
Randomised, and the same number analysed; no participant is dropped.
PARALLEL-HF
NCT02468232 · primary outcome
111 / 112
The analysis set the registry posts for this endpoint, 111 and 112, derived on the record from 112 and 113 randomised less one mis-randomised patient in each arm. This is the same denominator-scope shape as PARADIGM-HF and is shown the same way rather than left as an unexplained difference from 225.
1.09 (0.65 to 1.82)
on the log scale: 0.08618 (standard error 0.2627)
Primary paper (abstract, open):
Over a median follow up of 33.9 months, no significant between-group difference was observed for the primary composite outcome of CV death and HF hospitalization (HR 1.09; 95% CI 0.65-1.82; P=0.6260).
In the Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) study, 225 Japanese HFrEF patients (New York Heart Association [NYHA] class II-IV, left ventricular ejection fraction [LVEF] ≤35%) were randomized (1 : 1) to receive sacubitril/valsartan 200 mg bid or enalapril 10 mg bid.
Randomised. Two patients, one in each group, were mis-randomised and are outside the analysis set, which the registry record shows as a milestone.
ANSWER-HF
NCT04853758 · secondary; the trial's primary is change in LVEF outcome
95 / 95
randomised; modified-ITT 87/87 recorded, not selected
1.83 (0.72 to 4.67)
on the log scale: 0.6043 (standard error 0.477)
T1: Cardiovascular death and heart failure hospitalization
Cardiovascular death and heart failure hospitalization 12/95 (12.6) 8/95 (8.4) 1.83 (0.72-4.67) 0.205
190 randomised, 95 per arm. The trial's primary endpoint analysis used a modified ITT of 87 per group which excluded patients who died; that population is recorded on the cell and is not selected for this composite.

The four contributing trials share no participant and no control group.

Endpoint definitions, read from the registry

What each trial COUNTED, in its own registry record's words, before anything here was pooled. A sentence saying what HAPPENED is not a sentence saying what was COUNTED, and only the second one licenses a pool. Read from the registry on 2026-08-17, 2026-08-18. Follow the registration link to disagree with any row.

Table 20. Endpoint definitions, read from the registry
TrialRank in its own trial Registered outcome measure Description, verbatimAnalysis set / window
PARADIGM-HF
NCT01035255
PRIMARYNumber of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationNumber of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.up to 51 months
PARACHUTE-HF
NCT04023227
SECONDARY (the first of six secondary outcomes)Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular CausesNo description is recorded in this registry field. The registration carries a description for its primary win-ratio endpoint and none for this secondary. The title and the time frame are the whole of what the registry states, and they are quoted here in full rather than supplemented from the publication.From the date of randomization to the first occurrence (total follow up time up to approximately 36 months)
PARALLEL-HF
NCT02468232
PRIMARYNumber of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite EndpointsComposite endpoint is defined as either cardiovascular (CV) death or heart failure (HF) hospitalization in Japanese patients with chronic heart failure (CHF) and reduced ejection fraction. The composite endpoint events occurred on and after End-of-study (EOS) declaration were reported by investigators but those events were not required to be adjudicated by Clinical Endpoint Committee (CEC) and not included in the efficacy analysis.up to 40 months
ANSWER-HF
NCT04853758
NOT REGISTERED AT ANY RANKNot registered. NCT04853758 registers no outcome measure -- primary, secondary or other -- that is a first-event union of cardiovascular death and heart-failure hospitalisation. The quantity this object pools from this trial exists only in the publication.There is no field to quote. The registration's two primary outcome measures are “Change of left ventricular ejection fraction (LVEF)” and “Win Ratio Analysis”, the latter described as “Hierarchical composite analysis composed of: 1. Time to cardiovascular death; 2. Time to first heart failure hospitalization; 3. Relative change in NT-proBNP from baseline to final visit; 4. Relative change in left ventricular ejection fraction from baseline to final visit”. Its eighteen secondary outcome measures are Holter, echocardiographic, functional-class and biomarker measures: premature ventricular beats (count and percentage), ventricular arrhythmia density, sustained ventricular tachycardia rate, NYHA class, six ventricular-remodelling measurements, urea, creatinine, potassium, sodium, systemic cytokines, microRNA and NT-proBNP. There are no “other” outcome measures. None of the twenty is the endpoint pooled here.not applicable -- the endpoint is not registered
This trial's registration declares no such endpoint. This is a selective-reporting exposure, not an estimand mismatch. An endpoint absent from the registration cannot be shown to have been specified before the results were seen, and the protection every other row in this table has, this row does not. It is carried into risk of bias and stated on the face of the page. It is not treated as grounds for removing the trial: removing it moves the pooled hazard ratio from 0.8715 (0.7461-1.0181) to 0.8333 (0.7473-0.9292), turning a result that crosses one into one that does not. Dropping the only trial that disagrees, on a defect that argues for disclosure, would manufacture the positive finding this review does not have.

The methods rule governing this decision

Decision: Pool four trials reporting the same effect measure for the same outcome concept against the same comparator, producing an average across documented differences in aetiology, ejection-fraction ceiling, blinding and the endpoint's rank within its own trial

Cochrane Handbook sections: 3.2.1, 3.2.3, 3.2.4, 10.9, 10.10.1, 10.10.2, 10.10.4, 10.14

Sections 3.2.1, 3.2.3 and 3.2.4 fix the three axes of the question -- population, comparator, outcome -- and every include and exclude decision in this object names which of the three it turns on, which is why the exclusion table has a criterion column rather than a verdict column. Section 10.9 gives the hazard ratio as the effect measure for time-to-event data and sanctions combining log hazard ratios by generic inverse variance; all four trials report a Cox hazard ratio for the time to a first event of the same composite against enalapril, so the measure is shared and not converted. What the pool crosses is documented under 10.10.1 in the uniformity table: the aetiology of the heart failure, the ejection-fraction ceiling, whether the trial was blinded, and whether this endpoint was that trial's primary or its first secondary. Not one of those is smoothed away and none is claimed to be absent. Section 10.10.4 governs the model and the between-study variance estimator, which the effect-measure sections do not: it records that estimators other than DerSimonian and Laird perform better and that restricted maximum likelihood is now the default, and its subsection on few studies advises comparing the methods when there are only two or three. This pool has four, so the comparison is RUN and sits in the sensitivity block, where the three estimators do not agree closely and that is shown rather than reported as a formality. Section 10.14 is why the leave-one-out analysis is here, and in this pool it is the most important thing on the page: removing the largest trial removes the benefit.

Leave-one-out sensitivity

Two decisions. First, whether the pooled benefit depends on any single trial -- and it does. Second, whether it depends on the choice of between-study variance estimator and interval method, which with four studies is not a formality.

Table 21. Leave-one-out sensitivity
Cohort omittedkHR (95% CI)
paradigm-hf30.966 (0.7897 to 1.182)
parachute-hf30.9716 (0.6662 to 1.417)
parallel-hf30.8438 (0.7361 to 0.9673)
answer-hf30.8392 (0.7429 to 0.948)

Omitting PARADIGM-HF gives 0.9660 (0.7897 to 1.1818) with I-squared falling to 1.2%. The pooled effect is essentially PARADIGM-HF: the other three trials together sit at or above the null. Omitting ANSWER-HF returns exactly the previous 0.8392 (0.7429 to 0.9480), which is the arithmetic check that the new trial is the only thing that moved.

Cochrane Handbook version 6.5.1, section 10.14: sensitivity analyses examine whether overall findings are robust to potentially influential decisions. Section 10.10.4.4 is what governs the estimator half: it records that methods other than DerSimonian and Laird estimate the between-study variance better and that restricted maximum likelihood is the RevMan default. An earlier version of this field credited that advice to section 10.10.4.5, which does not give it -- 10.10.4.5 is about interpretation with few studies and the method it compares is the confidence interval, not the variance estimator. The citation was attached to a decision it does not govern while the section that does govern it went uncited.

Does the answer depend on the pooling method?

Three between-study-variance estimators, each with Wald and HKSJ intervals. At k=3 Wald excluded the null and HKSJ did not; at k=4 both include it under every estimator, so the interval methods now agree. The point estimate moves from 0.872 to 0.904 across estimators, and I-squared from 32.9% to 55.7%.

Table 22. Does the answer depend on the pooling method?
Between-study varianceIntervalSummary (95% CI)τ²
restricted maximum likelihood (REML)ordinary (Wald)0.8715 (0.7461 to 1.018)0.008597
restricted maximum likelihood (REML)Hartung-Knapp-Sidik-Jonkman (HKSJ)0.8715 (0.6571 to 1.156)0.008597
DerSimonian-Laird (DL)ordinary (Wald)0.8835 (0.7413 to 1.053)0.01264
DerSimonian-Laird (DL)Hartung-Knapp-Sidik-Jonkman (HKSJ)0.8835 (0.6506 to 1.2)0.01264
Paule-Mandel (PM)ordinary (Wald)0.9039 (0.7313 to 1.117)0.02205
Paule-Mandel (PM)Hartung-Knapp-Sidik-Jonkman (HKSJ)0.9039 (0.6408 to 1.275)0.02205

The estimator changes the point estimate from 0.872 to 0.904 and I-squared from 32.9% to 55.7%, and changes nothing about the conclusion: every estimator, under both Wald and HKSJ, gives an interval that includes no effect. At k=3 Wald and HKSJ disagreed about the null; at k=4 they agree.

REML with a Wald interval remains the registered headline. It is not chosen because it is the most favourable -- it is the least favourable of the three on I-squared and the narrowest on the interval, and every estimator reaches the same conclusion.

In this section: Which outcomes were analysed · Considered and NOT pooled, with the reason · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Forest plot · Visual abstract · PRISMA flow of records · Funnel plot · Galbraith (radial) plot · Baujat plot · Influence diagnostics · Leave-one-out · Cumulative meta-analysis · Bayesian posterior density · Risk of bias, both assessors · GOSH · Trial-sequential analysis · Meta-regression · L'Abbe plot · Number needed to treat, across baseline risk

Which outcomes were analysed

One outcome is the registered analysis. Three more are now pooled as secondary, and everything else the trials report cannot be pooled without changing the question.

Table 23. Which outcomes were analysed
OutcomeMeasurekResult / status
Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratioHR3Pooled -- the primary result
Cardiovascular death (component of the composite)RR4RR 0.858 (0.749 to 0.983), I² 16.9%
First heart-failure hospitalisation (component of the composite)RR4RR 0.878 (0.761 to 1.01), I² 20.4%
All-cause deathRR4RR 0.886 (0.803 to 0.979), I² 7.01%

The registered estimand is a single quantity: cardiovascular death or first heart-failure hospitalisation, whichever comes first, as a time-to-first-event hazard ratio. These three are risk ratios over the whole follow-up, computed from per-arm counts. A risk ratio and a hazard ratio answer different questions, and the protocol fixes the hazard ratio as the measure, so these cannot be promoted into the primary synthesis.

Two of the three are components of the composite. They share the same participants, so reading them alongside the composite counts the same people more than once. The composite counts first events and is not the sum of its components -- on PARADIGM-HF the components exceed it, which is expected. Nothing here is reconstructed by addition.

parallel-hf all-cause death is ClinicalTrials.gov only -- the Circ J primary paper does not report all-cause mortality at all, so that pair has no second source.

Considered and NOT pooled, with the reason

Table 24. Considered and NOT pooled, with the reason
Win ratio (PARACHUTE-HF primary)A hierarchical win ratio is not convertible to a hazard ratio or a risk ratio. It compares pairs of patients on an ordered hierarchy of events; there is no arithmetic that turns it into this review's estimand without inventing information.
NT-proBNP change (PIONEER-HF and others)A ratio of change in a biomarker is not an event-time quantity. Excluded on the measure axis at screening, not omitted here.
Recurrent-event rate ratiosThe estimand is time to first event. A recurrent-event rate ratio counts repeat events and answers a different question; scope decisions fixes this.
Quality of life (KCCQ)Reported on different instruments and timepoints across the four trials, and not by all three. No common scale, so no pool.

Before 2026-08-13 this object carried exactly one analysed outcome and the page did not say why. That was a real gap in what the page communicated, not merely in what it computed: a reader could not tell whether other outcomes had been considered and rejected or simply never looked at. The three secondary pools existed as per-arm counts in the object all along and had not been pooled.

Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio

Forest plot

Drawn from the same stored estimates the table above lists. Box area is proportional to inverse-variance weight.

x-axis range

0.7 1 1.2 1.5 2 2.5 3 4 HR (log scale). 1 = no difference. paradigm-hf 0.8 (0.73 to 0.87) parachute-hf 0.91 (0.73 to 1.13) parallel-hf 1.09 (0.65 to 1.82) answer-hf 1.83 (0.72 to 4.67) Pooled (HR)

⬇ SVG (vector) 3 KB ⬇ PNG 4500x1260 145 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 c78583472284f454…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — forest_fit.eps, 5 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — forest_fit.tiff, 16,611 KB.

Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.

Visual abstract

Sacubitril/valsartan in adults with heart failure and reduced ejection fraction In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril? no difference HR 0.872 95% CI 0.746 to 1.02 The interval INCLUDES no difference: this pooled estimate is compatible with no effect. 4 trials, 9,734 participants. Outcome: Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio. GRADE certainty: pending, not rated. Leave-one-out: 2 of 4 refits still exclude no difference; the estimate does not survive removal of the largest trial.

⬇ SVG (vector) 2 KB ⬇ PNG 4500x2100 295 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 850741fa801ff002…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — visual-abstract.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — visual-abstract.tiff, 27,685 KB.

Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.

PRISMA flow of records

Records identified from databases and registers n = 423 PubMed 331; ClinicalTrials.gov API v2 92 corpus tally: CTGov 92, PubMed 331 Records removed before screening n = 0 No de-duplication step recorded; retrieved totals sum exactly to the screened Records screened on title and abstract n = 423 2 further record(s) UNDETERMINED at this stage, not counted as exclusions. excluded 412 Full texts assessed for eligibility n = 9 excluded 2 Reports of included studies n = 7 Records, not studies: two trials contribute both a publication and a registry Studies contributing to the synthesis n = 4

⬇ SVG (vector) 3 KB ⬇ PNG 3600x2910 294 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 b81d315e593e83af…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — prisma-flow.eps, 5 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — prisma-flow.tiff, 30,691 KB.

Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.

Funnel plot

paradigm-hf parachute-hf parallel-hf answer-hf 0.3 0.4 0.5 0.7 1 1.2 1.5 2 2.5 0 0.2 0.4 HR -- dashed lines are the 95% and 99% funnel standard error (0 at top)

⬇ SVG (vector) 3 KB ⬇ PNG 3500x1700 238 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 98e2ac572275a002…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — funnel.eps, 6 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — funnel.tiff, 17,431 KB.

Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.

Galbraith (radial) plot

paradigm-hf parachute-hf parallel-hf answer-hf 5 10 15 20 -4 -2 0 precision (1/SE) z = effect / SE

⬇ SVG (vector) 2 KB ⬇ PNG 3500x1500 86 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 3eaceb1a73fa986b…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — galbraith.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — galbraith.tiff, 15,381 KB.

Each trial's standardised effect against its precision.

Baujat plot

paradigm-hf parachute-hf parallel-hf answer-hf 0.5 1 1.5 2 0.4 0.6 0.8 1 contribution to Q influence on the pooled estimate

⬇ SVG (vector) 2 KB ⬇ PNG 3500x1500 104 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 772bdfbf6f53ae2c…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — baujat.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — baujat.tiff, 15,381 KB.

Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.

Influence diagnostics

paradigm-hf parachute-hf parallel-hf answer-hf 0.2 0.4 0.5 1 1.5 leverage (hat) Cook's distance

⬇ SVG (vector) 1 KB ⬇ PNG 3500x1500 89 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 dab20113bc6246cd…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — influence.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — influence.tiff, 15,381 KB.

Leverage against Cook's distance, from metafor's influence diagnostics.

Leave-one-out

omitting paradigm-hf 0.966 (0.79 to 1.18) omitting parachute-hf 0.972 (0.666 to 1.42) omitting parallel-hf 0.844 (0.736 to 0.967) omitting answer-hf 0.839 (0.743 to 0.948) 0.7 0.8 0.9 1 1.2 HR (log scale). 1 = no difference. Each row is the pool WITHOUT that trial.

⬇ SVG (vector) 2 KB ⬇ PNG 3500x920 154 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 ec71aab4847ab304…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — leave-one-out.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — leave-one-out.tiff, 9,433 KB.

The pool refitted with each trial removed in turn.

Cumulative meta-analysis

through paradigm-hf (2014) 0.8 (0.733 to 0.873) through parallel-hf (2021) 0.838 (0.675 to 1.04) through answer-hf (2026) 0.972 (0.666 to 1.42) through parachute-hf (2026) 0.872 (0.746 to 1.02) 0.7 0.8 0.9 1 1.2 HR (log scale). 1 = no difference. Each row adds the next trial in year order.

⬇ SVG (vector) 2 KB ⬇ PNG 3500x920 161 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 b71542b3bcb40eaf…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — cumulative.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — cumulative.tiff, 9,433 KB.

The pool as each trial reported, in year order.

Bayesian posterior density

1 2 3 4 0.02 0.04 0.06 pooled ratio posterior density

⬇ SVG (vector) 5 KB ⬇ PNG 3500x1500 93 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 3a0dc30eeebd5489…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — posterior.eps, 13 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — posterior.tiff, 15,381 KB.

grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)

Risk of bias, both assessors

D1 D2 D3 D4 D5 paradigm-hf + + + + + + + + ? + parallel-hf ? + + + + + + + ? + parachute-hf + ? ? ? + + + + + ? answer-hf · · · · · · · · · · Left circle: openai. Right circle: google. + low, ? some concerns, − high, · not assessed.

⬇ SVG (vector) 7 KB ⬇ PNG 3130x1340 157 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 7a977b52482caafd…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — rob-traffic-light.eps, 21 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — rob-traffic-light.tiff, 12,287 KB.

Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured: {'per domain agreed': 10, 'per domain total': 15, 'per domain rate pct': 66.7, 'overall agreed': 1, 'overall total': 3, 'measured not asserted': True, 'comparison to screening': "This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one."}.

GOSH

GOSH plot — not drawn at this k Computable but uninformative at k = 4: the whole subset space is 15 points, and its shape is read for clustering that needs an order of magnitude more studies.

⬇ SVG (vector) 1 KB ⬇ PNG 3500x540 81 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 1ac0f91ef8ab0183…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — gosh.eps, 2 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — gosh.tiff, 5,537 KB.

Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.

Trial-sequential analysis

Trial-sequential analysis — not computable Not run: TSA needs a pre-specified target information size, and no anticipated relative risk reduction or control-arm event rate is registered in this object's protocol.

⬇ SVG (vector) 1 KB ⬇ PNG 3500x650 87 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 25ed9800fdf56614…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — tsa.eps, 2 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — tsa.tiff, 6,665 KB.

TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.

Meta-regression

Meta-regression bubble plot — not drawn at this k Not fitted: 4 trials and no pre-specified moderator. A regression on year would spend 2 of 4 degrees of freedom on a covariate this review never registered.

⬇ SVG (vector) 1 KB ⬇ PNG 3500x540 87 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 0a34e86921018df9…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — bubble.eps, 2 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — bubble.tiff, 5,537 KB.

The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.

L'Abbe plot

no effect paradigm-hf parachute-hf parallel-hf answer-hf 0.1 0.2 0.3 0.15 0.2 0.25 0.3 risk in the control arm risk in the treatment arm

⬇ SVG (vector) 2 KB ⬇ PNG 3500x1500 133 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 a2a8af212f9a5a20…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — labbe.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — labbe.tiff, 15,381 KB.

Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.

Number needed to treat, across baseline risk

0.2 0.4 0.6 50 100 150 assumed risk without treatment number needed to treat

⬇ SVG (vector) 3 KB ⬇ PNG 3500x1500 93 KB

All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 b02217e8c096cf1c…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.

Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — nnt-curve.eps, 7 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — nnt-curve.tiff, 15,381 KB.

The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.

In this section: Summary of findings · Reproducibility artifact · Other recorded qualifications · Comparison with published syntheses · The syntheses reconciled against · Where the numbers differ, and why · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Certainty of the evidence (GRADE) · Did the completed RoB-2 assessment move this rating?

Summary of findings

Table 25. Summary of findings
OutcomekPooled effectCertainty
Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio4 (lower bound)HR 0.872 (0.746 to 1.02)Low12
  1. Rated down from high for risk of bias, imprecision. The summary-of-findings record derives it as: start high; risk_of_bias serious (-1), imprecision serious (-1); total -2 -> low. The risk_of_bias rating was re-examined against the completed RoB-2 assessment on 2026-08-12 and did not move; see domains.risk_of_bias.rob2_effect_on_this_rating. Both stored locations rate this outcome Low, and their recorded grounds are not the same text. Both are stated above rather than one being chosen, because the two can differ in kind -- one recording what the trials were found to be, the other recording what could not be established about them.
  2. Read this beside `whether the estimand was established`. That flag records that every contributing trial measures the same quantity. It records nothing about what that quantity was measured against -- whether the comparators are of one kind, whether each comparison was randomised, whether it was concurrent. The two questions were never separated. Named as P48 in PAGE-STANDARD.md v1.21.0 and swept by scripts/audit_mixed_contrast_pools.py.

Reproducibility artifact

Table 26. Reproducibility artifact
Canonical objectssot/arni-hfref/arni-hfref.json
Registered at961400264a06 2026-08-10T05:13:40Z
Permalinkhttps://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/961400264a06bd940bef11e02b528ea0f73a8dee
Schema2
Object last updated2026-08-09
Page generated2026-08-25 08:10 UTC
Generator buildfa7ef6686 (uncommitted generator changes -- NOT REPRODUCIBLE from this stamp alone). The standard this page was built to is NOT ESTABLISHED: this object carries no build_stamp, so the version above is the standard that exists now, not the one this page was built against.
Statistical enginemetafor 5.0.1 under R 4.6.0, generic inverse variance on the same log point and log standard error this object stores

Everything a third party needs to rebuild this page. Each figure on the Analysis tab downloads as an SVG carrying exactly the values shown.

Other recorded qualifications

Statements this review records about the limits of what it establishes, which are not shown elsewhere on this page. They are reproduced from the object verbatim and are not summarised.

Table 27. Other recorded qualifications
Analysed scopeThe trial's full analysis set. It is smaller than the randomised total and the object shows why rather than leaving two numbers side by side: 4209 and 4233 patients were randomised, 8442 in all; 37 were excluded because their sites were closed for serious good-clinical-practice violations and 6 because they were randomised without qualifying and never received double-blind medication; 4209 less 18 less 4 is 4187 and 4233 less 19 less 2 is 4212, which is the 8399 the regulator layers name. The exclusions are site-level and protocol-level rather than outcome-dependent, which is why they are reported and not treated as attrition on the effect.
Analysed scopeThe full analysis set, which the registry defines as all participants to whom study treatment was assigned at randomisation, and which equals the randomised total here.
Registry results confirm the stored countsresultsSection outcome “Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes”: 33.5 in the sacubitril/valsartan group, 36.7 in the enalapril group. 155/462 = 33.55% and 169/460 = 36.74%. The stored arm sizes and event counts are the registry's own.
The cause in the registry own words"Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 55 months. Deaths were also collected in the survival follow-up phase from 31 days after last dose of study medication until the end of the study, for an additional 8 months. These were not considered AEs." -- ClinicalTrials.gov timeFrame, verbatim, read 2026-08-18.
Neither value is adopted over the otherBoth stand, each labelled with its window. The original decision to record both and refuse to choose was correct; what was missing was the reason.
Analysed scopeThe analysis set the registry posts for this endpoint, 111 and 112, derived on the record from 112 and 113 randomised less one mis-randomised patient in each arm. This is the same denominator-scope shape as PARADIGM-HF and is shown the same way rather than left as an unexplained difference from 225.
Endpoint rank in its own trial supersededa secondary endpoint; the trial's primary is change in left ventricular ejection fraction
Why it does not moveTwo reasons, and the second is the load-bearing one. First, RoB-2 confirmed the substance of the downgrade rather than removing it. Both assessors, independently and from different model families, rated PARACHUTE-HF domain 2 as some concerns on the open-label deviations point, which is the first of the three features the rating was already built on. The second assessor also rated its domain 5 as some concerns on the selective-reporting point, which is the second feature. The assessment agreed with the reasoning the rating rested on. Second, and this is why 'no domain reached HIGH' does not discharge the downgrade: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomization failure, a deviation, missing data, a measurement problem, or selective reporting of a result; it is a stopping-rule effect on the magnitude of the estimate, and the RoB-2 tool does not ask about it in any of its five domains. PARADIGM-HF was stopped early by prespecified rule for overwhelming benefit and the leave-one-out analysis shows the pooled benefit rests on that trial. That third feature is therefore untouched by a clean RoB-2 result, and it alone sustains a serious rating. Reading 'no domain HIGH' as grounds to remove the downgrade would be mistaking the silence of a tool for the absence of a problem.
Conditions under which it would moveIf the named human adjudicates the five open disagreements toward LOW, and separately judges that the early-stopping effect is adequately carried by the imprecision and leave-one-out analyses rather than here, then 'not serious' becomes defensible and certainty would rise to moderate. That is a human decision on the record, not an automatic consequence of the assessment.
Why not downgraded despite the spreadSuperseded at k=4 and flagged for re-reading rather than rewritten. The previous text argued that the low I-squared band justified no downgrade while the spread was carried by imprecision. Both inputs changed: I-squared is now 32.9% to 55.7% depending on estimator, and the four point estimates run 0.80 to 1.83. Whether that still supports 'not serious' is a judgement to be re-argued, not a label to be re-applied, and it is left open rather than settled by the script that changed the numbers.
The witness that needs no methods sectionAn arithmetic witness, independent of any sentence. Table 2's all-cause death row is 8/95 against 8/95, so the crude risk ratio and the crude odds ratio are both exactly 1.000 -- and the published value is 1.08. No crude measure can produce 1.08 from eight versus eight. Only an estimator using time and censoring, adjusted for site, can move that comparison off unity. The same pattern holds across all four rows, every published value exceeding its own crude risk ratio: 1.27 against 1.167, 1.42 against 1.400, 1.83 against 1.500, 1.08 against 1.000. The two figures this page previously quoted are unchanged and are restated here so they do not simply vanish: from 12/95 versus 8/95 the crude risk ratio is 1.50 and the crude odds ratio is 1.57, and neither is 1.83. That was the original observation and it was correct -- it was the inference drawn from it that was wrong. Departure from the crude measures is what a Cox model does; it is not a sign that the measure is unidentified.
What was wrong in what we publishedTwo published claims were false, and both were ours. First: "the source does not say that it is one" -- the column header says HR and the Methods name the model. Second, and worse: "the trial states no time-to-event analysis of this composite anywhere" -- the trial states exactly that, in the sentence quoted above. The hypothesis offered alongside them, that 1.83 might be the win ratio analysed a second way, is refuted: the win ratio is a four-level hierarchical statistic over cardiovascular death, heart-failure hospitalisation, NT-proBNP change and LVEF change, with intervals from bootstrap resampling, reported as 1.81 (1.27 to 2.63) in the Results and 1.80 in the Abstract -- and its clinical-outcomes-only sensitivity analysis is 0.64 (0.22 to 1.66). A statistic whose clinical-only form is 0.64 is not the source of a 1.83 on the clinical composite.
The answer was already in this objectAnd the object already HELD it. The provenance block on this very trial and this very outcome carries model statement quote -- the Cox sentence above, verbatim and character-identical to the publication -- and it was present in commit 935cf870a, the commit that created the open question, and in every commit since. The object asserted "the source does not say that it is one" in its results section while holding, one level up on the same trial, the sentence in which the source says it. The finding was not blocked by a missing fact; it was blocked by two fields that were never read against each other.
Why this ordering and not the reverseExcluding the trial converts a null result into a positive one by our own choice, and the Handbook gives no basis for the exclusion. Presenting the exclusion as a sensitivity analysis discloses the same fact without letting our judgement manufacture the finding. The direction of the error decides: a wrong inclusion leaves a null intact; a wrong exclusion publishes a positive result we created.
What this does not establishNot that ANSWER-HF's estimate is wrong -- the measure question was separately resolved and 1.83 (0.72-4.67) is a hazard ratio. Not that the pool is correct: the other uniformity axes (aetiology, follow-up length, ejection-fraction ceiling) differ and are stated separately on the page. This field decides eligibility only.
Verbatim scopeCovers bias arising when 'the reported result is selected (based on its direction, magnitude or statistical significance) from among multiple intervention effect estimates that were calculated by the trial authors'.
Why this was done and why it had not beenAuditing a topic's provenance is not auditing its arithmetic. This page has had more scrutiny than any other in the corpus -- ANSWER-HF's endpoint registration status, its measure question, its identity, its Handbook treatment -- and none of that recomputed the number the page publishes. The earlier headline-reproduction sweep returned 514 of 514, but it compared page to object: it establishes that the projection is faithful and says nothing about whether the object's own arithmetic is right. Those are two different questions and only the first had been answered.
Step 1 inputs against their own reported effectsEach trial's stored log point and log standard error were recomputed from the HR and CI recorded beside them. All four agree to 1e-6 or better: PARADIGM-HF 0.80 (0.73-0.87), PARACHUTE-HF 0.91 (0.73-1.13), PARALLEL-HF 1.09 (0.65-1.82), ANSWER-HF 1.83 (0.72-4.67).
What this does not establishNot that the four trials should be pooled -- that is the estimand and eligibility question settled elsewhere on this object, and re-derivation is arithmetic, not judgement. Not that the per-trial HRs are correctly read from their sources: this checked the object's internal consistency, from stored HR and CI through to the pooled value. Whether 0.80 is what PARADIGM-HF reports is a source check and is separate. Not that any other topic re-derives; 18 remain unchecked.
Why that quantity is never stored as a hazard ratioA recurrent-event rate ratio counts repeat events per person over time; a time-to-first hazard ratio counts each person once, at their first event. The two share a scale and a direction and answer different questions, and storing this trial's 0.87 in a hazard-ratio field would be indistinguishable, to any reader and to most software, from a hazard ratio of 0.87. It is stored nowhere in this object except in this sentence.
Limitation of this instrumentThe prompt given to screener B said that an undetermined later resolved is worth more than a confident wrong exclusion. That wording plausibly pushed it toward undetermined, and 91 of 91 disagreements running one way is consistent with an induced bias as well as with genuine caution. The agreement rate is therefore reported as measured but should not be read as an unbiased estimate of inter-screener reliability. Re-running screener B on neutral wording is the check, and it has not been done.
Review scopesacubitril/valsartan against enalapril in heart failure, any outcome, any design
Review scopesacubitril/valsartan against enalapril in heart failure with reduced ejection fraction due to Chagas cardiomyopathy
Access limitationBoth reviews are staged, at the depth that is open. Their abstracts are readable and are in the bundle, and they are the source of the patient total below. Their full texts are paywalled -- each returned a payment-required response when fetched on the date recorded here, and neither has a PubMed Central or other open-access copy -- and the full text is where the included-study list lives. The count is therefore checkable and the list is not, which is the whole shape of this unresolved item.
Why it does not change the poolIt does not change k and it must not. The patients it names are PARADIGM-HF patients, already counted once in this pool at the level of the randomisation they belong . An earlier version of this field said the opposite -- that nothing about the shortfall was known, not even a name -- and that had stopped being true the moment the ANSWER-HF registry record was staged. A stated unknown is something a reader trusts, so carrying one that the bundle itself refutes is worse than the gap it was describing.
Access limitationOne comparison review was fully readable and its included-study table is what made this reconciliation possible. The other relevant reviews -- those covering the Chagas sub-question -- are paywalled: each returned a payment-required response when fetched on the date recorded here and none has an open-access copy, so their included-study lists could not be read and only their abstracts could. Where a list could not be read, no agreement is claimed from a matching count: that is the coincidence-of-counts overclaim this step exists to avoid, and the arithmetic that fails to reconcile is written out instead.
What the commit evidence does not establishIt does not establish prospectiveness. A commit proves when text entered this repository; it cannot prove that no earlier or parallel version existed elsewhere, that the data had not already been seen when the text was written, or that the analysis plan was fixed before the results were known. It also says nothing about the independence of the people who wrote it. Those are claims about conduct, and a timestamp cannot carry them.
Why they must not be added upTwo of the three are components of the composite. They share the same participants, so reading them alongside the composite counts the same people more than once. The composite counts first events and is not the sum of its components -- on PARADIGM-HF the components exceed it, which is expected. Nothing here is reconstructed by addition.
Source caveatparallel-hf all-cause death is ClinicalTrials.gov only -- the Circ J primary paper does not report all-cause mortality at all, so that pair has no second source.
ScopePRISMA 2020, 42 items. Status recorded per item; boxes are not filled to make the diagram look complete.
Scopesacubitril/valsartan against enalapril in heart failure, any outcome, randomised or observational
The decision every field now statesAnswer-hf is in the pool. k=4. It is flagged HIGH risk on selection of the reported result, because its contributed endpoint is not registered at any rank in its own registration. k=3 stands as the sensitivity analysis, not the primary.
Why this matters more than a tidy upOmitting ANSWER-HF gives HR 0.8333 (0.7473-0.9292); including it gives 0.8715 (0.7461-1.0181). The interval crosses 1 only with it in. A reader who checks this object found it contradicting itself about the single trial that decides the inference.
Registry facts backfilledRead from ClinicalTrials.gov API v2 on 2026-08-21. The judgements above were not revisited -- this adds the registry evidence beside a verdict that was made from it and did not record it, so a blind second assessor can be shown the same facts. A second assessment built on fewer facts is not a comparable assessment.
Was a second assessment possible hereYes, and the earlier refusal was wrong. These three entries are keyed `paradigm-hf`, `parallel-hf` and `parachute-hf` and carry no `nct` field, so the backfill first reported them as 'the registration cannot be identified'. The object HELD the mapping two keys away: inputs.trials and results.by_outcome.*.per_trial both give paradigm-hf -> NCT01035255, parallel-hf -> NCT02468232, parachute-hf -> NCT04023227. Not a permanent refusal and not an obstacle in the evidence -- a lookup that read one field where this corpus uses two.
Why this topic disagrees on everythingARNI is the authored docmodel topic. Its risk-of-bias entries were written as prose judgements with domain keys the randomisation process..selection of the reported result and no registry fields at all -- the facts were backfilled on 2026-08-21, after those judgements were made. So assessor 1 judged from sources this comparison cannot see, and assessor 2 judged from the registry alone. The 100% rate is not a measure of the assessors; it is the fact-allow-list problem in its purest form, on the one topic where the first assessment did not come from the registry.

Comparison with published syntheses

Every paper this project ships carries this section. A synthesis that reports only its own result asks a reader to take the field on trust; one that reconciles itself against the published syntheses on the same question, names what they got right as prominently as what they got wrong, and shows the denominator, can be checked. The classes applied below are the classes this review must itself survive. On the night this section was written, this object failed three of them: analysis panels computed at k=3 under a k=4 headline, a title stating a study count its own contents contradicted, and a figure labelled as a diagnostic it was not drawing.

13 checks were applied to this review and 9 came back clean. The denominator is stated because a list of only the failures is not a finding, it is a selection.

Confirmations are listed in the same table, in the same detail, as errors. Two checks were designed to catch a fault and instead cleared the paper: including a cohort study is inside their own stated eligibility, and omitting a small-study test at nine studies is what the Handbook advises.

Table 28. Comparison with published syntheses
CheckVerdictWhat was found
Stated study count against the rows of its own Table 1
count-stated-vs-table
CONFIRMED
checked and clean
The abstract and Results both say nine. Table 1 carries exactly nine author rows: Bano, Desai, Li, McMurray, Pathadka, Piepoli, Tsutsui, Velazquez, Zhao. Counted from the staged full text, not taken from the abstract.
Quoted: “A total of nine studies were included in this meta-analysis.” — Abstract; Results, paragraph 1
Stated design mix against the Design column of Table 1
design-counts
CONFIRMED
checked and clean
Eight rows are typed RCT and one, Pathadka 2020, RC. The stated split is exact.
Quoted: “Out of nine studies, eight were RCTs.” — Results, paragraph 1
PARADIGM-HF arm sizes against our own source-read values
paradigm-arms
CONFIRMED
checked and clean
Their Table 1 gives 4187 and 4212. This object read 4187 and 4212 from the trial's own publication and registry record. Identical.
Quoted: “McMurray et al. 2014 RCT ... 4187 ... Enalapril 10 mg twice 4212” — Table 1
PARALLEL-HF arm sizes against our own source-read values
parallel-arms
CONFIRMED
checked and clean
Their Table 1 gives 111 and 112, matching this object exactly. This is the trial their list caused us to recover, so their record is also the reason our k rose from two to three.
Quoted: “Tsutsui et al. 2021 RCT ... 111 ... Enalapril 10 mg twice 112” — Table 1
Internal arithmetic of the study-selection flow
prisma-arithmetic
CONFIRMED
checked and clean
1,066 retrieved, 985 screened after duplicates, 28 full texts, nine included. Monotone decreasing and internally consistent; no stage exceeds the one above it.
Quoted: “We obtained 1,066 studies through online database searching. After removing duplicates, 985 studies were initially screened” — Results, paragraph 1
Whether their omission of PARACHUTE-HF is an error or a date
search-date-vs-our-newer-trial
CONFIRMED
checked and clean
Their search closed 15 September 2023. PARACHUTE-HF reported in 2026. Its absence from their review is correct and is not counted against them. A reconciliation that scored this as a miss would be scoring them for not seeing the future.
Quoted: “systematically searched online databases including PubMed, Cochrane Library, and Web of Science from inception till September 15, 2023” — Abstract; Methods
Whether including a retrospective cohort breaches their own stated eligibility
cohort-against-own-criterion
CONFIRMED
checked and clean
It does not. Their pre-specified criteria admit observational designs explicitly, so Pathadka 2020 is inside their own protocol. This object excludes it because this question is restricted to randomised evidence, which is a different question and not a fault in theirs. Checked precisely because population-included-against-the-paper's-own-criterion is one of the classes we look for, and here it is clean.
Quoted: “The pre-defined inclusion criteria were observational studies (retrospective cohorts and prospective cohorts) or RCTs comparing sacubitril” — Methods
Whether the influential non-randomised study was tested
sensitivity-reported
CONFIRMED
checked and clean
It was, and the result is reported in the body rather than buried: removing Pathadka moves all-cause mortality from 0.57 to 0.85 and heterogeneity from 94 per cent to 0. Reporting a sensitivity analysis that overturns your own headline is good practice and is recorded here as such.
Quoted: “We performed sensitivity analysis by removing the study conducted by Pathadka et al. as it was a retrospective study.” — Results, All-Cause Mortality
Absence of a funnel plot or small-study test
no-publication-bias-test
CONFIRMED
checked and clean
None is reported, and at nine studies none is expected: the Cochrane Handbook advises against interpreting these tests below about ten. Their omission is defensible and is not counted as a defect. This object applies the same caution to its own Egger's test at k = 4.
whole paper
Whether the Discussion's significance claim matches the primary estimate
discussion-significance-overstated
ERROR
a defect, in the source named
The primary all-cause mortality estimate is RR 0.57 with a 95 per cent interval of 0.31 to 1.04. That interval contains 1, so the comparison is not statistically significant. The Discussion nevertheless states that all three outcomes, all-cause mortality among them, were significantly higher. The statement is true of their RCT-only sensitivity result, 0.85 (0.78 to 0.93), and is not true of the analysis the abstract leads . It is an error of precision rather than a fabricated number, and it is recorded that way.
Quoted: “The present meta-analysis reported that the risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization was significantly higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan.” — Discussion, paragraph 1
Whether the abstract's headline carries the heterogeneity it rests on
abstract-headline-omits-i2
ERROR
a defect, in the source named
The abstract reports RR 0.57 (0.31 to 1.04) for all-cause mortality with no mention that I-squared for that pool is 94 per cent, nor that removing one retrospective study takes it to 0 and moves the estimate to 0.85. A pooled estimate at I-squared 94 is an average over results that disagree, and an abstract is where most readers stop. Their own body text is transparent about both facts; the abstract is not.
Quoted: “Significant heterogeneity was reported among the study results (p = 0.001; I-square: 94%).” — Results, All-Cause Mortality; Abstract
Per-study risk-of-bias or quality appraisal
no-risk-of-bias-appraisal
ABSENT
the thing checked for is not there
No Cochrane RoB, Jadad, Newcastle-Ottawa or equivalent appears anywhere in the text. The JBI reference is to the study-SELECTION protocol, not to an appraisal of the included studies. Risk of bias is a required PRISMA item, and pooling a retrospective cohort with randomised trials is exactly the situation it exists to surface.
Quoted: “The selection and critical appraisal of studies adhered to the Joanna Briggs Institute's (JBI) protocol, which offers a more precise and stringent set of criteria for the study selection process.” — Methods
Prospective protocol registration
no-registration
ABSENT
the thing checked for is not there
PROSPERO is not mentioned and no registration of any kind is stated, so the analysis cannot be checked against a pre-specified plan. Recorded as an absence rather than an error: an unregistered review is not a wrong one. This object states its own registration as a timestamped public commit with an ordering test, so it is a standard we hold ourselves .
whole paper

The syntheses reconciled against

Table 29. The syntheses reconciled against
38084196Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis. Cureus 2023;15(11):e48623.
Three differences, and none of them makes either review wrong. They admit observational designs and this object does not. They pool risk ratios over whole follow-up; this object pools a time-to-first-event hazard ratio, a different quantity. Their search closed in September 2023, before two of the four trials pooled here existed.

Where the numbers differ, and why

Table 30. Where the numbers differ, and why
This reviewHR 0.872 (0.746 to 1.018) for cardiovascular death or first heart-failure hospitalisation, k=4, time-to-first-event.
The published synthesisRR 0.76 (0.66 to 0.86) for cardiovascular hospitalisation and RR 0.75 (0.62 to 0.91) for cardiovascular mortality, reported as separate outcomes.
Why they differFour reasons, none of which is an error by either side: a different estimand (hazard of a first event against risk over whole follow-up); a different eligible set (they admit observational designs, we do not); a different search window (ours includes two trials published after theirs closed); and a different composite (they report hospitalisation and cardiovascular death separately, we pool the composite of the two). Decomposed rather than asserting ours is right: on the trials and the quantity the two reviews share, they agree.

How they were identified: By lookup, never recall. The comparison review's identifiers were resolved through the PubMed ID converter on 2026-08-14: DOI 10.7759/cureus.48623 returns PMID 38084196 and pmcid PMC10710849. Its full text is staged in this bundle and every quotation below was read from that file.

Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio

Certainty of the evidence (GRADE)

Certainty: Pending — not rated. The risk-of-bias assessment this rating reads is unadjudicated, so no certainty level is published for this outcome

Started at high — every contributing study is a randomised controlled trial.

start high; risk_of_bias serious (-1), imprecision serious (-1); total -2 -> low. The risk_of_bias rating was re-examined against the completed RoB-2 assessment on 2026-08-12 and did not move; see domains.risk_of_bias.rob2_effect_on_this_rating.

Table 31. Certainty of the evidence (GRADE)
DomainRatingWhy it was rated that way
Risk of biasseriousThree separate features, each read from a staged source rather than assumed. PARACHUTE-HF describes itself as an 'open-label, multicenter randomized clinical trial' with blinded endpoint adjudication; blinded adjudication protects how an event is classified but not the unblinded management decisions that produce a heart failure hospitalization, which is one of the two components. In the same trial this composite is the first secondary endpoint, the primary being a win ratio, so the result pooled here comes from that trial's secondary hierarchy and carries the multiplicity and selective-reporting exposure that goes with it; the separate question of the trial not being powered for this endpoint is random error and is carried in the imprecision domain, not here. PARADIGM-HF 'was stopped early, according to prespecified rules ... because the boundary for an overwhelming benefit with LCZ696 had been crossed', and a trial stopped early for benefit tends to overstate the effect it was stopped for -- which matters here because the leave-one-out analysis shows the pooled benefit rests on that trial. One level, not two: the trials are randomised, centrally adjudicated and large, and none of the three features is a failure of randomisation.
Inconsistencynot serious—
Indirectnessnot seriousAll four trials enrol the population the question names, randomise the intervention the question names against the comparator the question names, and report the outcome the question names. The Chagas aetiology of one trial makes its population narrower than the others, not indirect: it is heart failure with reduced ejection fraction, entered on an ejection fraction of 40% or less and NYHA class II to IV, exactly as the other two are. Directness is judged against the review's own question, and this question is about heart failure with reduced ejection fraction rather than about any one aetiology of it.
Imprecisionserious—
Publication biasnot assessable—

Did the completed RoB-2 assessment move this rating?

No, it does NOT move. It was serious before the assessment and is serious after it.

Two reasons, and the second is the load-bearing one. First, RoB-2 confirmed the substance of the downgrade rather than removing it. Both assessors, independently and from different model families, rated PARACHUTE-HF domain 2 as some concerns on the open-label deviations point, which is the first of the three features the rating was already built on. The second assessor also rated its domain 5 as some concerns on the selective-reporting point, which is the second feature. The assessment agreed with the reasoning the rating rested on. Second, and this is why 'no domain reached HIGH' does not discharge the downgrade: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomization failure, a deviation, missing data, a measurement problem, or selective reporting of a result; it is a stopping-rule effect on the magnitude of the estimate, and the RoB-2 tool does not ask about it in any of its five domains. PARADIGM-HF was stopped early by prespecified rule for overwhelming benefit and the leave-one-out analysis shows the pooled benefit rests on that trial. That third feature is therefore untouched by a clean RoB-2 result, and it alone sustains a serious rating. Reading 'no domain HIGH' as grounds to remove the downgrade would be mistaking the silence of a tool for the absence of a problem.

The opposite reading, recorded rather than suppressed: The opposite reading is available and is recorded here rather than suppressed: under a common mapping, trials at some concerns with none at HIGH support 'not serious', which would raise certainty from low to moderate. We do not adopt it, for the stopping-rule reason above, and because five of fifteen domain judgements are still unadjudicated -- changing a published certainty rating on the strength of a disagreement set nobody has resolved would be the wrong direction to move under uncertainty.

What would change it: If the named human adjudicates the five open disagreements toward LOW, and separately judges that the early-stopping effect is adequately carried by the imprecision and leave-one-out analyses rather than here, then 'not serious' becomes defensible and certainty would rise to moderate. That is a human decision on the record, not an automatic consequence of the assessment.

In this section: Manuscript — document view · Sacubitril/valsartan against enalapril in heart failure with reduced ejection fraction: a systematic review and meta-analysis of the four randomised trials that report cardiovascular death or heart failure hospitalization as a time-to-first hazard ratio · Contents · Abstract · Introduction · Methods · Protocol and registration · Eligibility criteria · Information sources and search · Study selection and data collection · Effect measures and synthesis · Risk of bias · Certainty and robustness · Recorded detail · Results · Study selection · Trial characteristics · Primary synthesis · Robustness · Cross-engine verification · Risk of bias · Certainty of the evidence · Subgroup analysis · Small-study effects · Comparison with published syntheses · Tables and figures · Extracted values, and where each came from · Certainty of the evidence · Risk of bias in the included results · Disagreements between sources · Comparison with published syntheses · Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a syst · Where our result differs from theirs · Statistical output, quoted verbatim · Discussion · Principal findings · Interpreting the estimate · Heterogeneity · The leave-one-out finding · Why the risk-of-bias rating did not change · Comparison with other evidence · Strengths · Limitations · Conclusions · Sections not written, and why · Funding and conflicts of interest · References · Keywords · Data availability · Software availability · Note on registration · Tables · Figure legends · Figures · Submission conformance

Manuscript — document view

Rendered from the same block sequence the Word file is built from: 18 tables and 16 figures, in the same order, with the same numbering. The figures are the identical PNG files the .docx embeds, not a second render. Built 2026-08-17T16:19:14Z.

Downloads

Sacubitril/valsartan against enalapril in heart failure with reduced ejection fraction: a systematic review and meta-analysis of the four randomised trials that report cardiovascular death or heart failure hospitalization as a time-to-first hazard ratio

In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril?

Submission readiness: NOT YET DETERMINED. Every number in this document is projected from a single canonical object; sections that could not be written from it say so in place.

Contents

Abstract

Background. Angiotensin receptor-neprilysin inhibition changed the treatment of heart failure with reduced ejection fraction on the strength of a single large trial. Because that trial dominates the guidelines and every later synthesis, what the accumulated randomised evidence shows when it is not treated as the answer on its own is a different question, and the one this review asks.

Methods. PubMed and ClinicalTrials.gov were searched on 2026-08-12 with no language, date or publication-status filter. Randomised trials of sacubitril/valsartan against enalapril in adults with heart failure and reduced ejection fraction were eligible if they reported the composite of cardiovascular death or first hospitalisation for heart failure as a time-to-first-event hazard ratio. Hazard ratios were pooled on the log scale by generic inverse variance under a random-effects model with the REML estimator. Risk of bias used the Cochrane risk-of-bias tool for randomised trials, effect-of-assignment variant, assessed independently by two assessors. Certainty used the Grading of Recommendations Assessment, Development and Evaluation approach.

Results. 423 records were screened and 4 trials met all eligibility conditions. Those trials randomised 9,779 participants. Of those, 9,734 participants were analysed. The pooled hazard ratio was 0.872 (0.746 to 1.02), an interval that includes no effect. Heterogeneity was moderate and estimator-dependent, with I-squared 32.9 percent under the registered estimator. The pooled result is dominated by one trial: omitting the largest gives 0.966 (0.79 to 1.18), and each of the three remaining trials has an interval that includes no effect. No risk-of-bias domain was rated high in the three trials that were assessed (PARADIGM-HF, PARALLEL-HF and PARACHUTE-HF); the fourth contributing trial was not assessed, so this is not a statement about the synthesis as a whole. Certainty is not rated pending adjudication.

Conclusions. Across 4 randomised trials the pooled estimate is compatible with no difference between sacubitril/valsartan and enalapril for a first cardiovascular death or heart failure hospitalisation. The point estimate favours sacubitril/valsartan and rests almost entirely on one large trial; the three smaller trials are individually and jointly compatible with no effect. This is an argument for reading that one trial as the evidence base rather than treating the pooled average as confirmation of it.

Introduction

Heart failure with reduced ejection fraction carries a mortality and rehospitalisation burden that renin-angiotensin system inhibition reduces but does not remove. Angiotensin receptor-neprilysin inhibition was developed to act on a second pathway at the same time, combining neprilysin inhibition, which raises natriuretic peptide concentrations, with angiotensin receptor blockade.

The pivotal comparison against enalapril reported a substantial reduction in the composite of cardiovascular death or heart failure hospitalisation and was stopped early by prespecified rule for overwhelming benefit. That trial is the reason the drug entered guidelines, and it remains by a wide margin the largest randomised comparison of these two agents on this endpoint.

Three later randomised comparisons against the same active comparator have reported the same composite in different populations. None was powered to detect the effect the pivotal trial found, one reports the composite as a secondary rather than a primary endpoint, and two enrolled a single aetiology. They are nonetheless the only additional randomised evidence on this estimand.

A meta-analysis in which one trial contributes most of the information is often criticised as adding nothing to that trial. The criticism is worth taking seriously rather than deflecting, and it is why this review reports leave-one-out as a principal result rather than a sensitivity appendix. The question it can answer is not whether the drug works, which the pivotal trial addresses directly, but how much of the pooled estimate survives that trial's removal.

Methods

Protocol and registration

The protocol was registered before any query was executed, as a timestamped commit in a public repository, and is reachable at a SHA-pinned permalink that cannot be rewritten without changing the hash. The interval between registration and the first executed query was +51 min 31 s to the attempt, +54 min 52 s to the first successful execution, and the ordering is re-tested at every build rather than asserted once. Amendments are recorded as further commits, each marked according to whether it precedes or post-dates the first search, so a reader can see which decisions were made in ignorance of the results and which were not.

Eligibility criteria

Trials were eligible if they randomised adults with heart failure and reduced ejection fraction to sacubitril/valsartan or to enalapril and reported the composite of cardiovascular death or first heart failure hospitalisation as a time-to-first-event hazard ratio. The fourth condition is a condition on the reported quantity, not on quality. Several excluded records are large, well conducted, and directly concerned with this drug; they are excluded because they report a different estimand, and the supplement records for each one which axis it failed and what it reported instead.

PubMed and ClinicalTrials.gov were searched on 2026-08-12. The query strings are reproduced in the supplement exactly as sent, with the endpoint, the parameters, the filters and the UTC time of execution, so that the search can be re-run rather than merely described. No language, date or publication-status filter was applied. 423 records were returned and every one is listed with its disposition.

Study selection and data collection

Records were screened against the eligibility axes, and each exclusion records the axis that failed and, where the failure was on a reported quantity, the quantity the record gave instead. One inclusion decision reversed a screener's original exclusion; that adjudication is shown as an override naming the adjudicator and the time, rather than being absorbed silently into the included set.

Effect measures and synthesis

Hazard ratios were analysed on the log scale by generic inverse variance, with the standard error implied by each published interval. A random-effects model was fitted with the REML estimator of the between-study variance; DerSimonian-Laird was not used, because it is known to be biased when the number of trials is small, and with 4 trials that condition holds. Heterogeneity is reported as tau-squared alongside I-squared, because I-squared is a proportion and says nothing about the magnitude of the between-trial spread. Results were computed with metafor under R at build time; the figures on this page are drawn from the stored estimates, not recomputed in the browser.

Risk of bias

Each pooled result was assessed with RoB-2 using the effect-of-assignment variant, at the level of the result being pooled rather than the trial overall. Two assessors worked independently, drawn from different model families and excluding whichever assembled this object. Every signalling question answer is published in the supplement. Agreement is reported as measured, before reconciliation, and disagreements that remain open are shown as open.

Certainty and robustness

Certainty was rated with GRADE. Robustness was examined by leave-one-out and by refitting under alternative between-study variance estimators, following the Cochrane Handbook's guidance that sensitivity analysis should test the decisions capable of changing the conclusion. The whole analysis was independently recomputed by a second engine and the two were compared to a stated tolerance.

Recorded detail

Protocol and registration

Registered as a timestamped public commit in https://github.com/mahmood726-cyber/rapidmeta-finerenone at path ssot/arni-hfref/arni-hfref.json. Commit 961400264a06, committed 2026-08-10T05:13:40Z. The protocol commit precedes the first executed query on both readings of 'first query'. The 12:19:18Z attempt is reported even though it returned nothing, because reporting only the successful execution would move the first-query time three minutes later and make the claim look better than it is. This is the test a PROSPERO record cannot offer: the timestamps are set by the repository and by the APIs, not by us, and both are independently checkable.

Eligibility criteria

A randomised trial of sacubitril/valsartan against enalapril, in adults with heart failure and reduced ejection fraction, reporting cardiovascular death or heart failure hospitalization as a time-to-first-event hazard ratio. All four conditions, and the last is a condition on the QUANTITY reported, not on the trial's quality: several excluded trials are large, well conducted and directly on topic, and report something that is not this.

Information sources and search

The search ran across PubMed and ClinicalTrials.gov for randomised comparisons of sacubitril/valsartan with enalapril in heart failure, and was then extended by the reconciliation step: the included-study list of every retrievable published synthesis of the same comparison was read and diffed against this one in both directions. That second pass is what found PARALLEL-HF, which the brief this object was built from did not name.

Each database's query string is recorded in the canonical object exactly as executed, with the endpoint, the parameters, the filters, the execution timestamp and the hit count the API returned, and all of it is reproduced in the extended data (search_capture.csv). The search is therefore reproducible from this record. This paragraph previously asserted the opposite -- that no query string was recorded and the search was not reproducible -- while the strings sat in the object six paragraphs away.

Synthesis methods

Random-effects model with the REML estimator.

Results

Table 1. PRISMA flow of records, as counts
Table 32. Results
StagenDetail
Records identified from databases and registers423PubMed: 331; ClinicalTrials.gov API v2: 92
Records removed before screening0No de-duplication step is recorded; the retrieved totals sum exactly to the screened corpus. Corpus tally: CTGov 92, PubMed 331
Records screened on title and abstract423
Records excluded at title and abstract412
Records undetermined at title and abstract2Not counted as exclusions.
Reports assessed for eligibility at full text9
Reports excluded at full text2
Studies contributing to the synthesis7

Study selection

423 records were screened and 4 trials met all four eligibility conditions. Those trials randomised 9,779 participants. Of those, 9,734 participants were analysed. The count of eligible trials is reported as a LOWER BOUND rather than as a settled number, because a small number of records could not be resolved to a decision from what is publicly reachable; treating an unresolved record as an exclusion would be an assumption presented as a count. The flow of records through screening, with the stages this corpus never recorded stated as such, is shown in the PRISMA figure.

Trial characteristics

The 4 trials differ in ways that matter for interpretation. One is a large double-blind trial reporting this composite as its own primary endpoint. Two enrolled chronic Chagas cardiomyopathy, one of them open-label with blinded adjudication and reporting this composite behind a win-ratio primary. One is double-blind and small. Characteristics are in Table 1 and per-arm counts in Table 2. Characteristics of the included trials are given in the table of included studies and their per-arm event counts in the table of per-arm counts.

Primary synthesis

The pooled hazard ratio was 0.872 (0.746 to 1.02, 95% interval), favouring sacubitril/valsartan over enalapril. Between-trial heterogeneity was low: I-squared 32.9%, tau-squared 0.0086, with Q of 5.16 on 3 degrees of freedom. The individual estimates range from 0.8 to 1.83, and that spread is real even though the heterogeneity statistics are small, because three of the four intervals include the null and two of those span more than a doubling of risk. The per-trial and pooled estimates are shown in the forest plot. The prediction interval for a future study runs from 0.686 to 1.11.

Robustness

The pooled result is not robust to the removal of the largest trial. Omitting it gives 0.966 (0.79 to 1.18), an interval that includes the null. The three smaller trials are therefore individually and jointly compatible with no effect on this composite, and the pooled estimate is best read as the large trial's result, slightly attenuated by the three smaller trials, which neither confirm nor contradict it. Refitting under alternative between-study variance estimators did not change this conclusion. Each refit is shown in the leave-one-out figure and tabulated in the leave-one-out table; 2 of 4 refits still exclude no difference.

Cross-engine verification

The whole synthesis was recomputed independently and the two engines agreed on the point estimate and both bounds to within the stated tolerance, with Q and its degrees of freedom matching exactly. This establishes that the arithmetic is reproducible; it does not establish that the inputs are correct, and it is reported as the former only.

Risk of bias

No domain in any trial was rated at high risk of bias by either assessor. The two assessors agreed on 10/15 domain judgements (66.7%), and on 1 of 3 overall judgements. That agreement rate is markedly lower than the agreement observed at screening, and it is published because an unreported agreement rate is not the same as a high one. Per-domain judgements from both assessors are shown in the risk-of-bias figure.

Certainty of the evidence

GRADE certainty for this outcome is low, downgraded for risk of bias and for imprecision. The completed RoB-2 assessment was checked against the risk-of-bias downgrade and did not change it, for reasons given in the discussion.

Subgroup analysis

One subgroup analysis was performed and it was NOT pre-specified. Splitting the pool by aetiology gives 0.838 (0.675 to 1.04) across the 2 trials in unrestricted heart failure and 1.11 (0.598 to 2.05) across the 2 trials restricted to Chagas cardiomyopathy. The test for interaction returns p = 0.538 and a ratio of hazard ratios of 1.16 (0.717 to 1.89), so the difference between the strata is compatible with chance. Splitting on aetiology does not explain the heterogeneity: the residual I-squared within strata is higher than the overall value, not lower. Because the analysis is post hoc it is reported as hypothesis-generating and is labelled post hoc wherever it appears, in keeping with the Cochrane Handbook v6.5 section 10.11.5 caution against presenting unplanned subgroup contrasts as findings.

Small-study effects

A funnel plot is shown and Egger's regression test was run for completeness, returning an intercept of -0.3 with p = 0.0106. Neither is interpreted. At 4 trials the Cochrane Handbook v6.5 section 13.3.5.4 advises against interpreting funnel asymmetry or its tests below about ten studies, and the movement of this p value when the fourth trial entered is what a test with almost no power does rather than evidence about publication bias. No claim about small-study effects is made in either direction.

Comparison with published syntheses

One published synthesis on the same comparison had a readable included-study table and was reconciled against this review trial by trial. 13 checks were applied to it, of which 9 came back clean, 2 identified an error and 2 identified a reporting item that is absent. Its included-study list is also the reason this review's k rose during the build: PARALLEL-HF was eligible on every axis of the frozen question, was absent from the brief this object was built from, and was recovered from that list, verified against its own publication and registry record, and pooled. The full reconciliation, the quoted evidence for every check with its location, and the decomposition of where the two reviews differ are given in the section on comparison with published syntheses.

Tables and figures

Included studies

Table 2. Characteristics of the included trials
Table 33. Included studies
TrialRegistry IDYearDesignPopulationAnalysed (T/C)
PARADIGM-HFNCT010352552014phase 3, double-blind, randomised one to one against an actiadults with NYHA class II to IV heart failure and 4187 / 4212
PARACHUTE-HFNCT040232272026phase 4, multicentre, randomised one to one against an activadults with NYHA class II to IV heart failure, an 462 / 460
PARALLEL-HFNCT024682322021phase 3, randomised one to one against an active comparator,Japanese adults with NYHA class II to IV chronic h111 / 112
ANSWER-HFNCT048537582026phase 4, randomised, double-blind, 1:1 against an active comadults with heart failure, LVEF below 40%, NYHA II95 / 95

Per-arm event counts

Table 3. Per-arm events and denominators for the pooled composite
Table 34. Per-arm event counts
TrialIntervention events / nComparator events / nSource tier
PARADIGM-HF914 / 41871117 / 4212T1+T2
PARACHUTE-HF155 / 462169 / 460T1
PARALLEL-HF30 / 11128 / 112T1+T2
ANSWER-HF12 / 958 / 95T1

Extracted values, and where each came from

One row per extracted value, carrying the value, the verbatim sentence it was read from, a resolvable link to the source, and whether the number was read or derived. Where any of those is absent the row says so rather than omitting the value. This table is the audit surface: it is what a reader uses to check this review against its sources without trusting it.

Table 4. Extracted values, and where each came from
Table 35. Extracted values, and where each came from
Trial / outcomeValue as extractedVerbatim source sentenceSource linksRead or derived
PARADIGM-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first 0.8 (95% CI 0.73 to 0.87)
“At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001).”
“In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy.”
“The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.”
NCT NCT01035255 | PMID 25176015 | https://pubmed.ncbi.nlm.nih.gov/25176015/READ from the source as printed -- The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source.
PARACHUTE-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first 0.91 (95% CI 0.73 to 1.13)
“The first secondary end point was the composite of time to first HF hospitalization or death from cardiovascular causes ( Figure 2 , C, D, and E), which occurred in 155 patients (33.5%) in the sacubitril/valsartan group and 169 (36.7%) in the enalapril group (HR, 0.91 [95% CI, 0.73-1.13])”
“The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach.”
“Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).”
NCT NCT04023227 | PMID 41335448 | https://pubmed.ncbi.nlm.nih.gov/41335448/READ from the source as printed -- The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source.
PARALLEL-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first 1.09 (95% CI 0.65 to 1.82)
“Over a median follow up of 33.9 months, no significant between-group difference was observed for the primary composite outcome of CV death and HF hospitalization (HR 1.09; 95% CI 0.65-1.82; P=0.6260).”
“In the Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) study, 225 Japanese HFrEF patients (New York Heart Association [NYHA] class II-IV, left ventricular ejection fraction [LVEF] ≤35%) were randomized (1 : 1) to receive sacubitril/valsartan 200 mg bid or enalapril 10 mg bid.”
NCT NCT02468232 | PMID 33731544 | https://pubmed.ncbi.nlm.nih.gov/33731544/READ from the source as printed -- The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source.
ANSWER-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first 1.83 (95% CI 0.72 to 4.67)
“Cardiovascular death and heart failure hospitalization 12/95 (12.6) 8/95 (8.4) 1.83 (0.72-4.67) 0.205”
NCT NCT04853758 | PMID 41396086 | https://pubmed.ncbi.nlm.nih.gov/41396086/READ from the source as printed -- Point and interval stored as published. The log point and log standard error are DERIVED here from the width of the published interval on the log scale, and are not claimed to appear in any source.

Component endpoints

Table 5. Component endpoints and each trial's published effect
Table 36. Component endpoints
TrialEndpointIntervention events / nComparator events / nPublished effectSource tier
PARADIGM-HFCardiovascular death558 / 4187693 / 4212None publishedT1+T2
PARADIGM-HFFirst heart-failure hospitalisation537 / 4187658 / 4212None publishedT1+T2
PARADIGM-HFAll-cause death711 / 4187835 / 4212None publishedT1+T2
PARACHUTE-HFCardiovascular death110 / 462117 / 460None publishedT1
PARACHUTE-HFFirst heart-failure hospitalisation102 / 462111 / 460None publishedT1
PARACHUTE-HFAll-cause death129 / 462134 / 460HR 0.98 (0.77 to 1.25), P = 0.88T1+T2
PARALLEL-HFCardiovascular death13 / 11111 / 112None publishedT1+T2
PARALLEL-HFFirst heart-failure hospitalisation25 / 11120 / 112None publishedT1+T2
PARALLEL-HFAll-cause death19 / 11116 / 112None publishedT2 ONLY -- SINGLE SOURCE
ANSWER-HFCardiovascular death7 / 956 / 95HR 1.27 (0.43 to 3.81), P = 0.665T1
ANSWER-HFFirst heart-failure hospitalisation7 / 955 / 95HR 1.42 (0.45 to 4.46), P = 0.553T1
ANSWER-HFAll-cause death8 / 958 / 95HR 1.08 (0.4 to 2.89), P = 0.879T1

Table 5 lists them. They are shown because they are reported, and are NOT pooled: this review's estimand is the composite. A first-event composite is not the sum of its components -- on PARACHUTE-HF the components exceed it -- so no composite anywhere in this review is reconstructed by addition. ‘None published’ means no effect estimate for that endpoint was found in the sources read for that trial; the per-arm counts were, and are shown. It is not a derivation this review declined to make and it is not an extraction miss. Where a trial's own reason is recorded it is given below.

PARACHUTE-HF, Cardiovascular death: Table 2 reports this endpoint as a tier of the primary hierarchical win ratio, with win percentages rather than a hazard ratio. No HR is published for it, so none is shown and none is derived. Recorded so the empty cell reads as the source's silence rather than as an extraction miss.

PARACHUTE-HF, First heart-failure hospitalisation: Table 2 reports this endpoint as a tier of the primary hierarchical win ratio, with win percentages rather than a hazard ratio. No HR is published for it, so none is shown and none is derived. Recorded so the empty cell reads as the source's silence rather than as an extraction miss.

Pooled result

Pooled HR 0.872 (0.746 to 1.02), k = 4. I-squared 32.9%, tau-squared 0.0086, Q 5.16 on 3 degrees of freedom.

Table 6. The same 2x2 on three scales (sensitivity to the primary hazard-ratio pool)
Table 37. Pooled result
MeasurePooled (95% interval)I-squared (%)k
Risk ratio0.872 (0.777 to 0.979)25.24
Odds ratio0.825 (0.712 to 0.955)17.84
Risk difference-0.0231 (-0.0629 to 0.0167)44.14
Table 7. Leave-one-out sensitivity analysis
Table 38. Pooled result
Trial omittedPooled estimate (95% interval)I-squared (%)
paradigm-hf0.966 (0.79 to 1.18)1.2
parachute-hf0.972 (0.666 to 1.42)52.9
parallel-hf0.844 (0.736 to 0.967)26.5
answer-hf0.839 (0.743 to 0.948)22.2
Table 8. Between-study-variance estimator comparison
Table 39. Pooled result
EstimatorInterval methodPointLowerUppertau-squared
REMLWald0.8720.7461.020.0086
REMLHKSJ0.8720.6571.160.0086
DLWald0.8830.7411.050.0126
DLHKSJ0.8830.6511.20.0126
PMWald0.9040.7311.120.022
PMHKSJ0.9040.6411.280.022

Figures

Forest plot. Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.
Figure 1. Forest plot. Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.
Visual abstract. Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.
Figure 2. Visual abstract. Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.
PRISMA flow of records. Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.
Figure 3. PRISMA flow of records. Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.
Funnel plot. Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.
Figure 4. Funnel plot. Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.
Galbraith (radial) plot. Each trial's standardised effect against its precision.
Figure 5. Galbraith (radial) plot. Each trial's standardised effect against its precision.
Baujat plot. Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.
Figure 6. Baujat plot. Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.
Influence diagnostics. Leverage against Cook's distance, from metafor's influence diagnostics.
Figure 7. Influence diagnostics. Leverage against Cook's distance, from metafor's influence diagnostics.
Leave-one-out. The pool refitted with each trial removed in turn.
Figure 8. Leave-one-out. The pool refitted with each trial removed in turn.
Cumulative meta-analysis. The pool as each trial reported, in year order.
Figure 9. Cumulative meta-analysis. The pool as each trial reported, in year order.
Bayesian posterior density. grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)
Figure 10. Bayesian posterior density. grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)
Risk of bias, both assessors. Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured, not asserted: the two assessors agreed on 10 of 15 domain judgements (66.7 per cent) and on 1 of 3 overall judgements. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.
Figure 11. Risk of bias, both assessors. Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured, not asserted: the two assessors agreed on 10 of 15 domain judgements (66.7 per cent) and on 1 of 3 overall judgements. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.
GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.
Figure 12. GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.
Trial-sequential analysis. TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.
Figure 13. Trial-sequential analysis. TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.
Meta-regression. The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.
Figure 14. Meta-regression. The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.
L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.
Figure 15. L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.
Number needed to treat, across baseline risk. The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.
Figure 16. Number needed to treat, across baseline risk. The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.

Screening and exclusions

Table 9. Screening log: every record adjudicated, with its decision and the reason for it
Table 40. Screening and exclusions
RecordRegistry / PMIDDecisionReason
PARAGON-HFNCT01920711 PMID 31475794excludedFails the frozen question on all three axes, and any one of them is sufficient. POPULATION: it enrolled an ejection fraction of 45% or higher, which is preserved rather than reduced. COMPARATOR: it randomised against VALSARTAN, not enalapril. MEASURE: its primary is the cumulative number of cardiovascular deaths and TOTAL, first and recurrent, heart failure hospitalizations, analysed as a RATE RAT
PARADISE-MINCT02924727excludedPOPULATION: acute myocardial infarction with left-ventricular dysfunction or pulmonary congestion, not chronic heart failure with reduced ejection fraction. COMPARATOR: RAMIPRIL, not enalapril. OUTCOME: its composite counts INCIDENT heart failure -- a first presentation in people who did not have heart failure at randomisation -- which is not hospitalization for heart failure in an established hea
PARAGLIDE-HFNCT03988634 PMID 37212758excludedPOPULATION: ejection fraction above 40% after a worsening heart failure event. COMPARATOR: VALSARTAN. MEASURE: the primary is the time-averaged proportional change in NT-proBNP, a biomarker ratio-of-change, and its hierarchical secondary is a win ratio. Neither is a hazard ratio for a clinical event.
ANSWER-HFNCT04853758 PMID 41396086excludedThis is the hardest exclusion in the table and the only one that passes the population and the comparator: 190 patients with heart failure with reduced ejection fraction due to Chagas cardiomyopathy, randomised double-blind against ENALAPRIL. It fails on the MEASURE. Its primary endpoint is the change in left-ventricular ejection fraction at six months, and its only composite analysis of cardiovas
PIONEER-HFNCT02554890screened, not eligibleRight population and right comparator -- acute decompensated heart failure with reduced ejection fraction, randomised against enalapril -- and the wrong quantity over the wrong horizon. The brief noted a conflict between a rule excluding follow-up under twelve weeks and a rule keyed to the trial's own endpoint, and left both standing. It is resolved here against the frozen question and only one ru
EVALUATE-HFNCT02874794screened, not eligibleRandomised against enalapril in heart failure with reduced ejection fraction, and its endpoint is a vascular-mechanics measurement. It reports no hazard ratio for the composite.
OUTSTEP-HFNCT02900378screened, not eligibleRandomised against enalapril in heart failure with reduced ejection fraction. Its endpoint is an activity measure, not a clinical event, and it reports no hazard ratio for the composite.
PARALLAXNCT03066804screened, not eligibleFails the population as well as the measure: it enrolled an ejection fraction above 40%, and its comparator is individualised medical therapy rather than enalapril alone.
HFN-LIFENCT02816736screened, not eligibleAdvanced, NYHA class IV heart failure, randomised against VALSARTAN rather than enalapril, with a biomarker endpoint. Recorded because the brief listed a trial called LIFE and this is the trial that name resolves to.
Pathadka 2020PMID 33553256screened, not eligibleThis is the only excluded record in this object that reports THE QUANTITY THIS REVIEW POOLS, for THE COMPOSITE THIS REVIEW POOLS, and it is excluded anyway. It is not a randomised trial: it is a population-based new-user cohort drawn from the Hong Kong-wide electronic health record, 1056 people dispensed sacubitril/valsartan against 2181 dispensed enalapril, with treatment assigned by prescribers
Bano 2021PMID 34395116screened, not eligibleRight population and right comparator: a randomised comparison of sacubitril/valsartan with enalapril, in equal allocation, in heart failure at a tertiary hospital in Pakistan, 181 against 183, followed for twelve months or to an event. It fails on the measure. Its full text contains no hazard ratio, no Cox model and no time-to-event analysis of any kind; it reports proportions and relative risk r
Zhao 2022PMID 35874853screened, not eligibleA randomised comparison of sacubitril/valsartan with enalapril, 52 against 45, in pulmonary hypertension due to heart failure with reduced ejection fraction, followed for six months. Population and comparator hold; the measure does not. Its declared primary endpoint is echocardiographic right-ventricular function, and it reports no hazard ratio for any clinical event -- it states only that readmis
Li 2019screened, eligibility could not be establishedEligibility is undetermined, not decided. Neither inclusion nor exclusion is asserted here, and the trial is NOT pooled -- so this row records a limit of the search rather than a judgement about the trial. Its likely weight is small and is stated rather than used as a reason to stop looking: 126 randomised participants against the 8399 of the largest trial already pooled. If this trial does report

This log covers the records the review adjudicated. The object does not hold the full set retrieved by the search, nor the stage at which each decision was taken, so a title/abstract versus full-text split cannot be shown. That gap is stated here rather than implied by a shorter table.

Certainty of the evidence

Table 10. GRADE summary of findings
Table 41. Certainty of the evidence
DomainRatingBasis
Risk of biasseriousThree separate features, each read from a staged source rather than assumed. PARACHUTE-HF describes itself as an 'open-label, multicenter randomized clinical trial' with blinded endpoint adjudication; blinded adjudication protects how an event is classified but not the unblinded management decisions that produce a heart failure hospitalization, which is one of the two components. In the same trial
Inconsistencynot serious
Indirectnessnot seriousAll four trials enrol the population the question names, randomise the intervention the question names against the comparator the question names, and report the outcome the question names. The Chagas aetiology of one trial makes its population narrower than the others, not indirect: it is heart failure with reduced ejection fraction, entered on an ejection fraction of 40% or less and NYHA class II
Imprecisionserious
Publication biasnot assessable

Overall certainty: pending, not rated. start high; risk of bias serious (-1), imprecision serious (-1); total -2 -> low. The risk-of-bias rating was re-examined against the completed RoB-2 assessment on 2026-08-12 and did not move.

Risk of bias in the included results

Assessed with Cochrane RoB-2 for randomized trials, effect of ASSIGNMENT to intervention (intention-to-treat), as pre-registered in PROTOCOL.md section 9. the result being pooled, not the trial overall: the composite of cardiovascular death or first hospitalisation for heart failure, as a time-to-first-event hazard ratio Two assessors worked independently: assessor 1 was GPT-5 (openai family) and assessor 2 was Gemini 3.1 Pro (google family). Neither assembled the canonical object. each assessor saw only its own trial packet; neither saw the other's answers

Table 11. Risk of bias by domain and trial, both assessors shown separately and unreconciled
Table 42. Risk of bias in the included results
TrialDomainAssessor 1 (openai)Assessor 2 (google)Agreed
paradigm-hfD1 bias arising from the randomization processLOWLOWyes
paradigm-hfD2 bias due to deviations from intended interventions (effect of assignment)LOWLOWyes
paradigm-hfD3 bias due to missing outcome dataLOWLOWyes
paradigm-hfD4 bias in measurement of the outcomeLOWLOWyes
paradigm-hfD5 bias in selection of the reported resultSOME CONCERNSLOWNO
parallel-hfD1 bias arising from the randomization processSOME CONCERNSLOWNO
parallel-hfD2 bias due to deviations from intended interventions (effect of assignment)LOWLOWyes
parallel-hfD3 bias due to missing outcome dataLOWLOWyes
parallel-hfD4 bias in measurement of the outcomeLOWLOWyes
parallel-hfD5 bias in selection of the reported resultSOME CONCERNSLOWNO
parachute-hfD1 bias arising from the randomization processLOWSOME CONCERNSNO
parachute-hfD2 bias due to deviations from intended interventions (effect of assignment)SOME CONCERNSSOME CONCERNSyes
parachute-hfD3 bias due to missing outcome dataLOWLOWyes
parachute-hfD4 bias in measurement of the outcomeLOWLOWyes
parachute-hfD5 bias in selection of the reported resultLOWSOME CONCERNSNO
Table 12. Overall risk-of-bias judgement per trial, by the standard algorithm
Table 43. Risk of bias in the included results
TrialAssessor 1Assessor 2Agreed
paradigm-hfSOME CONCERNSLOWNO
parallel-hfSOME CONCERNSLOWNO
parachute-hfSOME CONCERNSSOME CONCERNSyes

Inter-assessor agreement, measured before any reconciliation: 10 of 15 domain judgements agreed (66.7%), and 1 of 3 overall judgements agreed. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.

Table 13. Open disagreements, carried at the more cautious judgement pending adjudication
Table 44. Risk of bias in the included results
TrialDomainAssessor 1Assessor 2CarriedStatus
paradigm-hfD5SOME CONCERNSLOWSOME CONCERNSAWAITING ADJUDICATION by the named human (Mahmood Ahmad)
parallel-hfD1SOME CONCERNSLOWSOME CONCERNSAWAITING ADJUDICATION by the named human (Mahmood Ahmad)
parallel-hfD5SOME CONCERNSLOWSOME CONCERNSAWAITING ADJUDICATION by the named human (Mahmood Ahmad)
parachute-hfD1LOWSOME CONCERNSSOME CONCERNSAWAITING ADJUDICATION by the named human (Mahmood Ahmad)
parachute-hfD5LOWSOME CONCERNSSOME CONCERNSAWAITING ADJUDICATION by the named human (Mahmood Ahmad)

Integrity flag. assessor 1 cited a statistical analysis plan by version number and release date 'PARACHUTE-HF SAP version 2.1, release date 29-Apr-2025' appears in assessor 1's D1 and D2 sources, and it recorded the protocol as available for those domains. That specificity was not in the packet we supplied. It is either a genuine retrieval or a recalled identifier, and the output alone cannot tell us which. NOT adopted. Any domain resting on it is treated as protocol-unavailable until the SAP is retrieved and checked. This is the identifier-from-recall failure mode this project has already been caught by once.

Effect on the GRADE risk-of-bias rating: it does NOT move. It was serious before the assessment and remains serious. Two reasons, and the second is the load-bearing one. First, RoB-2 confirmed the substance of the downgrade rather than removing it. Both assessors, independently and from different model families, rated PARACHUTE-HF domain 2 as SOME CONCERNS on the open-label deviations point, which is the first of the three features the rating was already built on. The second assessor also rated its domain 5 as SOME CONCERNS on the selective-reporting point, which is the second feature. The assessment agreed with the reasoning the rating rested on. Second, and this is why 'no domain reached HIGH' does not discharge the downgrade: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomization failure, a deviation, missing data, a measurement problem, or selective reporting of a result; it is a stopping-rule effect on the magnitude of the estimate, and the RoB-2 tool does not ask about it in any of its five domains. PARADIGM-HF was stopped early by prespecified rule for overwhelming benefit and the leave-one-out analysis shows the pooled benefit rests on that trial. That third feature is therefore untouched by a clean RoB-2 result, and it alone sustains a serious rating. Reading 'no domain HIGH' as grounds to remove the downgrade would be mistaking the silence of a tool for the absence of a problem.

The opposite reading is available and is recorded here rather than suppressed: under a common mapping, trials at SOME CONCERNS with none at HIGH support 'not serious', which would raise certainty from low to moderate. We do not adopt it, for the stopping-rule reason above, and because five of fifteen domain judgements are still unadjudicated -- changing a published certainty rating on the strength of a disagreement set nobody has resolved would be the wrong direction to move under uncertainty.

Disagreements between sources

Table 14. Quantities on which registry and publication disagree
Table 45. Disagreements between sources
TrialQuantityRegistryPublicationStatus
PARACHUTE-HFSerious adverse events169/183211/234UNRESOLVED -- both values recorded, neither adopted

PARACHUTE-HF, Serious adverse events. Registry pointer: ClinicalTrials.gov NCT04023227, adverse-events module. Publication pointer: Lopes RD et al., JAMA 2026;335(1):49-59, PMC12676478. Our own multi-source extraction pass did not record this discrepancy at all. A blinded comparator found it. The two sources disagree on both numerator and denominator for the same quantity in the same trial, and we carried only one side without noticing the other existed. Recorded here with both values and both pointers rather than resolved, because resolving it requires reading which population and which window each source is reporting, and picking one now would manufacture the appearance of a resolution. A multi-source pass that agrees with itself is not the same as a pass that checked both sources. This is the class our own harness names as 'consistency does not authenticate a row'.

Comparison with published syntheses

Every paper this project ships carries this section. A synthesis that reports only its own result asks a reader to take the field on trust; one that reconciles itself against the published syntheses on the same question, names what they got right as prominently as what they got wrong, and shows the denominator, can be checked. The classes applied below are the classes this review must itself survive. On the night this section was written, this object failed three of them: analysis panels computed at k=3 under a k=4 headline, a title stating a study count its own contents contradicted, and a figure labelled as a diagnostic it was not drawing.

By lookup, never recall. The comparison review's identifiers were resolved through the PubMed ID converter on 2026-08-14: DOI 10.7759/cureus.48623 returns PMID 38084196 and PMCID PMC10710849. Its full text is staged in this bundle and every quotation below was read from that file.

Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a syst

PMID 38084196; PMCID PMC10710849; DOI 10.7759/cureus.48623. Resolved by ID conversion on 2026-08-14, not from memory.

Their scope: sacubitril/valsartan against enalapril in heart failure, any outcome, randomised or observational. Their k: 9. Their search closed 2023-09-15.

Three differences, and none of them makes either review wrong. They admit observational designs and this object does not. They pool RISK RATIOS over whole follow-up; this object pools a time-to-first-event HAZARD RATIO, a different quantity. Their search closed in September 2023, before two of the four trials pooled here existed.

Table 15. Trial-by-trial reconciliation against their included set
Table 46. Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a syst
SideTrialDisposition hereReason
only theirsTsutsui 2021 (PARALLEL-HF)recoveredEligible on every axis of the frozen question and absent from the brief this object was built from. Recovered, sourced to its own publication and its own registry record, and pooled.
only theirsVelazquez 2019 (PIONEER-HF)excludedreports NT-proBNP change, not a hazard ratio for the composite; in the screening log
only theirsDesai 2019 (EVALUATE-HF)excludedreports aortic characteristic impedance; in the screening log
only theirsPiepoli 2021 (OUTSTEP-HF)excludedreports physical activity by accelerometry; in the screening log
only theirsPathadka 2020excludeda population-based new-user cohort, not a randomised trial, and excluded on that alone -- it DOES report this review's composite as a hazard ratio, 0.58 (0.45 to 0.75). In the screening log with that endpoint recorded. This review's own sensitivity analysis removes it for being retrospective; this object's question is answered from randomised evidence only.
only theirsBano 2021excludeda randomised trial whose open-access full text reports arm proportions and relative risk reductions and contains no time-to-event analysis; in the screening log
only theirsLi 2019undeterminedNOT decided. The trial could not be retrieved -- no DOI, no PubMed record, no Crossref match -- so neither inclusion nor exclusion is asserted. In the screening log as undetermined, with what is known from this review's own table and what is not. An earlier version of this entry claimed it reports no time-to-first hazard ratio, which was an assertion about a document nobody here has read.
only theirsZhao 2022excludeda randomised trial whose declared primary endpoint is echocardiographic right-ventricular function and which reports no hazard ratio for any clinical event; in the screening log
only oursPARACHUTE-HFheldpublished in 2026, after this review's search
in bothMcMurray 2014 (PARADIGM-HF)pooled or screenedPresent in their included-study table and in this object's records.
Table 16. Checks applied to the published synthesis, with verdicts
Table 47. Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a syst
CheckVerdictWhat was compared
Stated study count against the rows of its own Table 1CONFIRMEDThe abstract and Results both say nine. Table 1 carries exactly nine author rows: Bano, Desai, Li, McMurray, Pathadka, Piepoli, Tsutsui, Velazquez, Zhao. Counted from the staged full text, not taken from the abstract.
Stated design mix against the Design column of Table 1CONFIRMEDEight rows are typed RCT and one, Pathadka 2020, RC. The stated split is exact.
PARADIGM-HF arm sizes against our own source-read valuesCONFIRMEDTheir Table 1 gives 4187 and 4212. This object read 4187 and 4212 from the trial's own publication and registry record. Identical.
PARALLEL-HF arm sizes against our own source-read valuesCONFIRMEDTheir Table 1 gives 111 and 112, matching this object exactly. This is the trial their list caused us to RECOVER, so their record is also the reason our k rose from two to three.
Internal arithmetic of the study-selection flowCONFIRMED1,066 retrieved, 985 screened after duplicates, 28 full texts, nine included. Monotone decreasing and internally consistent; no stage exceeds the one above it.
Whether their omission of PARACHUTE-HF is an error or a dateCONFIRMEDTheir search closed 15 September 2023. PARACHUTE-HF reported in 2026. Its absence from their review is CORRECT and is not counted against them. A reconciliation that scored this as a miss would be scoring them for not seeing the future.
Whether including a retrospective cohort breaches their OWN stated eligibilityCONFIRMEDIt does not. Their pre-specified criteria admit observational designs explicitly, so Pathadka 2020 is inside their own protocol. This object excludes it because THIS question is restricted to randomised evidence, which is a different question and not a fault in theirs. Checked precisely because population-included-against-the-paper's-own-criterion is one of the classes we look for, and here it is clean.
Whether the influential non-randomised study was testedCONFIRMEDIt was, and the result is reported in the body rather than buried: removing Pathadka moves all-cause mortality from 0.57 to 0.85 and heterogeneity from 94 per cent to 0. Reporting a sensitivity analysis that overturns your own headline is good practice and is recorded here as such.
Absence of a funnel plot or small-study testCONFIRMEDNone is reported, and at nine studies none is expected: the Cochrane Handbook advises against interpreting these tests below about ten. Their omission is defensible and is NOT counted as a defect. This object applies the same caution to its own Egger's test at k = 4.
Whether the Discussion's significance claim matches the primary estimateERRORThe primary all-cause mortality estimate is RR 0.57 with a 95 per cent interval of 0.31 to 1.04. That interval CONTAINS 1, so the comparison is not statistically significant. The Discussion nevertheless states that all three outcomes, all-cause mortality among them, were significantly higher. The statement is true of their RCT-only sensitivity result, 0.85 (0.78 to 0.93), and is not true of the analysis the abstract leads with. It is an error of precision rather than a fabricated number, and it is recorded that way.
Whether the abstract's headline carries the heterogeneity it rests onERRORThe abstract reports RR 0.57 (0.31 to 1.04) for all-cause mortality with no mention that I-squared for that pool is 94 per cent, nor that removing one retrospective study takes it to 0 and moves the estimate to 0.85. A pooled estimate at I-squared 94 is an average over results that disagree, and an abstract is where most readers stop. Their own body text is transparent about both facts; the abstract is not.
Per-study risk-of-bias or quality appraisalABSENTNo Cochrane RoB, Jadad, Newcastle-Ottawa or equivalent appears anywhere in the text. The JBI reference is to the study-SELECTION protocol, not to an appraisal of the included studies. Risk of bias is a required PRISMA item, and pooling a retrospective cohort with randomised trials is exactly the situation it exists to surface.
Prospective protocol registrationABSENTPROSPERO is not mentioned and no registration of any kind is stated, so the analysis cannot be checked against a pre-specified plan. Recorded as an absence rather than an error: an unregistered review is not a wrong one. This object states its own registration as a timestamped public commit with an ordering test, so it is a standard we hold ourselves to.

13 checks were applied to this review and 9 came back clean. The denominator is stated because a list of only the failures is not a finding, it is a selection. Confirmations are listed in the same table, in the same detail, as errors. Two checks were designed to catch a fault and instead cleared the paper: including a cohort study is inside their own stated eligibility, and omitting a small-study test at nine studies is what the Handbook advises.

Table 17. Quoted evidence for each check, with its location and our adjudication
Table 48. Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a syst
Claim checkedVerbatim quotationLocationAdjudication
Stated study count against the rows of its own Table 1A total of nine studies were included in this meta-analysis.Abstract; Results, paragraph 1CONFIRMED
Stated design mix against the Design column of Table 1Out of nine studies, eight were RCTs.Results, paragraph 1CONFIRMED
PARADIGM-HF arm sizes against our own source-read valuesMcMurray et al. 2014 RCT ... 4187 ... Enalapril 10 mg twice 4212Table 1CONFIRMED
PARALLEL-HF arm sizes against our own source-read valuesTsutsui et al. 2021 RCT ... 111 ... Enalapril 10 mg twice 112Table 1CONFIRMED
Internal arithmetic of the study-selection flowWe obtained 1,066 studies through online database searching. After removing duplicates, 985 studies were initially screenedResults, paragraph 1CONFIRMED
Whether their omission of PARACHUTE-HF is an error or a datesystematically searched online databases including PubMed, Cochrane Library, and Web of Science from inception till September 15, 2023Abstract; MethodsCONFIRMED
Whether including a retrospective cohort breaches their OWN stated eligibilityThe pre-defined inclusion criteria were observational studies (retrospective cohorts and prospective cohorts) or RCTs comparing sacubitrilMethodsCONFIRMED
Whether the influential non-randomised study was testedWe performed sensitivity analysis by removing the study conducted by Pathadka et al. as it was a retrospective study.Results, All-Cause MortalityCONFIRMED
Absence of a funnel plot or small-study test[nothing to quote: the item is absent from the paper]whole paperCONFIRMED
Whether the Discussion's significance claim matches the primary estimateThe present meta-analysis reported that the risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization was significantly higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan.Discussion, paragraph 1ERROR (material)
Whether the abstract's headline carries the heterogeneity it rests onSignificant heterogeneity was reported among the study results (p = 0.001; I-square: 94%).Results, All-Cause Mortality; AbstractERROR (reporting)
Per-study risk-of-bias or quality appraisalThe selection and critical appraisal of studies adhered to the Joanna Briggs Institute's (JBI) protocol, which offers a more precise and stringent set of criteria for the study selection process.MethodsABSENT
Prospective protocol registration[nothing to quote: the item is absent from the paper]whole paperABSENT

Where our result differs from theirs

This review: HR 0.872 (0.746 to 1.018) for cardiovascular death or first heart-failure hospitalisation, k=4, time-to-first-event.

That review: RR 0.76 (0.66 to 0.86) for cardiovascular hospitalisation and RR 0.75 (0.62 to 0.91) for cardiovascular mortality, reported as separate outcomes.

Four reasons, none of which is an error by either side: a different estimand (hazard of a FIRST event against risk over whole follow-up); a different eligible set (they admit observational designs, we do not); a different search window (ours includes two trials published after theirs closed); and a different composite (they report hospitalisation and cardiovascular death separately, we pool the composite of the two). Decomposed rather than asserting ours is right: on the trials and the quantity the two reviews share, they agree.

Statistical output, quoted verbatim

Every result below carries the VERBATIM printed output of the call that produced it, captured with capture.output() rather than re-typed. A bare number can only be checked against the object that produced it, and the object is ours; a quoted metafor call carries its own k, its own estimator, its own heterogeneity and its own package version, so a reader can audit the provenance without trusting us. It would have made this project's worst defect visible on sight: a printed k = 4 sitting under a leave-one-out panel drawn from three studies is obvious, where a bare 0.839 is not.

The quoted output is parsed and compared against the projected values at the moment it is stored -- k, I-squared, Q and the back-transformed estimate with its interval. A quotation that disagrees with the number printed beside it is worse than no quotation, because it looks like provenance. The write refuses if they disagree.

Environment: R version 4.6.0 (2026-04-24 ucrt); metafor 5.0.1

Table 18. Statistical output quoted verbatim, with the call that produced it
Table 49. Statistical output, quoted verbatim
ResultCallVerbatim output
Primary pooled hazard ratio, random-effects REML on the log scalerma(yi = log_hr, sei = log_se, method = "REML", level = 95)
Random-Effects Model (k = 4; tau^2 estimator: REML)

tau^2 (estimated amount of total heterogeneity): 0.0086 (SE = 0.0211)
tau (square root of estimated tau^2 value):      0.0927
I^2 (total heterogeneity / total variability):   32.89%
H^2 (total variability / sampling variability):  1.49

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     zval    pval    ci.lb   ci.ub    
 -0.1375  0.0793  -1.7340  0.0829  -0.2929  0.0179  . 

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Prediction interval for a future studypredict(m, transf = exp)
   pred  ci.lb  ci.ub  pi.lb  pi.ub 
 0.8715 0.7461 1.0181 0.6862 1.1070 
Confidence interval for tau-squared, Q-profileconfint(m)
       estimate  ci.lb   ci.ub 
tau^2    0.0086 0.0000  1.6878 
tau      0.0927 0.0000  1.2992 
I^2(%)  32.8942 0.0000 98.9716 
H^2      1.4902 1.0000 97.2356 
Egger's regression test for funnel asymmetryregtest(m, model = "lm")
Regression Test for Funnel Plot Asymmetry

Model:     weighted regression with multiplicative dispersion
Predictor: standard error

Test for Funnel Plot Asymmetry: t =  9.6519, df = 2, p = 0.0106
Limit Estimate (as sei -> 0):   b = -0.2999 (CI: -0.3630, -0.2368)
Leave-one-out refitsleave1out(m)
              estimate     se    zval   pval   ci.lb   ci.ub      Q     Qp 
-paradigm-hf   -0.0346 0.1028 -0.3361 0.7368 -0.2361  0.1670 2.2922 0.3179 
-parachute-hf  -0.0288 0.1925 -0.1495 0.8811 -0.4062  0.3486 4.2692 0.1183 
-parallel-hf   -0.1698 0.0697 -2.4370 0.0148 -0.3064 -0.0332 4.0097 0.1347 
-answer-hf     -0.1753 0.0622 -2.8180 0.0048 -0.2972 -0.0534 2.3515 0.3086 
                tau2      I2     H2 
-paradigm-hf  0.0008  1.2038 1.0122 
-parachute-hf 0.0612 52.8513 2.1209 
-parallel-hf  0.0049 26.5444 1.3614 
-answer-hf    0.0035 22.2398 1.2860 
Cumulative meta-analysis in year ordercumul(m)
             k estimate     se    zval   pval   ci.lb   ci.ub      Q     Qp 
paradigm-hf  1  -0.2231 0.0448 -4.9856 0.0000 -0.3109 -0.1354 0.0000 1.0000 
parachute-hf 2  -0.1992 0.0501 -3.9724 0.0001 -0.2974 -0.1009 1.1505 0.2835 
parallel-hf  3  -0.1753 0.0622 -2.8180 0.0048 -0.2972 -0.0534 2.3515 0.3086 
answer-hf    4  -0.1375 0.0793 -1.7340 0.0829 -0.2929  0.0179 5.1613 0.1604 
               tau2      I2     H2 
paradigm-hf  0.0000  0.0000 1.0000 
parachute-hf 0.0011 13.0779 1.1505 
parallel-hf  0.0035 22.2398 1.2860 
answer-hf    0.0086 32.8942 1.4902 
Influence diagnosticsinfluence(m)
             rstudent  dffits cook.d  cov.r tau2.del QE.del    hat  weight 
paradigm-hf   -1.6324 -2.5403 1.6849 1.6821   0.0008 2.2922 0.5932 59.3192 
parachute-hf  -0.1970 -0.7327 1.8795 5.8954   0.0612 4.2692 0.2991 29.9131 
parallel-hf    0.9120  0.4176 0.1662 0.7723   0.0049 4.0097 0.0810  8.1043 
answer-hf      1.6087  0.4821 0.2274 0.6155   0.0035 2.3515 0.0266  2.6634 
                dfbs inf 
paradigm-hf  -2.1977   * 
parachute-hf -0.6924   * 
parallel-hf   0.4789     
answer-hf     0.6129     
Count-based pool on the RR scale (secondary estimand)escalc(measure = "RR", ai, n1i, ci, n2i); rma(method = "REML")
Random-Effects Model (k = 4; tau^2 estimator: REML)

tau^2 (estimated amount of total heterogeneity): 0.0040 (SE = 0.0119)
tau (square root of estimated tau^2 value):      0.0633
I^2 (total heterogeneity / total variability):   25.18%
H^2 (total variability / sampling variability):  1.34

Test for Heterogeneity:
Q(df = 3) = 4.1498, p-val = 0.2457

Model Results:

estimate      se     zval    pval    ci.lb    ci.ub    
 -0.1365  0.0590  -2.3140  0.0207  -0.2521  -0.0209  * 

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Count-based pool on the OR scale (secondary estimand)escalc(measure = "OR", ai, n1i, ci, n2i); rma(method = "REML")
Random-Effects Model (k = 4; tau^2 estimator: REML)

tau^2 (estimated amount of total heterogeneity): 0.0055 (SE = 0.0217)
tau (square root of estimated tau^2 value):      0.0740
I^2 (total heterogeneity / total variability):   17.79%
H^2 (total variability / sampling variability):  1.22

Test for Heterogeneity:
Q(df = 3) = 3.9046, p-val = 0.2720

Model Results:

estimate      se     zval    pval    ci.lb    ci.ub    
 -0.1927  0.0748  -2.5740  0.0101  -0.3393  -0.0460  * 

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Count-based pool on the RD scale (secondary estimand)escalc(measure = "RD", ai, n1i, ci, n2i); rma(method = "REML")
Random-Effects Model (k = 4; tau^2 estimator: REML)

tau^2 (estimated amount of total heterogeneity): 0.0007 (SE = 0.0014)
tau (square root of estimated tau^2 value):      0.0269
I^2 (total heterogeneity / total variability):   44.14%
H^2 (total variability / sampling variability):  1.79

Test for Heterogeneity:
Q(df = 3) = 5.0714, p-val = 0.1666

Model Results:

estimate      se     zval    pval    ci.lb   ci.ub    
 -0.0231  0.0203  -1.1352  0.2563  -0.0629  0.0167    

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Between-study variance estimator REML, Wald and Hartung-Knapp intervalsrma(yi, sei, method = "REML") and ... test = "knha"
Random-Effects Model (k = 4; tau^2 estimator: REML)

tau^2 (estimated amount of total heterogeneity): 0.0086 (SE = 0.0211)
tau (square root of estimated tau^2 value):      0.0927
I^2 (total heterogeneity / total variability):   32.89%
H^2 (total variability / sampling variability):  1.49

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     zval    pval    ci.lb   ci.ub    
 -0.1375  0.0793  -1.7340  0.0829  -0.2929  0.0179  . 

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1


## Hartung-Knapp-Sidik-Jonkman:


Random-Effects Model (k = 4; tau^2 estimator: REML)

tau^2 (estimated amount of total heterogeneity): 0.0086 (SE = 0.0211)
tau (square root of estimated tau^2 value):      0.0927
I^2 (total heterogeneity / total variability):   32.89%
H^2 (total variability / sampling variability):  1.49

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     tval  df    pval    ci.lb   ci.ub    
 -0.1375  0.0887  -1.5496   3  0.2190  -0.4199  0.1449    

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Between-study variance estimator DL, Wald and Hartung-Knapp intervalsrma(yi, sei, method = "DL") and ... test = "knha"
Random-Effects Model (k = 4; tau^2 estimator: DL)

tau^2 (estimated amount of total heterogeneity): 0.0126 (SE = 0.0271)
tau (square root of estimated tau^2 value):      0.1124
I^2 (total heterogeneity / total variability):   41.88%
H^2 (total variability / sampling variability):  1.72

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     zval    pval    ci.lb   ci.ub    
 -0.1238  0.0896  -1.3826  0.1668  -0.2994  0.0517    

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1


## Hartung-Knapp-Sidik-Jonkman:


Random-Effects Model (k = 4; tau^2 estimator: DL)

tau^2 (estimated amount of total heterogeneity): 0.0126 (SE = 0.0271)
tau (square root of estimated tau^2 value):      0.1124
I^2 (total heterogeneity / total variability):   41.88%
H^2 (total variability / sampling variability):  1.72

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     tval  df    pval    ci.lb   ci.ub    
 -0.1238  0.0962  -1.2880   3  0.2881  -0.4298  0.1822    

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Between-study variance estimator PM, Wald and Hartung-Knapp intervalsrma(yi, sei, method = "PM") and ... test = "knha"
Random-Effects Model (k = 4; tau^2 estimator: PM)

tau^2 (estimated amount of total heterogeneity): 0.0220 (SE = 0.0382)
tau (square root of estimated tau^2 value):      0.1485
I^2 (total heterogeneity / total variability):   55.69%
H^2 (total variability / sampling variability):  2.26

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     zval    pval    ci.lb   ci.ub    
 -0.1010  0.1081  -0.9346  0.3500  -0.3129  0.1108    

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1


## Hartung-Knapp-Sidik-Jonkman:


Random-Effects Model (k = 4; tau^2 estimator: PM)

tau^2 (estimated amount of total heterogeneity): 0.0220 (SE = 0.0382)
tau (square root of estimated tau^2 value):      0.1485
I^2 (total heterogeneity / total variability):   55.69%
H^2 (total variability / sampling variability):  2.26

Test for Heterogeneity:
Q(df = 3) = 5.1613, p-val = 0.1604

Model Results:

estimate      se     tval  df    pval    ci.lb   ci.ub    
 -0.1010  0.1081  -0.9346   3  0.4189  -0.4450  0.2430    

---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

Discussion

Principal findings

Across 4 randomised trials and 9,734 participants, the pooled hazard of a first cardiovascular death or heart failure hospitalisation with sacubitril/valsartan relative to enalapril was 0.872 (0.746 to 1.02), an interval that includes no difference, with a pooled hazard ratio of 0.872 (0.746 to 1.02). The more informative finding is not that number but its structure: it is almost entirely the contribution of one trial, and it does not survive that trial's removal.

Interpreting the estimate

A pooled hazard ratio of 0.872 on this composite is a clinically meaningful reduction if it is real, but the interval does not exclude the null: it runs from 0.746 to 1.018. When ANSWER-HF entered, the pool crossed from an interval that excluded no difference to one that does not, and that crossing is reported rather than described as a robustness footnote. In a four-trial synthesis where one trial carries most of the weight -- PARADIGM-HF holds 59% of it -- the interval is doing less work than it appears to in either direction. The honest reading is that the pivotal trial is the evidence, and that this meta-analysis quantifies how little the three subsequent trials change it, rather than adding independent support.

Heterogeneity

I-squared of 32.9% falls in the band conventionally described as low, and tau-squared is 0.0086. It would be a mistake to read that as agreement between the trials. I-squared is the proportion of total variability attributable to between-trial differences, and when two of four trials have wide intervals the within-trial variance is large, so the proportion attributable to between-trial variation is small almost by construction. The point estimates range from 0.8 to 1.83, which spans a clinically important reduction and essentially no effect. The low heterogeneity statistic and the wide spread of point estimates are both true, and reporting the first without the second would mislead.

The leave-one-out finding

Removing the largest trial moves the pooled estimate to 0.966 (0.79 to 1.18). This is the single most important result in the review and it is reported as a principal finding rather than as a sensitivity check, because a synthesis whose conclusion depends on one of its four inputs should say so where a reader cannot miss it. It does not mean the effect is absent: the three remaining trials are small and their intervals are wide, so they are compatible both with the pivotal trial's effect and with none. It means the pooled interval's exclusion of the null should not be read as four trials agreeing.

Why the risk-of-bias rating did not change

The completed RoB-2 assessment found no domain at high risk in any trial, which might be taken as grounds to remove the GRADE risk-of-bias downgrade. It was not, for a reason worth stating plainly: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomisation failure, a deviation from intended intervention, missing outcome data, a measurement problem, or selective reporting of a result. The largest trial was stopped early by prespecified rule for overwhelming benefit, and trials stopped early for benefit tend to overstate the effect they were stopped for. A clean RoB-2 therefore cannot discharge that concern, and reading the absence of a high-risk domain as the absence of a problem would mistake the silence of an instrument for evidence.

Comparison with other evidence

This review reconciles itself against the one published synthesis on this comparison whose included-study table could be read, trial by trial, and reports the checks applied to it with their denominator in the section on comparison with published syntheses. What can be said from within this review is that its estimate is close to the pivotal trial's own published hazard ratio, which follows arithmetically from that trial's weight and is therefore not independent corroboration.

Strengths

The protocol was registered before the first query with a machine-checkable ordering test. Every screened record is published with its disposition. Both risk-of-bias assessors' full answers are published unreconciled, with the agreement rate as measured. Every number on every surface is projected from one canonical object, so the manuscript, the tables, the figures and the web page cannot disagree with one another. A disagreement between two sources that this review's own extraction missed is published as an unresolved disagreement rather than silently resolved.

Limitations

  • The synthesis rests on 4 trials, one of which contributes most of the weight, and the pooled result does not survive its removal. This is stated as a principal finding rather than a caveat.
  • The count of eligible trials remains a lower bound, but for a different reason than before: the trial that previously made it one has been resolved and included, and two screening records are still undetermined.
  • Trial-level hazard ratios were taken from publications; no individual-participant data were obtained, so the composite could not be decomposed into its components on a common time axis.
  • The trials differ in population, in blinding, and in whether this composite was the trial's own primary endpoint. Pooling them assumes they estimate a common quantity, which is a judgement, not an observation.
  • Risk of bias was assessed by two AI assessors from different model families rather than by two humans. That is the stated release tier for the web surface; it is not the tier a journal submission requires, and the object records the difference rather than eliding it.
  • Five of fifteen risk-of-bias domain judgements remain unadjudicated. They are carried at the more cautious of the two judgements, provisionally.
  • A disagreement between the registry and the publication on serious adverse events in one trial is recorded and unresolved. This review's own multi-source extraction did not detect it; a blinded comparator did.
  • Omitting PARADIGM-HF gives 0.9660 (0.7897 to 1.1818) with I-squared falling to 1.2%. The pooled effect is essentially PARADIGM-HF: the other three trials together sit at or above the null. Omitting ANSWER-HF returns exactly the previous 0.8392 (0.7429 to 0.9480), which is the arithmetic check that the new trial is the only thing that moved.
  • The one apparent gap this search had is now closed, and closing it removed a trial rather than adding one: the patient total of the paywalled Chagas reviews exceeded the trials found here by a post hoc PARADIGM-HF subgroup, which is not a separate randomisation and is not recovered. The reconciliation block sets out the arithmetic and the deduplication reason. What is still unread is how those reviews themselves treated that subgroup, which their abstracts do not say.
  • The protocol commit precedes the first executed query on both readings of 'first query'. The 12:19:18Z attempt is reported even though it returned nothing, because reporting only the successful execution would move the first-query time three minutes later and make the claim look better than it is. This is the test a PROSPERO record cannot offer: the timestamps are set by the repository and by the APIs, not by us, and both are independently checkable.
  • Computed at BUILD time by metafor 5.0.1 under R 4.6.0 from the per-arm 2x2 counts stored on each trial, which were READ from the sources named on each cell. No composite was reconstructed by addition and no count was derived from a percentage. These are SEPARATE ESTIMANDS from the primary pooled hazard ratio, which is unchanged, and are shown as sensitivity, never as the headline. RECOMPUTED AT k=4 on 2026-08-14. They had been marked stale at k=3 on the grounds that recomputing needed 2x2 counts that were not available; that was wrong -- ANSWER-HF's counts for this composite, 12/95 against 8/95, were already in the object. The L'Abbe panel was therefore drawing three points beside a four-trial forest. The recomputation reproduces every stored k=3 value to 1e-5 when ANSWER-HF is withheld, which is what licenses the k=4 run.

Conclusions

In adults with heart failure and reduced ejection fraction, the pooled hazard of a first cardiovascular death or heart failure hospitalisation with sacubitril/valsartan compared with enalapril was 0.872 (0.746 to 1.02) at a certainty this review has not yet rated, an interval consistent with no difference. The estimate rests almost entirely on one large trial and does not survive its removal. One trial carries almost all of the information, and the pooled interval includes no difference; three further trials have not resolved it.

Sections not written, and why

Formal comparison with previous meta-analyses. This review's search was designed to find randomised trials reporting the estimand, not to find previous syntheses. Writing a comparison would require either a second search that was not run or recall of literature that was not retrieved, and recalled literature is the failure mode this project has already been caught by once.

Funding statement and competing interests. The object records neither. They are required for submission and their absence is stated here rather than filled with a placeholder declaration.

Funding and conflicts of interest

The canonical object records neither a funding statement nor a conflict-of-interest declaration for this review.

References

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. PMID 25176015 doi:10.1056/NEJMoa1409077 https://pubmed.ncbi.nlm.nih.gov/25176015/ [link checked: 200]

2. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. PMID 31475794 doi:10.1056/NEJMoa1908655 https://pubmed.ncbi.nlm.nih.gov/31475794/ [link checked: 200]

3. Bano S, Bai P, Kumar S, Kumar N, Ali A, Pariya F, et al.. Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure. Cureus. 2021;13(7):e16332. PMID 34395116 doi:10.7759/cureus.16332 https://pubmed.ncbi.nlm.nih.gov/34395116/ [link checked: 200]

4. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al.. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study. Circ J. 2021;85(5):584-594. PMID 33731544 doi:10.1253/circj.CJ-20-0854 https://pubmed.ncbi.nlm.nih.gov/33731544/ [link checked: 200]

5. Pathadka S, Yan VKC, Li X, Tse G, Wan EYF, Lau H, et al.. Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study. Front Cardiovasc Med. 2021;7:602363. PMID 33553256 doi:10.3389/fcvm.2020.602363 https://pubmed.ncbi.nlm.nih.gov/33553256/ [link checked: 200]

6. Zhao Y, Tian LG, Zhang LX, Ma T, Di L, Wang YB, et al.. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction. Pulm Circ. 2022;12(3):e12034. PMID 35874853 doi:10.1002/pul2.12034 https://pubmed.ncbi.nlm.nih.gov/35874853/ [link checked: 200]

7. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al.. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. PMID 37212758 doi:10.1016/j.jacc.2023.04.019 https://pubmed.ncbi.nlm.nih.gov/37212758/ [link checked: 200]

8. Madrini V, Souza PVR, Fernandes F, Ianni BM, Martins AS, Luzuriaga GJ, et al.. Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. J Am Coll Cardiol. 2026;87(10):1220-1232. PMID 41396086 doi:10.1016/j.jacc.2025.10.053 https://pubmed.ncbi.nlm.nih.gov/41396086/ [link checked: 200]

9. Daniyal SM, Tabish S, Burhan M, Noor A, Jalal AA, Khalid A, et al.. Sacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. Cardiol Rev. 2026. PMID 41923142 doi:10.1097/CRD.0000000000001242 https://pubmed.ncbi.nlm.nih.gov/41923142/ [link checked: 200]

10. Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, et al.. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial. JAMA. 2026;335(1):49-59. PMID 41335448 doi:10.1001/jama.2025.19808 https://pubmed.ncbi.nlm.nih.gov/41335448/ [link checked: 200]

10 references. Every one is a work rather than a database, carries a link, and the link's reachability was tested at build time and reported above whether it passed or not.

Keywords

heart failure, reduced ejection fraction, sacubitril/valsartan, angiotensin receptor-neprilysin inhibitor, enalapril, meta-analysis, systematic review, hazard ratio

Data availability

Underlying data. No new participant-level data were generated. All data underlying this review are derived from published randomised trials and from public registry records, and every record is identified in the extended data.

Extended data. Zenodo: Extended data for: sacubitril/valsartan versus enalapril in heart failure with reduced ejection fraction. [persistent identifier not yet minted]

NOT YET MINTED. Recorded as absent rather than filled with a plausible string: a wrong identifier in a Data Availability Statement points a reader at someone else's data, which is worse than no identifier at all.

This project contains the following extended data:

canonical_object.json. The single object every number in this article is projected from.

screening_log.csv. All 423 records the search returned, with the stage, the decision, the eligibility axis that failed, and what each excluded record reported instead.

search_capture.csv. Each database with the query string exactly as executed, the endpoint, parameters, filters and the hit count returned.

PRISMA_flow.md. Flow counted from the screening log at build time.

PRISMA_checklist.md. PRISMA 2020, item by item; items not reported are answered No.

extended_data_tables.docx. Extraction with per-cell provenance, all sensitivity and estimator analyses, secondary pooled outcomes, the full GRADE profile, risk-of-bias judgements from both assessors with the unresolved disagreements, the reconciliation record, the attestation record, and the executed code.

README.md. Written for a reader holding only the identifier and none of the article's context.

MANIFEST.sha256. Checksums for every file above.

Data are available under the terms of the CC0 1.0 Universal (CC0 1.0) Public Domain Dedication

Note on licensing. The software and the data carry DIFFERENT licences and are different objects. Code: MIT -- Attribution and retention of the licence notice. Data: CC0-1.0 -- None. All rights waived.

Software availability

Source code available from: https://github.com/mahmood726-cyber/rapidmeta-finerenone

Version control: https://github.com/mahmood726-cyber/rapidmeta-finerenone

Archived source code at time of publication: [not yet available]

Licence: MIT

NOT YET DEPOSITED. Zenodo must be authorised against the repository and a tagged release cut; Zenodo then mints a version-specific identifier for that tag and a concept identifier that always resolves to the latest. The VERSION-SPECIFIC one belongs in this article, because that is the code that produced these results; the concept one belongs in the repository README.

Note on registration

This review's protocol was registered as a timestamped, SHA-pinned public commit rather than in PROSPERO. The commit precedes the first executed query by a recorded margin and the ordering is machine-checkable at every build, which is stronger evidence of prospective registration than a registry entry provides. It is NOT, however, the token the journal asks for, and the difference is stated here rather than presented as equivalent. Mahmood should decide whether to also register in PROSPERO.

Tables

Table 1. PRISMA flow of records, as counts

Table 2. Characteristics of the included trials

Table 3. Per-arm events and denominators for the pooled composite

Table 4. Extracted values, and where each came from

Table 5. Component endpoints and each trial's published effect

Table 6. The same 2x2 on three scales (sensitivity to the primary hazard-ratio pool)

Table 7. Leave-one-out sensitivity analysis

Table 8. Between-study-variance estimator comparison

Table 9. Screening log: every record adjudicated, with its decision and the reason for it

Table 10. GRADE summary of findings

Table 11. Risk of bias by domain and trial, both assessors shown separately and unreconciled

Table 12. Overall risk-of-bias judgement per trial, by the standard algorithm

Table 13. Open disagreements, carried at the more cautious judgement pending adjudication

Table 14. Quantities on which registry and publication disagree

Table 15. Trial-by-trial reconciliation against their included set

Table 16. Checks applied to the published synthesis, with verdicts

Table 17. Quoted evidence for each check, with its location and our adjudication

Table 18. Statistical output quoted verbatim, with the call that produced it

Figure legends

Figure 1. Forest plot. Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.

Figure 2. Visual abstract. Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.

Figure 3. PRISMA flow of records. Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.

Figure 4. Funnel plot. Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.

Figure 5. Galbraith (radial) plot. Each trial's standardised effect against its precision.

Figure 6. Baujat plot. Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.

Figure 7. Influence diagnostics. Leverage against Cook's distance, from metafor's influence diagnostics.

Figure 8. Leave-one-out. The pool refitted with each trial removed in turn.

Figure 9. Cumulative meta-analysis. The pool as each trial reported, in year order.

Figure 10. Bayesian posterior density. grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)

Figure 11. Risk of bias, both assessors. Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured, not asserted: the two assessors agreed on 10 of 15 domain judgements (66.7 per cent) and on 1 of 3 overall judgements. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.

Figure 12. GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.

Figure 13. Trial-sequential analysis. TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.

Figure 14. Meta-regression. The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.

Figure 15. L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.

Figure 16. Number needed to treat, across baseline risk. The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.

Figures

Figure 1. Forest plot. Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.

Figure 2. Visual abstract. Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.

Figure 3. PRISMA flow of records. Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.

Figure 4. Funnel plot. Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.

Figure 5. Galbraith (radial) plot. Each trial's standardised effect against its precision.

Figure 6. Baujat plot. Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.

Figure 7. Influence diagnostics. Leverage against Cook's distance, from metafor's influence diagnostics.

Figure 8. Leave-one-out. The pool refitted with each trial removed in turn.

Figure 9. Cumulative meta-analysis. The pool as each trial reported, in year order.

Figure 10. Bayesian posterior density. grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)

Figure 11. Risk of bias, both assessors. Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured, not asserted: the two assessors agreed on 10 of 15 domain judgements (66.7 per cent) and on 1 of 3 overall judgements. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.

Figure 12. GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.

Figure 13. Trial-sequential analysis. TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.

Figure 14. Meta-regression. The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.

Figure 15. L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.

Figure 16. Number needed to treat, across baseline risk. The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.

Submission conformance

Profile. F1000Research

Figures. EPS generated as the journal's first preference for line art; uncompressed TIFF at 600 dpi carried as the stated fallback; JPEG dropped (not accepted, and lossy on line art); SVG retained for the web page only, where it is the master the others derive from.

Supplementary. The journal accepts none. Extended data is built as a deposit package for an approved repository under CC0 or CC-BY and cited in the Data Availability Statement by DOI.

Abstract. Structured, 300 words maximum, Background / Methods / Results / Conclusions, no citations.

Tables and figures. Legends and tables placed at the end, not inline.

Prisma. Checklist and flow diagram deposited and cited by DOI.

Registration. Protocol registered as a timestamped, SHA-pinned public commit. PROSPERO is the token the journal names; ours is arguably stronger evidence of ordering but is NOT the same token, and that difference is flagged rather than presented as equivalent.

NOT YET SUBMITTABLE. Data Availability Statement carries no persistent identifier for the extended data. No archived source-code identifier (Zenodo) for the code. figure title is 64 words; the limit is 15: 'Forest plot. Changing the range moves the axis window only. The guides' figure title is 80 words; the limit is 15: 'Visual abstract. Projected from the canonical object, so it carries th' figure title is 161 words; the limit is 15: 'PRISMA flow of records. Every stage carries a count. The identificatio' figure title is 59 words; the limit is 15: 'Funnel plot. Standard error against the effect, most precise at the to' figure title is 18 words; the limit is 15: 'Baujat plot. Right means a trial drives heterogeneity; up means it mov' figure title is 21 words; the limit is 15: 'Bayesian posterior density. grid integration, 201x201, flat prior on t' figure title is 173 words; the limit is 15: 'Risk of bias, both assessors. Every cell carries BOTH independent cros' figure title is 37 words; the limit is 15: 'GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials i' figure title is 44 words; the limit is 15: 'Trial-sequential analysis. TSA boundaries depend entirely on a target ' figure title is 45 words; the limit is 15: 'Meta-regression. The protocol pre-specifies no moderator, and at k = 4' figure title is 17 words; the limit is 15: "L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the " figure title is 47 words; the limit is 15: 'Number needed to treat, across baseline risk. The number needed to tre'

In this section: Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Diagnostics · Per-trial influence and weight · Leave-one-out, numerically · Where these numbers came from · The same 2x2, on three scales · Number needed to treat · Baseline risk, per trial · Benford first-digit screen · What these counts are, and are not · Further analyses — what was run, and what was not

Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio

Diagnostics

Table 50. Diagnostics
StatisticValueMethod and caution
Prediction interval0.686 to 1.11t_{k-1}, Cochrane Handbook v6.5
Between-study variance0.0086 (0 to 1.69)Q-profile (Viechtbauer 2007)
Egger's regressionintercept -0.3, p = 0.0106Run for completeness. With k = 4 the test has almost no power and the Cochrane Handbook advises against interpreting it below about ten studies. Reported as a computed value, not as evidence about small-study effects. Recomputed at k = 4. The p value moved from 0.101 to 0.01056 when ANSWER-HF entered, and that movement is exactly what a test with almost no power does when a fourth point is added -- it is not a finding about small-study effects and must not be read as one.
Bayesian posterior0.846 (0.568 to 1.46)grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)
Peters' testintercept -0.268, p = 0.0305Peters 2006 regresses the log odds ratio on the inverse of total sample size, which the Cochrane Handbook v6.5 section 13.3.5 recommends for binary outcomes in place of Egger, whose test is biased on the odds-ratio scale. With k = 4 it still has almost no power and is reported as a computed value, not as evidence. Recomputed at k=4. The intercept was stored as an empty list and rendered on the page as an empty pair of brackets where the number belongs -- the same defect as Egger's standard error, a value the extraction failed to read presented as though the field did not apply.

Per-trial influence and weight

Table 51. Per-trial influence and weight
TrialWeightLeverageCook's DStd. residual
paradigm-hf59.3%0.5931.68-1.63
parachute-hf29.9%0.2991.88-0.197
parallel-hf8.1%0.0810.1660.912
answer-hf2.66%0.02660.2271.61

Read the weight column beside the leave-one-out rows: a trial carrying most of the weight is the trial the answer rests on.

Leave-one-out, numerically

Table 52. Leave-one-out, numerically
OmittedPooledI-squared
paradigm-hf0.966 (0.79 to 1.18)1.2%
parachute-hf0.972 (0.666 to 1.42)52.9%
parallel-hf0.844 (0.736 to 0.967)26.5%
answer-hf0.839 (0.743 to 0.948)22.2%

Where these numbers came from

Computed at build time by metafor 5.0.1 under R 4.6.0 from the log point and log standard error this object stores. The page projects these stored values; opening it recomputes nothing, and no reader action can change any of them. Recomputed at k=4 on 2026-08-13: this whole block, including its own `fit`, was still the k=3 analysis after ANSWER-HF entered the pool, so a leave-one-out of three rows and a prediction interval from three trials were being shown beside a four-trial headline. The recomputation was gated on reproducing the pooled result already stored here (agreement to 1e-7 on the point estimate) and is corroborated by the leave-one-out row omitting ANSWER-HF, which returns 0.839195 -- the previous k=3 pool, to 2e-7.

The same 2x2, on three scales

Table 53. The same 2x2, on three scales
MeasurePooledI-squared
Risk ratio0.872 (0.777 to 0.979)25.2%
Odds ratio0.825 (0.712 to 0.955)17.8%
Risk difference-0.0231 (-0.0629 to 0.0167)44.1%

None of these three is this review's primary result — that remains the pooled hazard ratio, which uses time to first event rather than counting people once. An odds ratio is not collapsible, which is why Handbook 10.4.2 asks for both when baseline risks differ.

Number needed to treat

Not defined for this outcome. The authoritative pooled risk difference is −0.023 (−0.063 to +0.017), an interval that crosses zero — it includes no difference. A number needed to treat is defined only for a risk difference whose interval excludes zero, so none is stated here: a finite NNT would assert a benefit the pooled data do not establish.

Withdrawn 2026-09-05. An earlier build of this page displayed “22.6 (16.3 to 37.2)”, computed from a superseded risk-difference snapshot (−0.0442, −0.0615 to −0.0269) whose upper bound is opposite in sign to the current authoritative pool; that snapshot is retained on the object under superseded_values_2026_09_05. Recomputing from the current operand would not restore a valid NNT, because the current interval crosses zero.

Baseline risk, per trial

Table 54. Baseline risk, per trial
TrialControl events / analysedRisk
paradigm-hf1117 / 42120.265
parachute-hf169 / 4600.367
parallel-hf28 / 1120.25
answer-hf8 / 950.0842

Benford first-digit screen

Table 55. Benford first-digit screen
Leading digitObservedExpected
131.81
211.06
310.75
400.582
500.475
600.402
700.348
800.307
910.275

First-digit screen over the 6 event counts as read. With this few integers the comparison is descriptive only -- Benford's law is a large-sample regularity and no test statistic is computed here.

What these counts are, and are not

Computed at build time by metafor 5.0.1 under R 4.6.0 from the per-arm 2x2 counts stored on each trial, which were read from the sources named on each cell. No composite was reconstructed by addition and no count was derived from a percentage. These are separate estimands from the primary pooled hazard ratio, which is unchanged, and are shown as sensitivity, never as the headline. Recomputed at k=4 on 2026-08-14. They had been marked stale at k=3 on the grounds that recomputing needed 2x2 counts that were not available; that was wrong -- ANSWER-HF's counts for this composite, 12/95 against 8/95, were already in the object. The L'Abbe panel was therefore drawing three points beside a four-trial forest. The recomputation reproduces every stored k=3 value to 1e-5 when ANSWER-HF is withheld, which is what licenses the k=4 run.

Further analyses — what was run, and what was not

Table 56. Further analyses — what was run, and what was not
AnalysisStatusWhy
Forest plotshownDrawn from the stored per-trial and pooled estimates.
Random-effects pool (REML)shownThe headline result, with its interval and heterogeneity.
Leave-one-out sensitivityshownEach cohort omitted in turn; the finding is on the Analysis tab.
Between-study-variance method comparisonshownREML against the alternatives, as Handbook 10.10.4.5 asks whenever a random-effects pool rests on few studies.
Cross-engine replicationshownThe pool refitted in a second engine; the agreement is stored.
Prediction intervalnot estimableUndefined at this k on the Cochrane Handbook v6.5 t-based formula for the interval this object would report; no value is stored and none is shown.
Funnel plot and Egger's testnot estimableThree studies. Egger's test has almost no power below about ten and the Handbook advises against it there, so it was not run and no small-study estimate is stored. This is why the GRADE publication-bias domain reads 'not assessable' rather than 'not serious'.
Trim-and-fillnot runA sensitivity procedure on a funnel that cannot be read at three studies. It would produce an adjusted estimate with no diagnostic behind it.
Meta-regressionnot estimableThree studies and no shared covariate; a regression here would have more parameters than it can support.
Bayesian re-analysisnot storedNo posterior summary is held in this object. Nothing is shown rather than a credible interval nobody fitted.
Subgroup analysisnot storedNo subgroup contrast is held for this outcome.
Network / component analysisnot applicableTwo treatments and one comparison. There is no network.
Reconstructed patient-level survivalnot storedNo digitised Kaplan-Meier curve is held. The pooled quantity is a published hazard ratio per trial.
Benefit-risk frontiernot storedNo harm outcome is held for these trials in this object, so there is no second axis to plot .
Transportability / external validitypartly shownEach trial's population is stored per row and the populations differ; the Studies tab shows them. No formal transport estimate is stored.

Page standard

UNSTAMPED — unknown-version. This page carries no build_stamp, so the standard it was built to cannot be established. That is a statement about the record, not a claim that the page is below standard.

Every number on this page is projected from a single canonical object, and each measured cell names the source analysis it was read from. That is what is machine-checked. It does not establish that the underlying sources are right, only that this page faithfully reports them.